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ABSTRACT OF DISSERTATION 
EFFECTS OF PITUITARY PARS INTERMEDIA DYSFUNCTION AND 
PRASCEND® TREATMENT ON ENDOCRINE AND IMMUNE FUNCTION IN 
SENIOR HORSES 
Pituitary pars intermedia dysfunction (PPID) is one of the most common endocrine 
diseases affecting senior horses. PPID causes abnormally high concentrations of 
adrenocorticotropic hormone (ACTH) in the plasma and a very distinct, long, shaggy 
haircoat (hypertrichosis). At present, the recommended treatment for PPID is daily oral 
administration of pergolide mesylate. Due to the increased ACTH levels associated with 
PPID, it is commonly thought that these horses are immunosuppressed and at increased 
risk of opportunistic infections, although current research in this area is sparse. 
Additionally, it is not well-understood how treatment with Prascend® (pergolide tablets) 
affects endocrine measures other than ACTH and if it also impacts the immune response. 
To better understand how PPID influences endocrine and immune function in the 
horse, Non-PPID horses (n=10), untreated PPID horses (n=9), and PRASCEND-treated 
PPID horses (n=9) were followed over 15 months. Endocrine measures assessed included 
basal ACTH, ACTH responses to thyrotropin-releasing hormone (TRH) stimulation tests, 
basal insulin, insulin responses to oral sugar tests (OST), total cortisol, and free cortisol. 
Systemic immune function measures included basal and stimulated whole blood and 
peripheral blood mononuclear cell (PBMCs) cytokine and receptor expression, plasma 
myeloperoxidase levels, and complete blood counts. Localized immune function measures 
within the lung included cytokine and receptor expression after stimulation of cells 
obtained via bronchoalveolar lavage (BAL), myeloperoxidase levels in BAL fluid, and 
BAL fluid cytology. We hypothesized that PPID would affect immune function, but that 
any alterations would be corrected by treatment with PRASCEND. 
Results for the endocrine analyses showed that basal ACTH was reduced in the 
PRASCEND-treated horses to the levels of the Non-PPID horses, but ACTH in response 
to TRH stimulation was only reduced in the PRASCEND-treated horses at non-fall 
timepoints. PPID did not affect basal insulin, insulin responses to OSTs, total cortisol, or 
free cortisol, and PRASCEND treatment did not appear to have an impact on these 
measures either. These results suggest that PPID and hyperinsulinemia/insulin 
dysregulation are distinct endocrine conditions, and that the excess ACTH in horses with 
PPID is inactive, as it is unable to stimulate a normal cortisol response. 
In the immune function analyses, PPID horses had decreased expression of 
interferon gamma (IFNγ) from PBMCs stimulated with Rhodococcus equi and Escherichia 
coli and increased transforming growth factor beta (TGFβ) expression from the E. coli-
stimulated PBMCs. TGFβ was also increased in PPID horses in the unstimulated whole 
blood samples. These results suggest that PPID horses are unable to mount an appropriate 
Th1 response, and that the regulatory subset of T-lymphocytes may be contributing to this 
decreased Th1 response. Results for the localized immune function analyses may indicate 
altered Th2 responses within the lung of PPID horses, although these results were severely 
limited by the sample size available for analyses. PRASCEND did not appear to affect 
immune function as measured in this study. 
In summary, PRASCEND successfully reduces basal ACTH in PPID horses and 
remains the best choice for veterinarians in monitoring dosage and response to 
PRASCEND treatment. Insulin, total cortisol, and free cortisol were not affected by PPID 
status or PRASCEND treatment in this study. Immune function was altered in horses with 
PPID, and it is likely that these horses are indeed at increased risk of opportunistic 
infection. PRASCEND treatment did not correct the differences in immune function in this 
study. Additional research is needed to further understand which mechanisms are driving 
the alterations in immune function for horses with PPID. 
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CHAPTER 1.  LITERATURE REVIEW 
1.1 Pituitary pars intermedia dysfunction and its effects on endocrine function 
The population of geriatric horses is steadily rising with advances in veterinary 
medicine and a shift in the role of the horse from that of a work animal to that of a 
companion animal. The most recent results from the National Animal Health Monitoring 
System survey in 2015 indicated that almost half of the U.S. equine operations surveyed 
(44.6%) had at least one horse over twenty years of age 1. Horses are generally considered 
to be old or geriatric when they are fifteen years of age or older 2. Pituitary pars intermedia 
dysfunction (PPID) is a common disease of aging horses. Several studies have investigated 
the prevalence of PPID, with the most reliable data indicating a prevalence of about 20% 
in horses over fifteen years old, with a range in prevalence reported as approximately 10-
22% in most of the epidemiological analyses conducted to date 2-6.  
The most frequent clinical sign observed in PPID horses is the development of an 
abnormal haircoat, termed hypertrichosis, which is long, can be with or without curl, and 
often exhibits absent or delayed shedding 2,5,7-10. This abnormal haircoat can be seen over 
the entire body or may be regional 7-9. Additional clinical signs associated with PPID 
include polyuria, polydipsia, hyperhidrosis, muscle wasting, weight loss, and possibly 
changes in reproductive and immune function as well 5,7-12. 
Pituitary pars intermedia dysfunction is caused by the loss of dopaminergic 
inhibition of the melanotropes of the pars intermedia of the pituitary 5,7,13. In a healthy 
horse, adrenocorticotropic hormone (ACTH) is produced by the pars distalis of the 
pituitary, whereas in horses with PPID, ACTH is also aberrantly produced by the pars 
intermedia of the pituitary 5,7.  
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In both the pars distalis and pars intermedia, the pre-prohormone, pro-
opiomelanocortin (POMC) is produced and cleaved by prohormone convertase I (PC-I) 
into ACTH and several other peptide hormones 5,7,13. A second enzyme is present only in 
the pars intermedia, prohormone convertase II (PC-II), which further cleaves ACTH into 
alpha-melanocyte-stimulating hormone (α-MSH) and corticotropin-like intermediate 
peptide (CLIP); in a healthy horse, essentially all ACTH produced by the pars intermedia 
is cleaved into these products 5,7,13. Without proper inhibition of the melanotropes of the 
pars intermedia by dopamine, as is the case in PPID horses, POMC production and PC-I 
activity increases, thereby increasing ACTH production 5,7. However, PC-II activity does 
not increase to the same extent and is no longer sufficient to cleave the greater influx of 
ACTH into α-MSH and CLIP 5,7. Therefore, this ACTH is released, increasing the plasma 
ACTH concentrations in horses with PPID 5,7-9,13.  
In horses, seasonal variation in endocrine function is well-described. ACTH 
increases within the fall time period (mid-July to mid-November) for the United States in 
both healthy and PPID horses, although this seasonal rise is exaggerated in horses with 
PPID 5,7-9,14,15. This change has been shown to be driven by seasonal changes in dopamine, 
but horses with PPID have been also been shown to have lower dopamine concentrations 
than Non-PPID horses in three of the four seasons 16,17. If the seasonal changes in ACTH 
in a horse’s geographic region are not considered when screening for PPID, false diagnosis 
of PPID is possible within this normal seasonal ACTH rise 15. 
A normal hypothalamus-pituitary-adrenal axis response to increased ACTH 
concentrations is to also increase cortisol concentrations 18. In response, both ACTH and 
cortisol can also control corticotropin-releasing hormone (CRH), POMC, and ACTH 
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release through negative feedback 18. However, the pars intermedia of horses does not 
contain receptors for these hormones, so ACTH production from the pars intermedia is 
unable to be shut down through these normal pathways 5.  
Due to the normal response of increasing cortisol as a result of increasing ACTH, 
cortisol has also been thought to be impacted by PPID. This, along with comparisons of 
PPID in horses to Cushing’s disease in other species, has generally been the basis behind 
which PPID horses were assumed to be immunosuppressed 5,18-20. However, Cushing’s 
Disease in other species, such as humans and dogs, affects different areas of the pituitary 
than in horses, thus preventing comparisons from being made between PPID in horses and 
Cushing’s Disease in other species 10. Research on the impacts of ACTH on cortisol in 
horses with PPID has been limited mainly to investigations of total cortisol concentrations 
and often produces conflicting results. One study that examined total cortisol over twenty-
four hours in each of the four seasons found that horses with PPID only had higher total 
cortisol levels at the summer timepoint (June) when compared to normal horses 16. This 
same study found that PPID did not impact the ability of the horse to follow normal 
responses to day-length and the photoperiod 16. Conversely, other studies have found no 
changes in resting total cortisol in horses with PPID 21,22. 
In general, total cortisol analyses are not thought to be reflective of cortisol’s active 
effects, as most cortisol is bound to corticosteroid-binding globulin (CBG) and is thus 
prevented from diffusing through cell membranes and exerting its effects; however, 
hydrocortisone bound to CBG has been recently shown to alter the function of equine 
neutrophils in vitro 23,24. In the two main studies that have examined the effects of PPID on 
free cortisol, one study found no difference in free cortisol, but found increased total 
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urinary cortisol in PPID horses, while the other found increased free cortisol fraction in 
PPID horses 22,25. In addition, another study found only a weak correlation between cortisol 
and ACTH in Non-PPID horses (r = 0.31 and r = 0.25, depending on the season in which 
the horses were sampled) 26. 
While a tendency to investigate the more systemic endocrine effects of PPID is 
often seen in the literature, the potential for more localized effects of these hormones 
should not be underestimated. To investigate whether local cortisol contributes to poor 
immune responses within the eyes of PPID horses, Hart et al. examined the cortisol 
concentrations in tears and found that PPID horses had significantly higher cortisol 
concentrations in their tears 27. Localized cortisol effects were also seen in one study that 
examined suspensory ligament failure in PPID horses; they found that horses with PPID 
had significantly higher numbers of glucocorticoid receptors within the suspensory 
ligament compared to Non-PPID horses 28. 
Hyperinsulinemia and/or insulin dysregulation, and thus laminitis, are also 
frequently thought to be related to PPID; however, it is often debated as to whether the two 
conditions are related or whether they are distinct and are both common conditions found 
in older horses 5,7,10,29-32.  Mastro et al. examined insulin sensitivity and its associated 
pathways in PPID horses from a research herd; they found no differences in insulin 
sensitivity between the PPID and age-matched Non-PPID horses, which supports the 
conclusion that hyperinsulinemia and/or insulin dysregulation and PPID are distinct, rather 
than related, conditions 33.  While literature regarding the impact of PPID on insulin may 
be inconsistent, it is well-accepted that insulin is not an appropriate tool for diagnosing 
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PPID, and that veterinarians should monitor older horses for hyperinsulinemia and/or 
insulin dysregulation, regardless of a horse’s PPID status 10,14,29,32,33.  
1.2  Diagnosing pituitary pars intermedia dysfunction in horses 
Given the role of ACTH in the pathogenesis of PPID, it follows that the current 
recommendations for the diagnosis of PPID in horses are focused on the measurement of 
ACTH, either basal or in response to a thyrotropin-releasing hormone (TRH) stimulation 
test 5,7-9. In horses already displaying signs of hypertrichosis, a basal ACTH above the 
seasonal reference range is indicative of PPID 5,7-10. However, detection of PPID before 
more severe clinical signs are apparent is possible by measuring the ACTH response to a 
TRH stimulation test 5,7-9,34. Veterinarians can perform this test at the farm or facility where 
a horse is typically located, as it does not require specialized equipment. First, a blood 
sample is collected to measure basal ACTH concentrations (T0) 5,7-9,34. Then, TRH is 
administered intravenously, and a second blood sample is collected ten minutes later (T10) 
for ACTH analysis 5,7-9. The administration of TRH stimulates ACTH production because 
TRH receptors are present in the pars intermedia of horses; in PPID horses, exaggerated 
responses to the TRH stimulation test are seen 5,14,35.  
After comparing the ACTH results to the seasonal reference ranges for the local 
region, a diagnosis of Non-PPID or PPID can be made 5,7-9. In cases where the results of 
the TRH stimulation test are ambiguous, it is recommended that the test be repeated in 
several months (during a different season) 5,7,8. Obtaining TRH has sometimes proven 
difficult, but it is currently available in ready-to-use compounded form or in research-grade 
powder form, which can be then be mixed with sterile 0.9% NaCl in aseptic fashion 5,7. 
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The dexamethasone-suppression test (DST) was also historically used to diagnose 
PPID but has fallen out of favor for several reasons 5,34,36. To perform a DST, a baseline 
cortisol sample was taken in the evening, followed by intramuscular dexamethasone 
administration at a dose of 40 μg per kilogram of body weight, and a follow-up cortisol 
sample was taken between fifteen and nineteen hours later 5. The reasoning behind this test 
is the thought that PPID impacts the hypothalamus-pituitary-adrenal axis responses of 
PPID horses, and that their high ACTH production by the pars intermedia stimulates 
cortisol increases that are not susceptible to negative feedback because the pars intermedia 
does not have glucocorticoid receptors 5,10. As discussed in the previous section, the impact 
of PPID on cortisol is not clear and even in healthy Non-PPID horses, cortisol appears to 
be only weakly linked, if at all, to increased ACTH levels 5,26,34. Given that 
hyperinsulinemia and laminitis occur in some horses with PPID, many veterinarians and 
owners are hesitant to administer dexamethasone, particularly when basal ACTH or the 
ACTH response to a TRH-stimulation test do not carry the same risks 10,21,37,38. 
Additionally, the DST is not reliable in detecting PPID in the preclinical stages 5,7,34. Since 
basal ACTH concentrations are sufficient for diagnosis in the more advanced presentations 
of PPID, the administration of the DST is rather unnecessary 5. Further, the DST generally 
requires multiple visits from a veterinarian because of the need for the evening and morning 
cortisol samples. For all of these reasons, the TRH stimulation test is the recommended 
diagnostic test for PPID at this time 5,7-9. 
It has been noted that feeding can impact ACTH levels in the horse 39. Therefore, 
when it is desired to compare multiple results over time, feeding status should be 
consistently maintained (i.e. always fed or always fasting) 39. Given the current 
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recommendations to also monitor insulin in geriatric horses, it is often more cost-efficient 
for owners and easier for veterinarians to sample in the same visit for both ACTH and 
insulin in a fasted horse 7-9,36. 
1.3 Treating pituitary pars intermedia dysfunction in horses 
Given the involvement of dopamine in the pathogenesis of PPID, it follows that the 
majority of treatment options for PPID have included the use of dopamine agonists 5,7-10. 
Currently, the only FDA-approved treatment for PPID is daily oral administration of 
Prascend® (pergolide tablets) (Boehringer-Ingelheim Animal Health; Duluth, GA), a 
dopamine agonist 7-9,36. Suggested starting doses are 0.002 milligrams (mg) per kilogram 
(kg) of body weight, but this can be increased up to 0.004 mg/kg of body weight if ACTH 
is not controlled 7. PRASCEND is generally given orally once per day, but recent work 
suggests that twice per day administration may produce more stable responses 40. It is 
currently recommended that ACTH concentrations be re-checked regularly to monitor the 
response to treatment with PRASCEND and to ensure dose adequacy 5,7-9,36. Additionally, 
present recommendations indicate that the method of testing used to originally diagnose 
PPID in a horse should continue to be used to monitor dose adequacy and response to 
treatment in that horse. 8,9.  
Aside from its proven ability to reduce ACTH concentrations in PPID horses, the 
impact of PRASCEND on other aspects of endocrine function is largely unknown at this 
time 40,41. One study found that PRASCEND did not appear to affect glucose or insulin; 
nevertheless, PRASCEND and other dopamine agonists are frequently given to Non-PPID 
horses with hyperinsulinemia/insulin dysregulation in an attempt to lower insulin 
concentrations 42,43. On the reproductive side of endocrine function, a single case report  
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noted that PRASCEND treatment did not appear to impact fertility in a stallion 11. Other 
dopamine agonists, such as bromocriptine and cabergoline, have also been used in horses 
with PPID, but at this time, their efficacy and usefulness remain unclear 44. 
Outside of the dopamine agonists, one drug sometimes used for the treatment of 
PPID is cyproheptadine, a serotonin antagonist 5,10. Cyproheptadine appears to be able to 
reduce ACTH concentrations, but is not nearly as effective as PRASCEND, which explains 
its infrequent use 5,10,36,45,46. It is sometimes used in addition to PRASCEND for horses that 
are not controlled on PRASCEND alone 5,46.  
While PRASCEND is currently the only FDA-approved treatment for horses with 
PPID, it is unclear whether PRASCEND influences immune function in these horses. 
1.4 Effects of pituitary pars intermedia dysfunction on immune function 
The impact of PPID on immune function in horses is currently not well-described, 
and research in this area is comprised mainly of case reports, with few experimentally 
controlled studies. Despite this, PPID is frequently noted anecdotally to cause 
immunosuppression in horses 5,7-9,47-49. Clinically, it appears that PPID horses may be at 
greater risk of infection caused by opportunistic bacteria and fungi due to the numerous 
reports of infection involving their respiratory and integumentary systems 5,7-9,47,49. 
Several studies by McFarlane et al. have examined immune responses in PPID 
horses 48,50. In one study, cytokine expression from total leukocytes and TNFα production 
from peripheral blood mononuclear cells (PBMCs) were analyzed. PPID horses had IFNγ 
and IL-6 expression that was similar to Non-PPID adult (younger) horses, but lower than 
age-matched Non-PPID horses 50. Additionally, PPID horses had elevated IL-8 expression 
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compared to Non-PPID adult horses, but it was similar to the expression in the age-matched 
Non-PPID horses in this study 50. For the PBMC stimulations in this same study, there were 
no differences between the groups in the unstimulated samples, but PPID horses had 
greater TNFα production from lipopolysaccharide (LPS)-stimulated PBMCs than both the 
age-matched and adult Non-PPID horses 50. Release of TNFα is a normal response to LPS, 
and this is consistent with studies in horses and other species; however, it appears to have 
been more exaggerated in PPID horses in the described study 50-53.  
Based on the differences in IL-8 described in the study above, McFarlane et al. 
further investigated neutrophil function in PPID horses 48. This study revealed that 
neutrophils in horses with PPID had decreased oxidative burst, but normal phagocytosis, 
compared to Non-PPID horses 48. Additionally, in response to IL-8, neutrophils from PPID 
horses showed similar chemotaxis to younger Non-PPID horses but decreased from age-
matched Non-PPID horses 48. Neutrophil adhesion was also decreased in PPID horses 
compared to Non-PPID horses when they were unstimulated or in the presence of mild 
stimuli, but was not different with maximal stimulation by phorbal 12-myristate 13-acetate 
(PMA) 48. However, in both of the studies described above, the samples were collected 
over a period of sixty to ninety days, which may complicate the analysis 48,50. 
In addition to the above studies that focused mainly on white blood cells (WBC) in 
PPID horses, some work has also been done in the area of parasitic load and response to 
anthelmintic treatment in PPID horses. One study found differences in fecal egg counts 
before and after ivermectin treatment with PPID horses having higher fecal egg counts than 
Non-PPID horses 54. A second study in this area focused on horses diagnosed with PPID 
based only on basal ACTH levels, with follow-up testing in the PPID horses approximately 
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seven months later 55. The authors found no difference between the PPID horses and Non-
PPID horses in this study and did not find a difference in the PPID horses that were 
untreated or treated with pergolide 55. However, the authors cautioned that they used horses 
that were pre-clinical or less severe cases of PPID in this study 55. This can be seen in their 
given ranges for basal ACTH, in which some of the horses were very close to the study’s 
Non-PPID cut-off values of less than 35pg/mL 55. Given the work in the more severe cases 
of PPID which indicated a difference in fecal egg counts before and after anthelmintic 
treatment compared to Non-PPID horses, it appears likely that PPID has some level of 
effect on parasitic load in horses. 
As mentioned in the section above on endocrine function in PPID horses, Hart et 
al. also investigated whether or not cortisol concentrations in the tears of horses may 
contribute to poor immune responses in the eye; they found that PPID horses had 
significantly higher cortisol concentrations in their tears, which may also indicate localized 
alterations in immune function in PPID horses 27. 
1.5 Effects of pituitary pars intermedia dysfunction on the lung 
Little is currently known regarding the impact of PPID on the lung of horses. It is 
often mentioned that these horses have higher rates of asthma or heaves, but to the author’s 
knowledge, there is no literature at this time that supports this conclusion 46. In one study 
that compared pathological findings in horses with PPID to both younger and age-matched 
Non-PPID horses, the PPID horses were found to have significantly higher rates of 
bronchiolitis and bronchointerstitial inflammation than either Non-PPID group 56. In this 
same study, lungs were scored based on severity, and PPID horses also had significantly 
higher lung scores than both the younger and age-matched Non-PPID horses 56. 
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1.6 An overview of opportunistic infection 
Across many species, opportunistic infections are frequently described in 
individuals with both primary and secondary immune dysfunction or suppression 19,57. 
These infections are often caused by pathogens that are commonly found in the external 
environment and on or within the host, but do not generally cause disease in a healthy host 
58. Due to their exposure to the external environment, the respiratory and integumentary 
systems are often affected by opportunistic infection. Indeed, in adult horses, most 
pneumonia cases occur in conjunction with some degree of breakdown in immune function, 
whether due to underlying chronic disease, secondary infection after viral disease, or 
administration of immunosuppressive drugs, such as corticosteroids 58-60. Additionally, 
pleuropneumonia is one of the most common causes of sepsis in adult horses 61. 
Escherichia coli is one of the most commonly isolated bacteria from equine 
pneumonia cases 58,60,62-64. E. coli is a ubiquitous gram-negative bacterium that is 
frequently encountered by adult horses 60. Generally, commensal E. coli does not cause 
harm; however, breakdowns in immune function can permit infection to occur 60.  
While Rhodococcus equi infections in horses are typically seen in foals, particularly 
in the first several months of life, R. equi infections have also been reported in adult horses 
and are generally accepted to be opportunistic pathogens in these cases 59,60,65-67. However, 
R. equi infection is still not common in adults despite the abundant presence of this gram-
positive bacterium in soil and its ability to thrive in manure  59,60,65-68. Additionally, R. equi 
infection has often been found in immunocompromised humans, such as HIV-positive 
individuals and transplant recipients on immunosuppressive medications, and tends to have 
high mortality rates in these cases 69-72. R. equi infections in immunocompetent humans 
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have also been described, but there does appear to be an association with age in these cases 
69,73,74. 
As in humans and foals, adult and aged horses can develop localized R. equi lesions 
within the lung, but also bacteremia, with R. equi spreading diffusely throughout the body 
59,66,67,75,76. Especially in foals, extrapulmonary lesions are quite common, demonstrating 
that the potential for an individual to develop bacteremia should not be underestimated 74,76-
80. Among the reported R. equi infections in adult horses, some cases note an 
immunocompromised host, while others do not 59,60,65-67. The onset of R. equi infection is 
often insidious in adult horses, potentially due to low awareness, which is problematic in 
both human and veterinary medicine 65-67,71,81. Pneumonia is the most common initial 
diagnosis, but R. equi is often not seen in these cultures, which can lead to delayed 
treatment and poor prognosis 66,67,70. It has been hypothesized that the tendency for R. equi 
to not be identified in culture could be due to its slower growth habits (approximately forty-
eight hours) compared to other commonly isolated species from  equine pneumonia cases; 
therefore, the growth of other isolates may obscure R. equi since cultures from pneumonia 
cases in horses are frequently positive for multiple species of bacteria and/or fungi 59,60,66,70. 
It is well-documented that the susceptibility of foals to R. equi infection is caused 
by their reduced expression of IFNγ and a reduced Th1 response compared to adult horses 
82. The Th1 response is crucial to clear an infection caused by R. equi, due to the 
intracellular nature of the bacterium and its ability to persist in the macrophages of the lung 
82. An appropriate Th1 response in young horses is generally developed by approximately 
six months of age, at which point the risk of R. equi infection drops substantially 82. 
Additionally, the presence of the virulence-associated protein A (VapA) in R. equi is 
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known to prompt a strong immune response, but R. equi expression of VapA also appears 
to contribute to the ability of the bacteria to evade the host immune response 82. In 
summary, both R. equi and E. coli infections in adult horses are generally considered 
opportunistic, meaning that a breakdown in the host immune response often precedes 
infection, particularly of the respiratory tract, by these bacteria. 
Currently, studies of PPID in horses are rather limited. In addition, the results of 
the available works have often yielded conflicting results, making it difficult for clinicians 
and researchers alike to determine how to best care for horses with PPID. Further, it is not 
well-understood whether PPID affects the immune responses of horses and whether these 
horses should be considered immunosuppressed. Therefore, the use of horses housed in a 
research setting proves ideal and necessary for examining the effects of PPID and 










1.7 Hypotheses and Specific Aims 
The focus of the work in this dissertation was to gain further understanding of how 
endocrine function affects the immune response of horses with PPID and how treatment 
with a dopamine agonist, PRASCEND, affects these measures. Our hypotheses were that 
altered endocrine function in PPID horses would cause changes in immune function, both 
systemically and locally within the lung, when compared to age-matched Non-PPID 
horses, and that PRASCEND treatment would normalize the measured endocrine and 
immune responses to levels similar to the Non-PPID horses. 
Specific Aim 1: To gain further understanding of the complexities of endocrine function in 
PPID horses and to investigate the endocrine effects of PRASCEND treatment (Chapter 2) 
Specific Aim 2:  To investigate the effects of PPID and PRASCEND treatment on systemic 
immune function and in vitro immune responses to stimuli (Chapter 3) 
Specific Aim 3:  To examine the effects of PPID and PRASCEND treatment on localized 














CHAPTER 2. EFFECTS OF PITUITARY PARS INTERMEDIA DYSFUNCTION AND 
PRASCEND® TREATMENT ON ENDOCRINE FUNCTION IN HORSES 
The material in this chapter has been submitted in consideration for publication and is 
currently under review. The author of this dissertation is the primary author on this paper. 
Co-authors on this paper provided laboratory analyses, advice on study design or statistical 
methods, and reviewed the manuscript prior to submission. 
 
2.1 Abstract 
Background: It remains unclear how Pituitary Pars Intermedia Dysfunction (PPID) and 
treatment with Prascend® (pergolide tablets) affect endocrine function in horses. 
Hypothesis/Objectives: Our hypothesis was that untreated (PPID Control) horses would 
have altered endocrine function compared to Non-PPID and PRASCEND-treated (PPID 
Treatment) horses as measured by ACTH, insulin, total cortisol, and free cortisol. 
Animals: 28 horses from a research herd (10 Non-PPID, 9 PPID Control, and 9 PPID 
Treatment) horses. 
Methods: Blood was collected regularly over approximately 15 months.  PRASCEND 
treatment was initiated after Day 0 collections. Results were analyzed using a linear mixed 
model (SAS v9.4), with significance set at P<.05. 
Results: Significant group (P<.01) and group by time (P<.001) effects were observed in 
basal ACTH such that PPID Treatment horses differed from Non-PPID horses only at Day 
0 (Least squares mean/standard error: 244.44/54.5861 (PPID Treatment-Day 0) versus 
54.62/51.7849 (Non-PPID-Day 0) (pg/mL); P=.012). PPID Treatment horses had 
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significantly lower ACTH change scores in response to TRH stimulation tests than PPID 
Control horses at non-fall timepoints only, Mid-late February 2018 (least squares 
mean/standard error: 441.72/84.99 versus 733.12/82.8638 (pg/mL); P=.016) and Early 
April 2018 (least squares mean/standard error: 272.84/87.4494 versus 563.57/82.7348 
(pg/mL); P=.017). No significant group or group by time effects were seen in insulin, total 
cortisol, or free cortisol; however, significant time effects were seen in these measures 
(P<.0001). 
Conclusions and clinical importance: Basal ACTH remains the best choice for determining 
successful response to PRASCEND treatment. Neither PPID nor PRASCEND appear to 
influence insulin, total cortisol, and free cortisol.  
 
2.2 Introduction 
Pituitary Pars Intermedia Dysfunction (PPID) is a common endocrine disease 
affecting older horses. Horses with PPID have increased plasma concentrations of 
adrenocorticotropic hormone (ACTH) and often develop distinct hypertrichosis, with 
difficulty shedding their coats appropriately 5,9. Clinical signs often associated with PPID 
include abnormal sweating, polyuria, polydipsia, frequent infections, laminitis, and loss of 
muscle mass 5,9. Currently, the only FDA-approved treatment for PPID is daily oral 
administration of Prascend® (pergolide tablets) (Boehringer-Ingelheim Animal Health, 
Inc., Duluth, GA), a dopamine agonist 36.  
Due to increased ACTH concentrations, it is frequently thought that other endocrine 
changes may exist in horses with PPID, such as changes in insulin, total cortisol, and free 
cortisol. Presently, it is not well understood if and how PPID may affect these endocrine 
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measures, since many current studies have come to contradictory conclusions 8-
10,14,22,25,27,42,83,84. Additionally, it is unclear what impact PRASCEND treatment, which is 
known to decrease plasma ACTH levels, has on other aspects of endocrine function and on 
ACTH responses to thyrotropin-releasing hormone (TRH) stimulation tests 41,42,45,85. 
Current literature is also rather mixed in whether PPID and hyperinsulinemia are separate 
or related endocrine diseases, and few long-term studies have been conducted to determine 
whether PRASCEND treatment improves insulin responses 86.  
Challenges for studies seeking to further understand PPID include often needing to 
use client-owned horses, with samples collected and stored over a range of times, and 
horses often treated on different schedules based on owner availability. Given the known 
seasonal changes in ACTH, along with other hormones, this can be problematic when 
interpreting results . Thus, the objective of this study was to characterize the effects of 
long-term PRASCEND treatment with PPID on multiple endocrine parameters in 
university-owned horses under consistent treatment, seasonal, and environmental 
conditions. We hypothesized that untreated PPID horses would have altered endocrine 
function compared to the Non-PPID and PRASCEND-treated PPID horses. 
 
2.3 Materials and Methods 
 
2.3.1 Animal Selection and Study Design 
Horses were initially selected for potential inclusion in the study from a university-
owned research herd based on prior screenings and clinical history (absence or presence of 
hypertrichosis and/or absence or presence of history of hypertrichosis/difficulty shedding 
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and/or results of multiple TRH stimulation tests). PPID status was confirmed using ACTH 
responses to TRH stimulation tests approximately two weeks prior to Day 0 of the study 
(Early September 2017) and basal ACTH values on Day 0. An oral sugar test (OST) was 
also performed prior to the study, approximately one week after the TRH stimulation test, 
to assess hyperinsulinemia or insulin dysregulation status 87. Horses that did not screen as 
either Non-PPID or PPID for both the TRH stimulation test and basal ACTH screenings 
were excluded from the study.  As these initial screenings were obtained during the fall 
season in the USA (late August and early September), a basal ACTH value of ≥100pg/mL 
and ACTH 10 minutes post-TRH injection (T10) value of ≥400pg/mL were used for 
selection into the PPID group 8,9.  
Thirty-one horses were originally selected to proceed through the study. However, 
three horses assigned to the PRASCEND-treated group had ACTH values that failed to 
become controlled and remained uncontrolled throughout the study; these horses were 
excluded from all analyses and are not discussed further. Non-PPID horses (n=10) were 
blocked into one group. An attempt was made to randomly assign the PPID horses into the 
untreated and treated groups, however, due to also attempting to block for insulin status, 
true randomization was not possible. PPID Control horses (n=9) remained untreated for 
the duration of the study, and PPID Treatment horses (n=9) began receiving PRASCEND 
within approximately 24 hours of their completion of all Day 0 sample collections. Horses 
were started at the lowest label dose (2 μg/kg) to the nearest half-tablet for their body 
weight, based on the manufacturer’s label recommendations. Basal ACTH was checked 
weekly for the first 4 weeks, and the dose was increased each week until basal ACTH levels 
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were reduced to controlled (Non-PPID) values or until the maximum label dose (4 μg/kg) 
to the nearest half-tablet was reached.  
Throughout the approximately 15-month study, six horses were euthanized due to 
non-study related health issues. The study ended with 9, 7, and 6 horses in the Non-PPID, 
PPID Control, and PPID Treatment groups, respectively. At the start of the study, there 
was no statistical difference in age between the groups (P =.17) (Table 2.1). Age ranges 
were 20-29 years for Non-PPID horses, 21-31 years for PPID Control horses, and 19-29 
years for PPID Treatment horses. Only mares and geldings were included (Table 2.2). 
Breed representations, either confirmed or to the best of the researchers’ knowledge, 
included Thoroughbred (n=14), American Quarter Horse (n=4), Standardbred (n=1), 
Standardbred cross (n=1), Mustang (n=1), Paint (n=1), Arabian (n=1), Tennessee Walking 
Horse (n=1), Appaloosa (n=1), and unknown or mixed breed (n=3) horses (Table 2.2). 
Breakdowns of sex and breed by group are included in Table 2.2. All horses were cared for 
and sampled with approval of the University of Kentucky’s Institutional Animal Use and 
Care Committee (IACUC) (#2014-1225 and #2018-3004). 
2.3.2 Sampling 
On sampling days, horses were grain fasted (if part of their normal ration) until all 
collections were completed. Blood samples were collected via jugular venipuncture within 
a four-hour window during morning hours (approximately 08:00 to 12:00), for 
measurement of ACTH and insulin at fourteen timepoints and for measurement of total 
cortisol and free cortisol at ten of these timepoints. At each timepoint, all blood samples 
(not including the TRH stimulation tests or OSTs) were collected over a period of 1-4 days, 
but within the same time window above (08:00 to 12:00); when multiple days were needed 
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to complete all of the collections, a mixture of horses from the three groups were screened 
each day. Appendix 2 contains a sample timeline. TRH stimulation tests and OSTs were 
performed at six timepoints. Body weight, body condition score (BCS), cresty neck score 
(CNS), and hypertrichosis score were evaluated in each horse at 10, 7, and 8 timepoints, 
respectively.  
For the TRH stimulation tests, a blood sample (T0) was collected, 1mg. of TRH 
was administered intravenously, and a second blood sample was collected 10 minutes later 
(T10) 8,9. The TRH (Sigma Aldrich; St. Louis, MO) was prepared aseptically by dissolving 
1 mg. of TRH in 1 mL of sterile saline (0.9% NaCl).  
For OSTs, a blood sample (T0) was collected, Karo® light corn syrup (ACH Food 
Companies Inc, Cordova, TN) was administered orally, and a second blood sample was 
collected 60 minutes later (T60); the corn syrup dose used was 0.15 mL of corn syrup per 
kilogram of body weight with an extra 5 mL included for wastage during administration 87. 
Horses were weighed for accurate dosing of corn syrup using a portable agricultural scale 
within one week prior to the test. 
Regular assessment of BCS 88, CNS89, and hypertrichosis score using a previously 
published method by Schott et al. 90 was completed by three individuals, and the average 
of the three scores was used. The hypertrichosis score range was 0 (normal) to 3 (severe 
coat changes) 90. 
ACTH, insulin, total cortisol concentration, estimated free cortisol concentration, 
and free cortisol fraction (%) were analyzed. For ACTH analysis, blood was collected into 
tubes containing EDTA and kept on ice until processed within 6 hours. For insulin, total 
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cortisol, and free cortisol concentration analyses, blood was collected into tubes with no 
additive and allowed to clot. Plasma and serum were separated by centrifugation at 800g 
for 10 minutes, frozen at -20oC, and sent to Cornell University’s Animal Health Diagnostic 
Center (Ithaca, NY) for analysis by previously validated chemiluminescent assays 
(Immulite, Diagnostics Product Corporation; Los Angeles, CA) for ACTH and total 
cortisol and previously validated radioimmunoassay (EMD Millipore; Billerica, MA) for 
insulin 22,85. Free cortisol concentration and free cortisol fraction were determined using 
the previously published radioactive ligand-binding ultrafiltration assay 91. 
2.3.3 Statistical Methods 
Age, basal ACTH, and basal insulin at Day 0 were summarized with descriptive 
statistics (PROC UNIVARIATE, SAS v9.4). Distributional assumptions were evaluated 
using graphical and numerical summaries for the presence of gross normality violations. 
The primary analyses were the longitudinal analysis of all measures over time; linear mixed 
models included main effects for group and time. The primary comparisons were the PPID 
Treatment to PPID Control groups and the PPID to Non-PPID groups, when the PPID 
groups were combined. To determine if groups changed differently over time, an F-test for 
the interaction of group and time was used. Graphical summaries and model fit were used 
to determine the specifications of the linear mixed model (PROC MIXED, SAS v9.4). To 
account for repeated measures, an ARMA (1,1) variance-covariance structure was used for 
ACTH, ACTH change scores in response to TRH stimulation tests, hypertrichosis scores, 
insulin change scores in response to OSTs, total cortisol, and estimated free cortisol 
concentration. A TOEP variance-covariance structure was used for BCS, CNS, and body 
weight. A TOEPH variance-covariance structure was used for basal insulin and free 
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cortisol fraction (%). All analyses were conducted using SAS v9.4 (Cary, NC), and a two-
sided significance level of .05 was used for all statistical tests. Graphs were created using 
GraphPad Prism v.8.0.2 (San Diego, CA). 
Results for PPID Control and PPID Treatment horses were analyzed first. If 
significant group by time differences were observed, these groups remained separate for 
comparison to Non-PPID horses. If no significant group by time differences were observed, 
the PPID Control and PPID Treatment groups were combined before comparison to Non-
PPID horses. If no significant group or group by time differences were observed between 
the combined PPID group and Non-PPID group, all groups were combined for analysis of 
time effects only. 
If starting differences (P<.1) were observed between PPID Control and PPID 
Treatment horses in the initial analyses, starting values were included as a covariate within 
the model to account for potential confounding. If starting differences (P<.1) were 
observed between PPID and Non-PPID horses, analyses were performed without starting 
values as a covariate within the model, in order to analyze group effects, and then with 
starting values as a covariate, in order to analyze group by time effects; results for each of 
the methods are presented if applicable. 
For dynamic testing (TRH stimulation test and OST), the differences between the 
T0 sample and the second timepoint sample (T10 for TRH stimulation test and T60 for 
OST) were calculated; this is often referred to as the delta ACTH or delta insulin. In 
addition, T0 values were included in the model as a covariate to account for potential 
differences in disease severity. Thus, the dynamic testing results are further reported as 
ACTH or insulin change scores. 
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Pearson correlation coefficients were examined for basal ACTH, basal insulin, total 





Significant group (P=.032), time (P<.0001), and group by time effects (P=.032) 
were seen in ACTH between the PPID Control and PPID Treatment groups. Therefore, the 
groups were kept separate for comparison to Non-PPID horses. Initial analyses of Non-
PPID to PPID Control and PPID Treatment horses showed significant group (P<.01), time 
(P<.0001), and group by time (P<.001) effects (Table 2.3; Figure 2.1A). Between PPID 
Treatment horses and Non-PPID horses, ACTH only differed at Day 0 (Early September 
2017) (P=.012). ACTH was significantly higher in PPID Control horses compared to Non-
PPID horses at eight time points, but was not significantly higher at the Early September 
2017 (P=.059), Early February 2018 (P=.068), Early April 2018 (P=.17), Mid-June 2018 
(P=.16), Early August 2018 (P=.23), and Early September 2018 (P=.12) timepoints. ACTH 
in Non-PPID horses did not differ significantly from their starting ACTH values (Early 
September 2017) at any timepoint. Due to starting differences between PPID Control and 
Non-PPID horses and between PPID Treatment horses and Non-PPID horses, the analyses 
were run again with starting ACTH values (Early September 2017) included as a covariate 
in the model; significant group (P<.001), time (P<.0001), and group by time (P<.001) 
effects  remained. The commonly seen rise in ACTH in the fall season was exaggerated in 
PPID Control horses compared to the Non-PPID and PPID Treatment groups. 
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ACTH change score in response to TRH stimulation test 
Significant time (P<.0001) and group by time (P=.027) effects, but not a group 
effect alone), were seen in ACTH change scores between the PPID Control and PPID 
Treatment groups. PPID Treatment horses had significantly lower change scores in ACTH 
in response to the TRH stimulation test than PPID Control horses at only the Mid-late 
February 2018 timepoint (P=.047). ACTH change scores in PPID Treatment horses were 
comparable to PPID Control horses at the Early April 2018 timepoint (P=.05) and all other 
timepoints (P-value range: .24 - .86) Due to the group by time differences, the PPID 
Control and PPID Treatment horses were kept separate for comparison to Non-PPID 
horses.  
Significant group (P<.0001), time (P<.0001), and group by time (P=.0005) effects 
were seen in ACTH change scores in response to the TRH stimulation test in the PPID 
Control, PPID Treatment, and Non-PPID comparison (Table 2.4; Figure 2.1B). Non-PPID 
horses had significantly lower ACTH change scores at all time points compared to both 
PPID Control and PPID Treatment horses (P<.01). PPID Treatment horses had 
significantly lower ACTH change scores than PPID Control horses at both non-fall 
timepoints (Mid-late February 2018 (P=.016) and Early April 2018 (P=.017)) but did not 
differ at the other timepoints (P-value range: .16 - .82). Significant time effects were seen 
in all groups between the non-fall timepoints (Mid-late February 2018 and Early April 






Significant time (P<.001) and group by time (P=.034) effects were seen in 
hypertrichosis scores between the PPID Control and PPID Treatment groups. However, 
PPID Control and PPID Treatment horses did not differ at any timepoint; the significant 
group by time effects appear to have been driven by the fact that PPID Treatment horses 
started out slightly lower than PPID Controls, although not significantly different, and 
ended the study with slightly higher, but not significantly different, scores than PPID 
Controls. Given the significant group by time effect, the PPID Control and PPID Treatment 
groups were kept separate for comparisons with the Non-PPID group. 
Initial analysis of hypertrichosis scores for the Non-PPID, PPID Control, and PPID 
Treatment horses showed significant group (P<.0001), time (P <.0001), and group by time 
(P =.023) effects (Table 2.5; Figure 2.2). Both PPID groups had significantly higher 
hypertrichosis scores than Non-PPID horses at all timepoints but did not differ significantly 
from each other at any timepoint. Due to starting differences between the groups, the 
analysis was run again with starting hypertrichosis scores as a covariate. The time and 
group by time effects remained significant, suggesting that the groups did in fact change 
over time based on their group status, despite starting differences. However, this still 
appeared to be attributed to the fact that the PPID Treatment horses started lower and ended 
higher than PPID Control horses, even though the PPID groups were not statistically 






No significant group or group by time effects were seen in insulin between any of 
the groups. Significant time effects were observed in the PPID Control to PPID Treatment 
(P<.0001), Non-PPID to all PPID (P<.0001), and all groups combined (P<.0001) 
comparisons. Table 2.6 and Figure 2.3A display results for the Non-PPID to all PPID 
comparison. 
Insulin change score in response to OST 
No significant group, time, or group by time effects were seen in insulin change 
scores in response to an oral sugar test between any of the groups. Table 7 and Figure 3B 
display results for the Non-PPID to all PPID comparison. 
Body Weight 
No significant group or group by time effects were seen in body weight, measured 
in pounds, between the PPID Control and PPID Treatment horses; a significant time effect 
(P<.0001) was seen. After combining these groups for comparison to Non-PPID horses, 
significant group (P=.0033) and time (P<.0001) effects, but not a significant group by time 
effect, were observed with PPID horses weighing significantly less than Non-PPID horses 
at all timepoints (P<.01) (Table 2.8; Figure 2.4A). Due to significant starting differences 
between Non-PPID and PPID horses, the analysis was run again with starting weight as a 
covariate in the model to determine if significant group by time changes were present. This 
subsequent analysis revealed no significant group by time effects; therefore, these groups 




BCS & CNS 
No significant group or group by time effects were seen in BCS between any of the 
groups. Significant time effects in BCS were observed when all PPID horses were 
compared to Non-PPID horses (P<.001) and when all groups were combined (P=.0044). 
Table 9 and Figure 4B display results for the Non-PPID to all PPID comparison. 
No significant group, time, or group by time effects were seen in CNS between any 
of the groups. Table 2.10 and Figure 2.4C display results for the Non-PPID to all PPID 
comparison. 
Total Cortisol 
No significant group or group by time effects were seen in total cortisol 
concentration between any of the groups.  Significant time effects were observed in the 
PPID Control to PPID Treatment (P=.006), Non-PPID to all PPID (P<.0001), and all 
groups combined (P<.0001) comparisons. Table 2.11 and Figure 2.5A display results for 
the Non-PPID to all PPID comparison. 
Free Cortisol 
No significant group or group by time effects were seen in estimated free cortisol 
concentration or free cortisol fraction (%) between any of the groups, but significant time 
effects were observed in all comparisons for both measures (P<.0001). Tables 2.12 and 
2.13 and Figures 2.5B and 2.5C display results for the Non-PPID to all PPID comparison 





No significant correlations were seen between ACTH and insulin, ACTH and total 
cortisol, and ACTH and estimated free cortisol concentration or free cortisol fraction (%). 
Similarly, no significant correlations were observed between insulin and total cortisol and 
insulin and estimated free cortisol concentration or free cortisol fraction (%). Statistically 
significant correlations were seen between estimated free cortisol concentration and both 
total cortisol concentration and free cortisol fraction (%) (r=.77 and r=.62; P<.0001). 
 
2.5 Discussion 
The goal of this study was to evaluate endocrine function (ACTH, basal insulin, 
total and free cortisol) across seasons in horses with and without PPID and the extent to 
which PRASCEND treatment affects these measures in horses with PPID. The lack of 
change in total and free cortisol observed in this study provides evidence that excess ACTH 
generated in horses with PPID may be inactive, which has previously been hypothesized, 
and that PRASCEND treatment successfully reduces ACTH to the level of Non-PPID 
horses regardless of season 92-94. Additionally, the results suggest that PPID and 
hyperinsulinemia and/or insulin dysregulation are likely distinct diseases, and that 
PRASCEND treatment does not impact insulin, total cortisol, or free cortisol. 
To our knowledge, this is the only long-term PRASCEND administration study that 
followed Non-PPID, PPID Control, and PPID Treatment horses from the beginning of one 
fall season until the end of the subsequent fall season, and that used non-client owned 
horses that were all managed in consistent fashion on the same farm. It has been reported 
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extensively that horses experience a seasonal fall rise in ACTH 15,83,95,96. In this study, 
PRASCEND successfully reduced ACTH levels, so that despite statistically significant 
starting ACTH differences in Early September 2017, Non-PPID and PPID Treatment 
horses did not differ in ACTH values after six weeks of treatment (by Mid-October 2017). 
Therefore, despite treatment starting near the beginning of the seasonal fall ACTH rise, 
PRASCEND treatment was able to control ACTH within the fall seasonal rise (by Mid-
October 2017). As seen in the results, the fall rise in ACTH is evident in both Non-PPID 
and PPID horses but is very exaggerated in the PPID Control horses. The results discussed 
earlier showed that ACTH in Non-PPID horses did not differ significantly at any point in 
the study from their starting ACTH values, further supporting the conclusion that the 
seasonal fall rise in ACTH is exaggerated in horses with PPID. This data demonstrates that 
the exaggerated fall ACTH rise in PPID horses can be corrected with PRASCEND 
treatment, in contrast to previous work 41.  
The differences in ACTH change scores in response to the TRH stimulation test 
between PPID Control and PPID Treatment horses suggest that PRASCEND treatment 
may improve responses to the TRH stimulation at non-fall timepoints but does not reduce 
ACTH change scores to the level of a Non-PPID horse. Additionally, the ACTH change 
scores in response to TRH stimulation tests demonstrate clear temporal differences in both 
Non-PPID and PPID horses between non-fall and fall timepoints. Currently, veterinarians 
are encouraged to monitor basal ACTH to evaluate responses to PRASCEND dose and 
treatment 9. The results of this study also suggest that monitoring of basal ACTH appears 
most appropriate for the assessment of responses to PRASCEND treatment.  
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While the ability to see differences between PPID and Non-PPID hypertrichosis 
scores was clear, the significant differences seen between PPID Control and PPID 
Treatment horses are difficult to interpret. Horses were scored at each timepoint, which 
might have led to high levels of inter-timepoint variation, potentially masking differences. 
Additionally, the scoring scale may not have been detailed enough to determine differences 
within the PPID groups but was sensitive enough to detect Non-PPID to PPID differences. 
For management purposes, some animals had to be body-clipped. While scorers were 
notified if a horse was body-clipped, this may also have impacted results by preventing 
differentiation between higher scores (i.e. difficult to determine whether a horse would 
have been 2 or 3 on the scoring scale before body-clipping). Anecdotally, improvement in 
hypertrichosis is commonly reported with PRASCEND treatment; therefore, the authors 
present these results to show that haircoat differences indeed existed between the Non-
PPID and PPID horses but are unable to make conclusions on the efficacy of PRASCEND 
at improving hypertrichosis in horses with PPID. 
The similarities in insulin and insulin change scores in response to OSTs between 
all three groups, along with the lack of correlation seen between ACTH and insulin in this 
study, support the idea that insulin dysregulation and PPID are distinct endocrine diseases 
or conditions, rather than PPID horses being pre-disposed to hyperinsulinemia and/or 
insulin dysregulation. Additionally, in this study, PRASCEND treatment did not influence 
basal insulin or insulin change scores in response to OSTs. However, the authors caution 




The lack of changes in BCS and CNS demonstrate that these measures were 
consistent throughout the study and were not confounding variables in the analysis of basal 
insulin values or insulin change scores in response to OSTs; this also verifies that 
PRASCEND treatment did not lead to changes in BCS or CNS. The significant difference 
in weight between PPID and Non-PPID horses is consistent with common clinical signs in 
horses with PPID 9, and the lack of weight change over time shows that body weight was 
also not influencing changes in insulin values. 
Due to increased ACTH concentrations in horses with PPID, it has frequently been 
assumed that cortisol levels are affected downstream, following normal hypothalamus-
pituitary-adrenal (HPA) axis physiology. A recent publication examined free cortisol in 
horses with PPID and found no difference in free cortisol but found altered total urinary 
cortisol 25. An additional study also previously examined the effects of PPID on total and 
free cortisol and found no differences in total cortisol, but significantly higher free cortisol 
fraction in PPID horses compared to age and season-matched control animals 22. To our 
knowledge, no studies have evaluated the effects of PRASCEND on total or free cortisol. 
The study described in this manuscript expands upon previous works by confirming PPID 
status in all subjects via the currently recommended dynamic TRH stimulation testing and 
by sampling the same animals over time, at the same timepoints, to account for seasonal 
and individual animal differences 8,9. The results from this study both support and 
contradict previously published work, as they support the hypothesis that total and free 
cortisol are not affected by PPID. Additionally, total and free cortisol do not appear to be 
affected by PRASCEND treatment. Significant time effects in both total and free cortisol 
suggest that normal temporal changes are present in both Non-PPID and PPID horses, 
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making it crucial that further work in this area include control animals for each timepoint 
and avoid comparisons between samples collected at separate points in time. 
Furthermore, the lack of association between cortisol and ACTH supports earlier 
work hypothesizing that excess ACTH generated as a result of PPID may be inactive or 
incapable of prompting normal HPA axis responses 92-94. This would explain why increased 
free and total cortisol is not seen in the plasma of PPID horses, despite their increased 
ACTH concentrations, and why PRASCEND treatment can reduce ACTH without 
impacting total or free cortisol. Since cortisol levels did not correlate with ACTH or change 
in response to PPID status or with PRASCEND treatment, it is likely that the excess ACTH 
is inactive, potentially due to its aberrant production in the pars intermedia of the pituitary 
5,92,94. However, this also raises additional questions on how and where the excess ACTH 
seen in horses with PPID is contributing to the disease process. 
In summary, neither PPID nor treatment with PRASCEND influenced insulin, total 
cortisol, or free cortisol in the horses in this study. PRASCEND treatment successfully 
reduced basal ACTH but was limited in its ability to reduce ACTH change scores to TRH 
stimulation tests. Therefore, we suggest that current recommendations that veterinarians 
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Table 2.1 Age, basal ACTH, and basal insulin at Day 0 (Early September 2017). 
PPID-pituitary pars intermedia dysfunction. 
Group Number 
in group 










































Table 2.2. Sex and breed representation at Day 0 (Early September 2017). 
PPID-pituitary pars intermedia dysfunction. 






















Quarter Horse (n=2) 
Thoroughbred (n=4) 
Standardbred (n=1) 
Tennessee Walking Horse (n=1) 








Quarter Horse (n=1) 
Thoroughbred (n=4) 
Standardbred cross (n=1) 
Mustang (n=1) 
Appaloosa (n=1) 

















Table 2.3. Basal ACTH (pg/mL): Least squares mean and standard error values. 
At Day 0 (Early September 2017), there were 10, 9, and 9 horses in the Non-PPID, PPID 
Control, and PPID Treatment groups, respectively. By the end of the study, there were 9, 
7, and 6 horses in the Non-PPID, PPID Control, and PPID Treatment groups, respectively. 
* denotes a significant difference (P<.05) between Non-PPID and PPID Control.  denotes 
a significant difference (P<.05) between Non-PPID and PPID Treatment. # denotes a 
significant difference (P<.05) between PPID Treatment and PPID Control groups. PPID-










Non-PPID Early September 2017 54.62 51.7849   
Non-PPID Mid-October 2017 43.55 51.7849   
Non-PPID Early November 2017 33.39 51.7849   
Non-PPID Early February 2018 22.51 51.7849   
Non-PPID Early April 2018 19.2652 53.4461   
Non-PPID Mid-June 2018 24.7312 53.4875   
Non-PPID Early August 2018 50.0875 53.963   
Non-PPID Mid-late August 2018 38.8408 53.5399   
Non-PPID Early September 2018 56.2866 53.7659   
Non-PPID Mid-September 2018 58.3969 53.7204   
Non-PPID Early October 2018 92.6605 53.9811   
Non-PPID Mid-October 2018 45.0534 53.9503   
Non-PPID Late October 2018 34.3335 53.582   
Non-PPID Mid-November 2018 27.3273 53.9257   
PPID Control Early September 2017 197.33 54.5861   
PPID Control Mid-October 2017 268.51 54.5861 * 
PPID Control Early November 2017 227.31 54.5861 * 
PPID Control Early February 2018 160.64 54.5861   
PPID Control Early April 2018 124.36 54.5861   
PPID Control Mid-June 2018 136.96 58.9986   
PPID Control Early August 2018 146.44 60.207   
PPID Control Mid-late August 2018 317.55 59.1067 * 
PPID Control Early September 2018 179.98 59.3118   
PPID Control Mid-September 2018 273.37 58.0757 * 
PPID Control Early October 2018 429.49 59.8308 * 
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PPID Control Mid-October 2018 366.04 60.234 * 
PPID Control Late October 2018 223.96 59.1864 * 
PPID Control Mid-November 2018 284.14 60.2105 * 
PPID Treatment Early September 2017 244.44 54.5861 ‡ 
PPID Treatment Mid-October 2017 62.9556 54.5861 # 
PPID Treatment Early November 2017 50.5 54.5861 # 
PPID Treatment Early February 2018 50.5553 57.0457   
PPID Treatment Early April 2018 50.9431 58.9962   
PPID Treatment Mid-June 2018 54.6641 62.294   
PPID Treatment Early August 2018 83.4889 64.2716   
PPID Treatment Mid-late August 2018 87.7006 62.3966 # 
PPID Treatment Early September 2018 98.4636 63.1949   
PPID Treatment Mid-September 2018 100.65 62.5643 # 
PPID Treatment Early October 2018 97.4923 64.0234 # 
PPID Treatment Mid-October 2018 61.8212 64.1921 # 
PPID Treatment Late October 2018 68.6374 62.8891   






























Table 2.4. ACTH (pg/mL) change score (in response to thyrotropin-releasing hormone 
(TRH) stimulation test): Least squares mean and standard error values.  
At Day 0 (Early September 2017), there were 10, 9, and 9 horses in the Non-PPID, PPID 
Control, and PPID Treatment groups, respectively. By the end of the study, there were 9, 
7, and 6 horses in the Non-PPID, PPID Control, and PPID Treatment groups, respectively. 
* denotes a significant difference (P<.05) between Non-PPID and PPID Control.  denotes 
a significant difference (P<.05) between Non-PPID and PPID Treatment. # denotes a 
significant difference (P<.05) between PPID Treatment and PPID Control groups. PPID-









Non-PPID Late August 2017 165.1 78.7565   
Non-PPID Early-mid November 2017 186.91 79.0622   
Non-PPID Mid-late February 2018 -25.0414 80.8563   
Non-PPID Early April 2018 -46.0584 80.9273   
Non-PPID Early-mid September 2018 174.41 80.4203   
Non-PPID Mid-October 2018 215.97 80.6503   
PPID Control Late August 2017 925 88.4257 * 
PPID Control Early-mid November 2017 921.01 82.8611 * 
PPID Control Mid-late February 2018 733.12 82.8638 * 
PPID Control Early April 2018 563.57 82.7348 * 
PPID Control Early-mid September 2018 912.76 87.6444 * 
PPID Control Mid-October 2018 919.43 88.3016 * 
PPID Treatment Late August 2017 951.51 85.4795 
PPID Treatment Early-mid November 2017 755.41 82.9373 
PPID Treatment Mid-late February 2018 441.72 84.9901 
PPID Treatment Early April 2018 272.84 87.4494 
PPID Treatment Early-mid September 2018 871.7 89.9972 




Table 2.5. Hypertrichosis score: Least squares mean and standard error values.  
At Day 0 (Early September 2017), there were 10, 9, and 9 horses in the Non-PPID, PPID 
Control, and PPID Treatment groups, respectively. By the end of the study, there were 9, 
7, and 6 horses in the Non-PPID, PPID Control, and PPID Treatment groups, respectively. 
* denotes a significant difference (P<.05) between Non-PPID and PPID Control.  denotes 
a significant difference (P<.05) between Non-PPID and PPID Treatment. # denotes a 
significant difference (P<.05) between PPID Treatment and PPID Control groups. PPID-









Non-PPID Early October 2017 0.05 0.2101   
Non-PPID Early-mid November 2017 0.0167 0.2101   
Non-PPID Mid-February 2018 0.3667 0.2101   
Non-PPID Early April 2018 0.5281 0.2132   
Non-PPID Late May 2018 0.2685 0.2132   
Non-PPID Late June 2018 0.2779 0.2132   
Non-PPID Early August 2018 0.09293 0.2132   
Non-PPID Mid-October 2018 0.2501 0.2132   
PPID Control Early October 2017 1.2222 0.2215 * 
PPID Control Early-mid November 2017 1.0184 0.2215 * 
PPID Control Mid-February 2018 1.7593 0.2215 * 
PPID Control Early April 2018 1.5 0.2215 * 
PPID Control Late May 2018 1.1845 0.2293 * 
PPID Control Late June 2018 1.5181 0.2292 * 
PPID Control Early August 2018 1.3993 0.2292 * 
PPID Control Mid-October 2018 1.2793 0.2294 * 
PPID Treatment Early October 2017 1.7963 0.2215 
PPID Treatment Early-mid November 2017 1.6111 0.2215 
PPID Treatment Mid-February 2018 1.8891 0.2255 
PPID Treatment Early April 2018 1.9223 0.2301 
PPID Treatment Late May 2018 1.5896 0.2301 
PPID Treatment Late June 2018 1.438 0.2355 
PPID Treatment Early August 2018 1.3398 0.2355 
PPID Treatment Mid-October 2018 1.7856 0.2356 
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Table 2.6. Basal insulin (uIU/mL): Least squares mean and standard error values.  
At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 
horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID 







Non-PPID Early September 2017 27.562 6.1047 
Non-PPID Mid-October 2017 21.668 5.148 
Non-PPID Early November 2017 18.555 3.1995 
Non-PPID Early February 2018 22.686 6.1181 
Non-PPID Early April 2018 18.09 12.3466 
Non-PPID Mid-June 2018 26.1476 21.129 
Non-PPID Early August 2018 16.0345 8.518 
Non-PPID Mid-late August 2018 13.7838 3.9131 
Non-PPID Early September 2018 14.738 2.7366 
Non-PPID Mid-September 2018 13.7832 4.1685 
Non-PPID Early October 2018 19.3905 3.7686 
Non-PPID Mid-October 2018 16.7949 5.1729 
Non-PPID Late October 2018 11.8217 4.7314 
Non-PPID Mid-November 2018 15.1288 2.1761 
PPID Early September 2017 39.6922 4.5502 
PPID Mid-October 2017 22.0261 3.8371 
PPID Early November 2017 16.1183 2.3848 
PPID Early February 2018 28.0769 4.6561 
PPID Early April 2018 32.6302 9.2488 
PPID Mid-June 2018 48.3645 17.0531 
PPID Early August 2018 28.2703 6.912 
PPID Mid-late August 2018 20.602 3.1713 
PPID Early September 2018 19.2748 2.2252 
PPID Mid-September 2018 20.4193 3.2397 
PPID Early October 2018 24.0439 3.0508 
PPID Mid-October 2018 24.8148 4.1992 
PPID Late October 2018 23.9773 3.7735 




Table 2.7. Insulin (uIU/mL) change score (in response to oral sugar test (OST)): Least 
squares mean and standard error values.  
At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 
horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID 








Non-PPID Late August 2017 16.7213 5.6309 
Non-PPID Early-mid November 2017 24.0003 5.6245 
Non-PPID Mid-late February 2018 24.2892 5.6205 
Non-PPID Early April 2018 18.9912 5.9202 
Non-PPID Early-mid September 2018 24.7916 5.9506 
Non-PPID Mid-October 2018 23.127 5.9764 
PPID Late August 2017 19.1173 4.2651 
PPID Early-mid November 2017 22.9834 4.2059 
PPID Mid-late February 2018 23.291 4.312 
PPID Early April 2018 20.1876 4.5514 
PPID Early-mid September 2018 29.0158 4.9258 





Table 2.8. Body weight (lbs): Least squares mean and standard error values. 
At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 
horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID 










Non-PPID Early September 2017 1283.1 40.8431   
Non-PPID Mid-October 2017 1280.1 40.8431   
Non-PPID Early November 2017 1257.5 40.8431   
Non-PPID Early-mid February 2018 1254.3 40.8431   
Non-PPID Early April 2018 1227.51 40.957   
Non-PPID Late May 2018 1264.4 41.0115   
Non-PPID Late June 2018 1268.83 41.0544   
Non-PPID Early August 2018 1234.07 41.1056   
Non-PPID Early September 2018 1201.54 41.0723   
Non-PPID Mid-October 2018 1204.78 41.092   
PPID Early September 2017 1125.28 30.4427 * 
PPID Mid-October 2017 1108.78 30.4427 * 
PPID Early November 2017 1080.39 30.4427 * 
PPID Early-mid February 2018 1101.1 30.5136 * 
PPID Early April 2018 1077.51 30.5596 * 
PPID Late May 2018 1095.19 30.765 * 
PPID Late June 2018 1089.8 30.9197 * 
PPID Early August 2018 1088.04 31.0069 * 
PPID Early September 2018 1059.21 30.9735 * 






Table 2.9. Body Condition Score: Least squares mean and standard error values.  
At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 
horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID 







Non-PPID Early-mid September 2017 5.4867 0.2276 
Non-PPID Early-mid November 2017 5.3567 0.2276 
Non-PPID Mid-February 2018 5.0602 0.2276 
Non-PPID Early April 2018 5.1739 0.2304 
Non-PPID Late May 2018 5.5591 0.2319 
Non-PPID Early August 2018 5.07 0.2322 
Non-PPID Mid-October 2018 4.9013 0.2315 
PPID Early-mid September 2017 5.063 0.1696 
PPID Early-mid November 2017 4.9298 0.1696 
PPID Mid-February 2018 4.9528 0.1714 
PPID Early April 2018 4.9623 0.1726 
PPID Late May 2018 4.9954 0.178 
PPID Early August 2018 4.9454 0.1804 









Table 2.10. Cresty Neck Score: Least squares mean and standard error values.  
At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 
horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID 








Non-PPID Early-mid September 2017 1.35 0.23 
Non-PPID Early-mid November 2017 1.2 0.23 
Non-PPID Mid-February 2018 1.1332 0.23 
Non-PPID Early April 2018 1.1502 0.2328 
Non-PPID Late May 2018 1.3776 0.2346 
Non-PPID Early August 2018 1.1727 0.2345 
Non-PPID Mid-October 2018 1.2824 0.2335 
PPID Early-mid September 2017 1.4815 0.1715 
PPID Early-mid November 2017 1.3888 0.1715 
PPID Mid-February 2018 1.3602 0.1729 
PPID Early April 2018 1.2656 0.1741 
PPID Late May 2018 1.4461 0.18 
PPID Early August 2018 1.4305 0.182 








Table 2.11. Total Cortisol (ug/dL): Least squares mean and standard error values.  
At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 
horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID 








Non-PPID Early September 2017 3.857 0.4415 
Non-PPID Mid-October 2017 4.453 0.4415 
Non-PPID Early November 2017 3.877 0.4415 
Non-PPID Early February 2018 4.13 0.4415 
Non-PPID Early April 2018 3.8458 0.4526 
Non-PPID Mid-June 2018 5.0622 0.4525 
Non-PPID Mid-September 2018 3.6702 0.4529 
Non-PPID Early October 2018 3.6504 0.4524 
Non-PPID Mid-October 2018 4.6622 0.4528 
Non-PPID Late October 2018 3.4502 0.4524 
PPID Early September 2017 4.2078 0.329 
PPID Mid-October 2017 3.9567 0.329 
PPID Early November 2017 3.6839 0.329 
PPID Early February 2018 3.6883 0.3337 
PPID Early April 2018 4.5759 0.3386 
PPID Mid-June 2018 4.7303 0.3565 
PPID Mid-September 2018 4.1113 0.3575 
PPID Early October 2018 3.8601 0.3561 
PPID Mid-October 2018 4.4507 0.3571 







Table 2.12. Estimated Free Cortisol Concentration (ug/dL): Least squares mean and 
standard error values.  
At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 
horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID 







Non-PPID Early September 2017 0.2144 0.03755 
Non-PPID Mid-October 2017 0.2382 0.03755 
Non-PPID Early November 2017 0.217 0.03755 
Non-PPID Early February 2018 0.2744 0.03755 
Non-PPID Early April 2018 0.2115 0.03905 
Non-PPID Mid-June 2018 0.3463 0.03905 
Non-PPID Mid-September 2018 0.2799 0.03907 
Non-PPID Early October 2018 0.2827 0.03904 
Non-PPID Mid-October 2018 0.3093 0.03906 
Non-PPID Late October 2018 0.2577 0.03904 
PPID Early September 2017 0.2544 0.02799 
PPID Mid-October 2017 0.2389 0.02799 
PPID Early November 2017 0.1964 0.02799 
PPID Early February 2018 0.2165 0.0286 
PPID Early April 2018 0.2985 0.02927 
PPID Mid-June 2018 0.3886 0.03166 
PPID Mid-September 2018 0.325 0.03172 
PPID Early October 2018 0.3229 0.03164 
PPID Mid-October 2018 0.3315 0.03169 







Table 2.13. Free Cortisol Fraction (%): Least squares mean and standard error values.  
At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 
horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID 







Non-PPID Early September 2017 5.5754 0.6839 
Non-PPID Mid-October 2017 5.349 1.0727 
Non-PPID Early November 2017 5.4958 0.4062 
Non-PPID Early February 2018 6.4789 0.6326 
Non-PPID Early April 2018 5.3631 0.5613 
Non-PPID Mid-June 2018 6.9072 0.3034 
Non-PPID Mid-September 2018 7.5914 0.3131 
Non-PPID Early October 2018 7.7452 0.6856 
Non-PPID Mid-October 2018 6.7057 0.3545 
Non-PPID Late October 2018 7.4663 0.3258 
PPID Early September 2017 6.1802 0.5097 
PPID Mid-October 2017 6.3086 0.7995 
PPID Early November 2017 5.4835 0.3027 
PPID Early February 2018 5.9078 0.4846 
PPID Early April 2018 6.0496 0.421 
PPID Mid-June 2018 8.0187 0.2508 
PPID Mid-September 2018 7.8824 0.256 
PPID Early October 2018 8.4763 0.5669 
PPID Mid-October 2018 7.3311 0.2933 















Figure 2.1. (A) Basal ACTH and (B) ACTH change scores (TRH stimulation test) 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID Treatment (PRASCEND) horses are 
represented by lines with closed triangles. PPID Control horses are represented by lines with closed squares. At Day 0 (Early 
September 2017), there were 10, 9, and 9 horses in the Non-PPID, PPID Control, and PPID Treatment groups, respectively. By 
the end of the study, there were 9, 7, and 6 horses in the Non-PPID, PPID Control, and PPID Treatment groups, respectively. * 
denotes a significant difference (P<.05) between Non-PPID and PPID Control.  ‡ denotes a significant difference (P<.05) 
between Non-PPID and PPID Treatment. # denotes a significant difference (P<.05) between PPID Treatment and PPID Control 

















































































Figure 2.2. Hypertrichosis scores 
(Mean +/- SEM). Non-PPID horses are represented by lines with closed circles. PPID 
Treatment (PRASCEND) horses are represented by lines with closed triangles. PPID 
Control horses are represented by lines with closed squares. At Day 0 (Early September 
2017), there were 10, 9, and 9 horses in the Non-PPID, PPID Control, and PPID Treatment 
groups, respectively. By the end of the study, there were 9, 7, and 6 horses in the Non-
PPID, PPID Control, and PPID Treatment groups, respectively. * denotes a significant 
difference (P<.05) between Non-PPID and PPID Control. ‡ denotes a significant difference 
(P<.05) between Non-PPID and PPID Treatment. PPID-pituitary pars intermedia 






Figure 2.3 (A) Basal Insulin and (B) Insulin change scores (OST) 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses are represented by lines with open 
squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 horses in the PPID group. By 
the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID group. OST- oral sugar test; PPID-








Figure 2.4. (A) Body Weight, (B) body condition score, and (C) cresty neck score 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses are represented by lines with open squares. 
At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 horses in the PPID group. By the end of the 
study, there were 9 horses in the Non-PPID group and 13 horses in the PPID group. * denotes a significant difference (P<.01) between 






Figure 2.5. (A) Total Cortisol, (B) Estimated Free Cortisol Concentration, (C) Serum Free Cortisol Fraction 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses are represented by lines with open squares. 
At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 horses in the PPID group. By the end of the 




CHAPTER 3. EFFECTS OF PITUITARY PARS INTERMEDIA DYSFUNCTION AND 
PRASCEND® TREATMENT ON SYSTEMIC IMMUNE FUNCTION IN HORSES 
3.1 Abstract 
Background: It remains unclear how Pituitary Pars Intermedia Dysfunction (PPID) and 
treatment with Prascend® (pergolide tablets) affect systemic immune function in horses. 
Animals: 28 horses from a research herd (10 Non-PPID, 9 untreated PPID (PPID Control), 
and 9 PRASCEND-treated PPID horses (PPID Treatment)) were used. 
Hypotheses: Our hypotheses were that PPID horses would have altered immune function 
compared to Non-PPID horses, and that after treatment with PRASCEND, immune 
function in PPID Treatment horses would normalize to that of the Non-PPID horses. 
Methods: Horses were sampled over approximately fifteen months for analysis of complete 
blood counts, plasma myeloperoxidase, basal whole blood cytokine and receptor gene 
expression, in vitro whole blood stimulations for cytokine and receptor gene expression 
and in vitro stimulated peripheral blood mononuclear cell (PBMC) stimulations for 
cytokine and receptor gene expression. For all in vitro stimulations, heat-inactivated 
Rhodococcus equi, heat-inactivated Escherichia coli, and phorbal 12-myristate 13-acetate 
(PMA)/ionomycin were used. PRASCEND treatment was initiated after Day 0 collections. 
Results were analyzed using a linear mixed model (SAS v9.4), with significance set at 
P<.05. 
Results: PPID horses had decreased white blood cell (WBC) counts, decreased absolute 
lymphocyte counts, and decreased red blood cell counts compared to Non-PPID horses. In 
whole blood (Tempus™) samples, PPID horses had increased expression of IL-8 at the 
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Early September 2017, Early April 2018, and Mid-October 2018 timepoints. In the whole 
blood stimulations, a decrease in IL-8 expression to R. equi stimulation was also seen at 
the Early November 2017 timepoint, and a decrease in IL-6 expression to R. equi 
stimulation was observed at the Early September 2017 and Early November 2017 
timepoints in PPID horses. Compared to Non-PPID horses, PPID horses had lower TLR4 
expression in unstimulated whole blood at the Mid-October 2017 timepoint, higher TLR4 
expression in R. equi-stimulated whole blood at the Mid-October 2017 and Early 
November 2017 timepoints, and greater TGFβ expression in unstimulated whole blood at 
the Early September 2017 timepoint. PPID horses displayed decreased IFNγ production 
from PBMCs in response to stimulation with R. equi and E. coli. Additionally, in response 
to E. coli stimulation, PPID horses displayed increased TGFβ expression. Compared to 
PPID Treatment horses, PPID Control horses had greater IL-13 expression in unstimulated 
whole blood at the Mid-October 2017 timepoint only. PPID Treatment horses also had 
greater IL-17α expression from PBMCs in response to R. equi than both PPID Control and 
Non-PPID horses at the Early February 2018 timepoint only.  
Conclusions: Overall, the most striking and temporally consistent results were the 
decreases in absolute lymphocyte and red blood counts, as well as the decreased IFNγ 
production from PBMCs in PPID horses after in vitro stimulation to R. equi and E. coli and 
the increased TGFβ production from PBMCs in PPID horses after E. coli stimulation 
compared to Non-PPID horses. Treatment with PRASCEND did not seem to influence 





Due to their increased plasma ACTH concentrations, PPID horses are often thought 
to be immunosuppressed compared to Non-PPID horses 7,48. The normal hypothalamus-
pituitary-adrenal axis responses to increased ACTH concentrations dictate that cortisol, 
which is known to impact immune function in many species, should also be increased 18,19. 
Therefore, while it is commonly stated that horses with PPID have altered immune 
responses and clinically appear to have more frequent infections than Non-PPID horses, 
research in this area is currently rather sparse. In the available published research, some 
differences in immune function in PPID horses have been described; however, the 
mechanisms behind any potential differences in the immune function of PPID horses are 
unclear. Additionally, while daily treatment with Prascend® (pergolide tablets) 
(Boehringer-Ingelheim Animal Health; Duluth, GA) is currently the preferred treatment 
option for PPID, it is not known whether it influences immune function.  
In animals with decreased immune function, opportunistic infections are often noted, 
and can result in severe disease. Infection with R. equi, a gram-positive bacterium, and E. 
coli, a gram-negative bacterium, are generally considered opportunistic infections in adult 
horses, and thus were selected for in vitro stimulations in this work to aid in the evaluation 
of the immune response in PPID horses 59,65-67. Our hypothesis was that PPID horses would 
have altered immune function, both basally and in response to in vitro stimuli, compared 
to Non-PPID horses, and that PRASCEND treatment would normalize the immune 
function in PPID Treatment horses. To analyze this, complete blood counts, basal whole 
blood cytokine and receptor expression, and peripheral blood mononuclear cell (PBMC) 
and whole blood responses to in vitro stimulation with heat-inactivated R. equi, heat-
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inactivated E. coli, and phorbal 12-myristate 13-acetate (PMA)/ionomycin were measured. 
Additionally, based on published work by McFarlane et al. indicating that PPID horses had 
decreased oxidative burst in neutrophils, basal plasma myeloperoxidase (MPO), a marker 
of neutrophil degranulation, was measured 48. 
 
3.3 Materials and Methods 
 
3.3.1 Animal Selection and Study Design 
Horses were initially selected for potential inclusion in the study from a university-
owned research herd based on prior screenings and clinical history (absence or presence of 
hypertrichosis and/or absence or presence of history of hypertrichosis/difficulty shedding 
and/or results of multiple TRH stimulation tests). PPID status was confirmed using ACTH 
responses to TRH stimulation tests approximately two weeks prior to Day 0 of the study 
(Early September 2017) and basal ACTH values on Day 0. An oral sugar test (OST) was 
also performed prior to the study, approximately one week after the TRH stimulation test, 
to assess hyperinsulinemia or insulin dysregulation status 87. Horses that did not screen as 
either Non-PPID or PPID for both the TRH stimulation test and basal ACTH screenings 
were excluded from the study.  As these initial screenings were obtained during the fall 
season in the USA (late August and early September), a basal ACTH value of ≥100pg/mL 
and ACTH 10 minutes post-TRH injection (T10) value of ≥400pg/mL were used for 
selection into the PPID group 8,9.  
Thirty-one horses were originally selected to proceed through the study. However, 
three horses assigned to the PRASCEND-treated group had ACTH values that failed to 
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become controlled and remained uncontrolled throughout the study; these horses were 
excluded from all analyses and are not discussed further. Non-PPID horses (n=10) were all 
assigned into one group. An attempt was made to randomly assign the PPID horses into 
the untreated and treated groups, however, due to also attempting to block for insulin status, 
true randomization was not possible. PPID Control horses (n=9) remained untreated for 
the duration of the study, and PPID Treatment horses (n=9) began receiving PRASCEND 
within approximately 24 hours of their completion of all Day 0 sample collections. Horses 
were started at the lowest label dose (2 μg/kg) to the nearest half-tablet for their body 
weight, based on the manufacturer’s label recommendations. Basal ACTH was checked 
weekly for the first 4 weeks, and the dose was increased each week until basal ACTH levels 
were reduced to controlled (Non-PPID) values or until the maximum label dose (4 μg/kg) 
to the nearest half-tablet was reached.  
Throughout the approximately 15-month study, six horses were euthanized due to 
non-study related health issues. The study ended with 9, 7, and 6 horses in the Non-PPID, 
PPID Control, and PPID Treatment groups, respectively. At the start of the study, there 
was no statistical difference in age between the groups (P=.1747) (Table 2.1). Age ranges 
were 20-29 years for Non-PPID horses, 21-31 years for PPID Control horses, and 19-29 
years for PPID Treatment horses. Only mares and geldings were included (Table 2.2). 
Breed representations, either confirmed or to the best of the researchers’ knowledge, 
included Thoroughbred (n=14), American Quarter Horse (n=4), Standardbred (n=1), 
Standardbred cross (n=1), Mustang (n=1), Paint (n=1), Arabian (n=1), Tennessee Walking 
Horse (n=1), Appaloosa (n=1), and unknown or mixed breed (n=3) horses (Table 2.2). 
Breakdowns of sex and breed by group are included in Table 2.2. All horses were cared for 
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and sampled with approval of the University of Kentucky’s Institutional Animal Use and 
Care Committee (IACUC) (#2014-1225 and #2018-3004). 
3.3.2 Sampling 
On sampling days, horses were grain fasted (if part of their normal ration) until all 
collections were completed. At six main timepoints (Early September 2017, Mid-October 
2017, Early November 2017, Early February 2018, Early April 2018, and Mid-October 
2018), resting blood samples were collected aseptically via jugular venipuncture within a 
four-hour window during morning hours (approximately 08:00 to 12:00) for systemic 
immune measures. This allowed for sampling and analyses for short PRASCEND 
treatment time periods (6 weeks and 8 weeks), and longer PRASCEND treatment time 
periods, as well as analyses of PPID effects within different seasons. Summer samples were 
not collected to avoid sampling during the seasonal fall rise in ACTH. At each timepoint, 
all blood samples were collected over a period of 1-4 days, but within the same time 
window above (08:00 to 12:00); when multiple days were needed to complete all of the 
collections, a mixture of horses from the three groups were screened each day. The 
systemic immune function measures investigated at the six main time points include 
complete blood counts (CBCs), plasma myeloperoxidase (MPO) analysis, and 
cytokine/receptor gene expression analysis of unstimulated whole blood and stimulated 
peripheral blood mononuclear cells (PBMCs). Stimulated whole blood cytokine and gene 
expression analyses were performed at the first three timepoints only (Early September 
2017, Mid-October 2017, Early November 2017). Rectal temperature, pulse, and 





Complete blood counts: 
Complete blood counts and fibrinogen analyses were performed by the laboratory 
at Rood and Riddle Equine Hospital (Lexington, Kentucky) using a Beckman Coulter AcT 
diff and refractometer, respectively. 
Plasma myeloperoxidase (MPO): 
Myeloperoxidase is considered a marker for neutrophil degranulation. For plasma 
MPO analysis, blood was collected into tubes containing EDTA and placed on ice. Within 
six hours of collection, plasma was separated by centrifugation at 800g for 10 minutes and 
frozen at -20oC until used for a previously-validated equine MPO enzyme-linked 
immunosorbent assay (ELISA) 97. Plasma was diluted 1:100 in phosphate-buffered saline 
(PBS) (Gibco™; Life Technologies) for the assay and absorbance was read at 450nm, as 
recommended by the manufacturer. 
Whole blood (Tempus™) cytokine and receptor gene expression 
Whole blood was collected directly from each horse into Tempus™ Blood RNA 
tubes. This allowed for analysis of circulating cytokine and receptor gene expression with 
immediate RNA stabilization as opposed to the other stimulations, which were either 
processed and frozen prior to stimulation (PBMC stimulations) or had longer incubation 
times after blood collection (whole blood stimulations). The blood tubes were stored at 
room temperature until approximately 24 hours after collection, at which point they were 
frozen at -20oC until further processed. RNA was isolated using the iPrep PureLink system 
and stored at -80oC until reverse transcribed (described below). Gene expression of IFNγ, 
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IL-12α, IL-13, IL-17α, IL-1β, IL-6, IL-8, TGFβ, TNFα, TLR2, and TLR4 was then 
measured using RT-PCR (described below).  
PBMC (unstimulated and stimulated) cytokine and receptor gene expression 
Blood was collected into sodium heparin tubes for isolation of PBMCs using a 
Ficoll® (GE Healthcare) density gradient. After isolation, the cells were washed twice with 
phosphate-buffered saline (PBS) and frozen in freeze media (50% HyClone™ RPMI 1640 
media (GE Healthcare), 40% fetal bovine serum (Sigma Aldrich; St. Louis, MO), and 10% 
dimethyl sulfoxide (DMSO) (Sigma Aldrich)) at -80°C , and transferred to liquid nitrogen 
after at least 24 hours in the -80°C until they were needed for further analyses. 
After thawing the PBMCs and resuspending in complete RPMI (96.4% HyClone™ 
RPMI 1640 media (GE Healthcare), 2.5% fetal equine serum, 1% penicillin, streptomycin, 
L-Glutamine solution (Sigma Aldrich), and 0.1% 2-mercaptoethanol (Gibco™)), the cells 
were counted using a Vi-CELL counter (Beckman Coulter; Indianapolis, Indiana), and 
plated at 4x106 cells per well into a total of four wells of a cell culture plate. For the six 
main sampling timepoints, each horse had four cell stimulations. One well remained 
unstimulated, while one well was stimulated with heat-inactivated Rhodococcus equi 103+ 
(107 colony-forming units (CFU) in 10 μL of complete RPMI) for 24 hours, one well was 
stimulated with heat-inactivated Escherichia coli (ATCC #35218) (107 CFU in 10 μL of 
complete RPMI) for 24 hours, and one well was stimulated with 10 μL phorbal 12-
myristate 13-acetate (PMA)/ionomycin for the last four hours of the incubation. A dose 
response pilot study was conducted in advance to determine the best dose for each of the 
bacteria used in the stimulations that would elicit a sub-maximal response. The cells were 
incubated at 37°C with 5% CO2 after plating and bacterial stimulations. Brefeldin A was 
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added to all wells after 20 hours of incubation. After 24 hours, approximately half of the 
cells were removed, and TRIzol™ (Invitrogen™) was added. These samples were stored at 
-80°C until RNA was isolated via phenol-chloroform extraction. After RNA isolation, the 
samples were placed back in the -80°C freezer until reverse transcribed (described below).  
Gene expression of IFNγ, IL-1β, IL-6, IL-8, IL-10, IL-17α, IL-12α, IL-13, TGFβ, TNFα, 
and TLR4 was then measured using RT-PCR (described below). 
Stimulated whole blood cytokine and receptor gene expression 
At the first three timepoints only, (Early September 2017, Mid-October 2017, Early 
November 2017), whole blood was collected into several 3 mL sodium heparin tubes. For 
each horse, one tube remained unstimulated (nothing added), one was stimulated with heat-
inactivated R. equi suspended in PBS (106 CFU per mL of blood), one was stimulated with 
heat-inactivated E. coli suspended in PBS (107 CFU per mL of blood), and one was 
stimulated with PMA/ionomycin (10 μL per mL of blood). A dose response pilot study was 
conducted in advance to determine the best dose for each of the bacteria used in the 
stimulations that would elicit a sub-maximal response. After addition of stimuli, the blood 
tubes were incubated at 37°C with 5% CO2 for 24 hours. At the end of the 24-hour 
stimulations, all of the blood tubes were transferred to Tempus™ Blood RNA tubes. The 
blood tubes were stored at room temperature for approximately 24 hours after collection, 
at which point they were frozen at -20oC until further processed. RNA was isolated using 
the manufacturer’s protocol for Tempus™ Blood RNA extraction kits (Qiagen) and the 
iPrep PureLink system; samples were then stored at -80oC until reverse transcribed 
(described below) 98. Gene expression of IFNγ, IL-12α, IL-13, IL-17α, IL-1β, IL-6, IL-8, 




Prior to reverse transcription, RNA was quantified via Epoch microplate 
spectrophotometer (Biotek; Winooski, Vermont). Master mix reagents (Promega; 
Madison, Wisconsin) were used to transcribe the RNA; after addition of the reagents, 
samples were placed into a thermocycler (Applied Biosystems; Foster City, California) for 
a cycle of 15 minutes at 42oC, followed by a cycle of 5 minutes at 95oC 98-102. After 
completion of RNA reverse transcription to cDNA, the samples were stored -80oC until 
used for RT-PCR (described below).  
RT-PCR 
For the desired cytokine analyses described in each subsection and the endogenous 
control gene, β-gus, equine-specific intron spanning primers and probes (Applied 
Biosystems), nuclease-free water (Qiagen), TaqMan™ (Applied Biosystems), and the 
desired cDNA samples were loaded onto plates in duplicate via a robotic pipetting machine 
(Eppendorf) 98-102. RT-PCR was then performed using the 7900HT Fast RT-PCR System 
(Applied Biosystems) with the first cycle of 10 minutes at 95oC, and an additional 40 cycles 
of 15 seconds at 95oC and 60 seconds at 60oC 98-102. After determination of cycle threshold 
values using linear regression analysis (LinRegPCR version 2018; Heart Failure Research 
Center, Amsterdam University Medical Centers), relative quantity (RQ) values were 
calculated using the 2-ΔΔCt method 98-103. The calibrators for the PBMC and whole blood 
stimulations were the average ΔCT of the Day 0 (Early September 2017) 
media/unstimulated values for all of the Non-PPID horses. For the whole blood analyses 
using Tempus™ Blood RNA tubes, the calibrator was the average ΔCT of the Day 0 (Early 
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September 2017) samples for all of the Non-PPID horses. All RQs were natural log 
transformed prior to statistical analyses. 
Rhodococcus equi culture and heat-inactivation 
A Rhodococcus equi 103+ culture was kindly supplied by the lab of Dr. David 
Horohov, University of Kentucky. The stock solution was streaked onto plates containing 
tryptic soy agar (VWR®) using a sterile inoculating loop (VWR® International). After 
approximately 48 hours of growth at 37°C, one colony was selected and used to inoculate 
a tube of tryptic soy broth (Corning®). After sealing the tube and brief vortexing, a sterile 
inoculating loop was used to inoculate additional broth tubes. These broth tubes were then 
incubated at 37°C for approximately 48 hours with caps in aerobic growth positioning. The 
main broth tube was then aliquoted and frozen for future use. The additional broth tubes 
were used to establish a growth curve and to determine the ideal time to heat-inactivate the 
bacteria. Based on the growth curve results, the bacteria were then pulled in the exponential 
growth period (after approximately 40 hours of growth) for all further work. Heat 
inactivation time was selected so that the minimum heat and time necessary for inactivation 
was achieved, in order to minimize any changes to the bacteria. Inoculated broth tubes were 
placed into a water bath at 60°C for various times and then streaked onto tryptic soy agar 
plates to confirm inactivation. The plates were checked at 48 hours after plating to 
determine if growth was present. The minimum time needed for heat-inactivation of R. 
equi was 50 minutes at 60°C.  
Once the growth curve and heat inactivation time were determined, the final batches 
were prepared in similar fashion to the above descriptions. The stock solution was streaked 
onto tryptic soy agar plates and after approximately 48 hours of growth, a colony was 
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selected to inoculate a broth tube. After sealing the tube and briefly vortexing it, a sterile 
inoculating loop was used to inoculate multiple broth tubes, which were then incubated at 
37°C. After approximately 40 hours, the broth tubes were removed from the incubator, and 
the volume of broth was measured as the tubes were combined into a sterile glass bottle. 
After a brief vortex, 100μL of broth was removed and serially diluted five times before 
plating 25μL in duplicate. The number of colonies was then counted on these two plates at 
approximately 48 hours of growth and averaged; this count was used to determine the 
colony-forming units (CFU) per milliliter.  Then, the broth was aliquoted into new sterile 
tubes, and heat-inactivated for 50 minutes at 60°C. After heat inactivation, the broth was 
combined again into a sterile glass bottle, 25μL was plated in duplicate, and the final 
volume of broth was measured, so that accurate counts could be obtained. The final heat-
inactivated broth was then frozen at -20°C. When needed for stimulations, the broth was 
thawed, centrifuged at 3,400g for 10 minutes, and the pellet resuspended in either saline 
(whole-blood stimulations) or complete RPMI (PBMC stimulations). The final broth was 
positive for R. equi and VapA expression on Real Time PCR, performed by the University 
of Kentucky Veterinary Diagnostic Lab (Lexington, Kentucky). 
Escherichia coli culture and heat-inactivation 
Escherichia coli (ATCC #35218) was obtained from VWR (Microbiologics, Inc.; 
St. Cloud, Minnesota) in KWIK-STIK™ vials. The KWIK-STIK™ vial was crushed, and 
the sterile swab was streaked onto plates containing Difco™ nutrient agar (VWR®; BD 
Biosciences). After approximately 24 hours of growth at 37°C, one colony was selected 
and used to inoculate a tube of Difco™ nutrient broth (VWR®, BD Biosciences). After 
sealing the tube and brief vortexing, a sterile inoculating loop was used to inoculate 
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additional broth tubes. These broth tubes were then incubated at 37°C for approximately 
24 hours with caps in aerobic growth positioning. The main broth tube was then aliquoted 
and frozen for future use. The additional broth tubes were used to establish a growth curve 
and to determine the ideal time to heat-inactivate the bacteria. Based on the growth curve 
results, the bacteria were then pulled in the exponential growth period (after approximately 
24 hours of growth) for all further work. Heat inactivation time was selected so that the 
minimum heat and time necessary for inactivation was achieved, in order to minimize any 
changes to the bacteria. Inoculated broth tubes were placed into a water bath at 60°C for 
various times and then streaked onto tryptic soy agar plates to confirm inactivation. The 
plates were checked at 24 hours after plating to determine if growth was present. The 
minimum time needed for heat-inactivation of E. coli was 7.5 minutes at 60°C.  
Once the growth curve and heat inactivation time were determined, the final batches 
were prepared in similar fashion to the above descriptions. The stock solution was streaked 
onto Difco™ nutrient agar plates and after approximately 24 hours of growth, a colony was 
selected to inoculate a broth tube. After sealing the tube and briefly vortexing it, a sterile 
inoculating loop was used to inoculate multiple broth tubes, which were then incubated at 
37°C. After approximately 24 hours, the broth tubes were removed from the incubator, and 
the volume of broth was measured as the tubes were combined into a sterile glass bottle. 
After a brief vortex, 100μL of broth was removed and serially diluted six times before 
plating 25μL in duplicate. The number of colonies was then counted on these two plates at 
24 hours of growth and averaged; this count was used to determine the CFU/mL. Then, the 
broth was aliquoted into new sterile tubes, and heat-inactivated for 7.5 minutes at 60°C. 
After heat inactivation, the broth was combined again into a sterile glass bottle, 25μL was 
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plated in duplicate, and the final volume of broth was measured, so that accurate counts 
could be obtained. The final heat-inactivated broth was then frozen at -20°C. When needed 
for stimulations, the broth was thawed, centrifuged at 3,400g for 10 minutes, and the pellet 
resuspended in either saline (whole-blood stimulations) or complete RPMI (PBMC 
stimulations).  
 
3.3.3 Statistical Methods 
Distributional assumptions were evaluated using graphical and numerical 
summaries for the presence of gross normality violations. The primary analyses were the 
longitudinal analysis of all measures over time; linear mixed models included main effects 
for group and time. The primary comparisons were the PPID Treatment to PPID Control 
groups and the PPID to Non-PPID groups, when the PPID groups were combined. To 
determine if groups changed differently over time, an F-test for the interaction of group 
and time was used. Graphical summaries and model fit were used to determine the 
specifications of the linear mixed model (PROC MIXED, SAS v9.4). To account for 
repeated measures, an UN, ARMA(1,1), AR(1), TOEP, or TOEPH variance-covariance 
structure was used for each measure, depending on the best model fit based on information 
criteria (BIC, AIC). All analyses were conducted using SAS v9.4 (Cary, North Carolina), 
and a two-sided significance level of .05 was used for all statistical tests. Graphs were 
created using GraphPad Prism v.8.0.2 (San Diego, California). 
Results for PPID Control and PPID Treatment horses were analyzed first. If 
significant group by time differences were observed, these groups remained separate for 
comparison to Non-PPID horses. If no significant group by time differences were observed, 
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the PPID Control and PPID Treatment groups were combined before comparison to Non-
PPID horses. If no significant group or group by time differences were observed between 
the combined PPID group and Non-PPID group, all groups were combined for analysis of 
time effects only. 
If starting differences (P<.1) were observed between PPID Control and PPID 
Treatment horses in the initial analyses, starting values were included as a covariate within 
the model to address the potential for confounding. If starting differences (P<.1) were 
observed between PPID and Non-PPID horses, analyses were performed without starting 
values as a covariate within the model, in order to analyze group effects, and then with 
starting values as a covariate, in order to analyze group by time effects; results for each of 
the methods are presented if applicable. 
For the stimulated samples (whole blood stimulations and PBMC stimulations), the 
media/unstimulated values for each cytokine/receptor were included within the model as a 
covariate to account for changes based on where the individual animals started. 
Additionally, for the RT-PCR and plasma MPO results, outliers were removed prior to 
statistical analyses if they were determined to be more than five times lower or higher than 
the median absolute deviation (MAD) from the median for each cytokine and receptor and 








Due to having no degrees of freedom in the PPID Control to PPID Treatment 
analysis for the variance-covariance structure with the best information criteria, the UN 
variance-covariance structure was used. No group, time, or group by time effects were 
found in the PPID Control to PPID Treatment comparison. After combining the PPID 
Control and PPID Treatment groups for comparison to the Non-PPID group, significant 
group (P=.043) and time (P=.0249) effects, but not a significant group by time effect alone, 
were observed (Figure 3.1). In this analysis, the PPID horses had significantly lower body 
temperature than the Non-PPID horses at the Mid-October 2018 timepoint only (P=.0278). 
Pulse: 
Due to having no degrees of freedom in the PPID Control to PPID Treatment 
analysis for the variance-covariance structure with the best information criteria, the UN 
variance-covariance structure was used. No significant group or group by time effects were 
found in the PPID Control to PPID Treatment comparison, but a significant time effect was 
observed (P=.0445).  
After combining the PPID Control and PPID Treatment groups for comparison to 
the Non-PPID group, significant group (P=.0014) and time (P=.0098) effects, but not a 
significant group by time effect alone, were observed. In this analysis, the PPID horses had 
significantly lower heart rates than the Non-PPID horses at the Early September 2017 
(P=.0009), Early February 2018 (P=.0005), and Mid-October 2018 (P=.021) timepoints 
(Figure 3.2A). However, due to starting differences between the two groups, the analysis 
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was run again with starting values as a covariate (Figure 3.2B). In this subsequent analysis, 
no significant group, time, or group by time effects were observed; therefore, the groups 
did not change over time as a result of their group status. 
Respiration: 
Due to having no degrees of freedom in the PPID Control to PPID Treatment 
analysis for the variance-covariance structure with the best information criteria, the UN 
variance-covariance structure was used. No significant group, time, or group by time 
effects were found in the PPID Control to PPID Treatment comparison; however, due to 
starting differences between the two groups, the analysis was run again with starting values 
as a covariate. In this subsequent analysis, no significant time or group by time effects were 
observed, so the groups did not change over time as a result of their group status. The group 
effect could not be determined in this comparison due to having no degrees of freedom. 
After combining the PPID Control and PPID Treatment groups for comparison to 
the Non-PPID group, significant group (P=.0336) and time (P=.0289) effects, but not a 
significant group by time effect alone, were observed (Figure 3.3). In this analysis, the 
PPID horses had significantly higher respiration rates than the Non-PPID horses at the 
Early November 2017 (P=.038) and Mid-October 2018 (P=.0017) timepoints only. 
 
Complete blood counts: 
White blood cell (WBC), absolute segmented neutrophil, absolute banded 
neutrophil, absolute monocyte, absolute lymphocyte, absolute eosinophil, absolute 
basophil, and red blood counts (RBC) were measured and described below. Fibrinogen, 
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hemoglobin (Hgb), packed cell volume (PCV), and total protein were also measured and 
described below. 
White blood cell (WBC) count 
No significant group or group by time effects were seen in white blood cell (WBC) 
counts between the PPID Control and PPID Treatment groups; a significant time effect 
(P=.0046) was observed in this comparison. After combining the PPID Control and PPID 
Treatment groups for comparison to Non-PPID horses, a significant group by time effect 
(P=.041), but not a group or time effect alone, was observed (Figure 3.4). PPID horses had 
significantly lower WBC counts than Non-PPID horses at the Early February 2018 and 
Early August 2018 timepoints only. 
Absolute segmented neutrophil count, absolute monocyte count, hemoglobin, and packed 
cell volume 
No significant group or group by time effects were seen in absolute segmented 
neutrophil counts, absolute monocyte counts, hemoglobin, or packed cell volume between 
any of the groups. Significant time effects in absolute segmented neutrophil counts were 
observed in the PPID Control to PPID Treatment (P=.0099) and all groups combined 
(P=.0395) comparisons. Significant time effects in absolute monocyte counts were 
observed in the PPID Control to PPID Treatment (P=.027), Non-PPID to PPID (P=.0002), 
and all groups combined (P<.0001) comparisons. Significant time effects in hemoglobin 
were observed in the PPID Control to PPID Treatment (P=.0022), Non-PPID to PPID 
(P=.0011), and all groups combined (P=.0006) comparisons. Significant time effects in 
70 
 
packed cell volume were observed in the PPID Control to PPID Treatment (P<.0001), Non-
PPID to PPID (P<.0001), and all groups combined (P<.0001) comparisons. 
Absolute banded neutrophil count 
No significant group, time, or group by time effects were seen in absolute banded 
neutrophil counts between the PPID Control and PPID Treatment groups. After combining 
the PPID Control and PPID Treatment groups for comparison to Non-PPID horses, 
significant time (P=.0039) and group by time (P=.0112) effects, but not a group effect 
alone, were observed. This appeared to be driven by the Non-PPID horses having higher 
counts than PPID horses at the Early April 2018 timepoint only, and the PPID horses 
having higher counts than the Non-PPID horses at the Early February 2018 timepoint. This 
group by time effect may not represent a biologically significant result as the small sample 
sizes may have allowed a few high results to influence the group by time effect and also 
because the groups do not appear to be visually distinct from one another in graphical 
representation. 
Additionally, none of the horsed exhibited a clinically significant left-shift at any 
point in the study, defined as greater than 300/μL banded neutrophils 104. 
Absolute lymphocyte count 
No significant group or group by time effects were seen in absolute lymphocyte 
counts between the PPID Control and PPID Treatment horses; a significant time effect 
(P=.0284) was observed in this comparison. After combining these groups for comparison 
to Non-PPID horses, significant group (P=.028) and time (P=.0044) effects, but not a group 
by time effect, were observed with PPID horses generally having lower absolute 
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lymphocyte counts than Non-PPID horses (Figure 3.5A). Due to starting differences 
between the Non-PPID and PPID horses, the analysis was run again with starting values as 
covariate in the model to determine if significant group by time changes were present 
(Figure 3.5B). This subsequent analysis revealed no significant group by time effects; 
therefore, these groups did not change over time as a result of their group status.  
Absolute basophil count 
A significant group effect (P=.062), but no time or group by time effect, was seen 
in absolute basophil counts between the PPID Control and PPID Treatment groups. After 
combining the PPID Control and PPID Treatment groups for comparison to Non-PPID 
horses, no significant group or group by time effects were seen. Significant time effects in 
absolute basophil counts were observed in the Non-PPID to PPID (P=.0164) and all groups 
combined (P=.0233) comparisons. 
Absolute eosinophil count 
No significant group or group by time effects were seen in absolute eosinophil 
counts between the PPID Control and PPID Treatment horses. Due to starting differences 
between the PPID Control and PPID Treatment horses, the analysis was run again with 
starting values as a covariate in the model to determine if significant group by time changes 
were present. This subsequent analysis revealed no significant group by time effects; 
therefore, these groups did not change over time as a result of their group status. After 
combining these groups for comparison to Non-PPID horses, no significant group or group 
by time effects were observed. Significant time effects in absolute eosinophil counts were 
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observed in the PPID Control to PPID Treatment (P=.0015), Non-PPID to PPID (P<.0001), 
and all groups combined (P<.0001) comparisons. 
Fibrinogen 
A significant group effect (P=.0303), but no time or group by time effect, was seen 
in fibrinogen between the PPID Control and PPID Treatment groups. After combining the 
PPID Control and PPID Treatment groups for comparison to Non-PPID horses, no 
significant group or group by time effects were found. No significant time effects were 
observed between any of the groups. 
Total Protein 
No significant group or group by time effects were seen in total protein between 
the PPID Control and PPID Treatment horses. Due to starting differences between the 
PPID Control and PPID Treatment horses, the analysis was run again with starting values 
as a covariate in the model to determine if significant group by time changes were present. 
This subsequent analysis revealed no significant group by time effects; therefore, these 
groups did not change over time as a result of their group status. After combining these 
groups for comparison to Non-PPID horses, no significant group or group by time effects 
were observed. Significant time effects in total protein were observed in the PPID Control 
to PPID Treatment (P<.0001), Non-PPID to PPID (P<.0001), and all groups combined 
(P<.0001) comparisons. 
Red blood cell count 
No significant group or group by time effects were seen in red blood cell counts 
between the PPID Control and PPID Treatment horses; a significant time effect (P<.0001) 
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was observed in this comparison. After combining these groups for comparison to Non-
PPID horses, significant group (P=.0203) and time (P<.0001) effects, but not a group by 
time effect, were observed with PPID horses generally having lower red blood cell counts 
than Non-PPID horses (Figure 3.6A). Due to starting differences between the Non-PPID 
and PPID horses, the analysis was run again with starting values as a covariate in the model 
to determine if significant group by time changes were present (Figure 3.6B).  This 
subsequent analysis revealed no significant group by time effects; therefore, these groups 
did not change over time as a result of their group status.  
Summary of significant CBC results: 
PPID horses had significantly lower WBC counts than Non-PPID horses at the 
Early February 2018 and Early August 2018 timepoints only. PPID horses generally had 
lower absolute lymphocyte counts and red blood counts than Non-PPID horses. Significant 
time effects for the Non-PPID to PPID comparisons are shown in Figures 3.7 and 3.8. 
 
Plasma myeloperoxidase: 
No significant group or group by time effects were found in plasma 
myeloperoxidase concentrations between any of the groups. Significant time effects were 
observed in the PPID Control and PPID Treatment (P<.0001), Non-PPID to PPID 
(P<.0001), and all horses combined comparisons (P<.0001). Figure 3.9 displays the Non-




Whole blood (Tempus™) cytokine/receptor gene expression:  
No significant group or group by time effects were seen in IL-12α, IL-1β, IL-6, 
TGFβ, or TNFα between any of the groups. Significant time effects were seen in IL-12α 
expression for the PPID Control to PPID Treatment comparison (P=.0006), Non-PPID to 
PPID comparison (P<.0001), and when all groups were combined (P<.0001). Significant 
time effects were seen in IL-1β expression for the PPID Control to PPID Treatment 
comparison (P=.001), Non-PPID to PPID comparison (P<.0001), and when all groups 
were combined (P<.0001). Significant time effects were seen in IL-6 expression for the 
PPID Control to PPID Treatment comparison (P<.0001), Non-PPID to PPID comparison 
(P<.0001), and when all groups were combined (P<.0001). Significant time effects were 
seen in TGFβ expression for the PPID Control to PPID Treatment comparison (P<.0001), 
Non-PPID to PPID comparison (P<.0001), and when all groups were combined (P<.0001). 
Significant time effects were seen in TNFα expression for the Non-PPID to PPID 
comparison (P=.0172) and when all groups were combined (P=.0165). 
Significant group by time effects were seen in IL-13 expression between the PPID 
Control and PPID Treatment groups (P=.0025). Therefore, the groups were kept separate 
for comparison to Non-PPID horses. In the Non-PPID to PPID Control to PPID Treatment 
comparison, there were no significant group or group by time differences between any of 
the groups. Therefore, all of the groups were combined for analysis of time effects. 
Significant time effects were seen in the PPID Control to PPID Treatment (P<.0001), Non-




No significant group or group by time effects were seen in IL-17α or TLR4 between 
any of the groups. Due to starting differences between the PPID and Non-PPID groups, 
these analyses were run again with starting values as a covariate in the model; the group 
and group by time effects remained insignificant. Significant time effects in IL-17α 
expression were observed in the PPID to Non-PPID comparison (P=.0007) and when all 
groups were combined (P=.0014). Significant time effects in TLR4 expression were 
observed in the PPID Control to PPID Treatment (P<.0001), Non-PPID to PPID (P<.0001), 
and all groups combined (P<.0001) comparisons. 
No significant group or group by time effects were seen in IFNγ or TLR2 between 
any of the groups. Due to starting differences between the PPID Control and PPID 
Treatment groups, these analyses were run again with starting values as covariates in the 
model; the group and group by time effects remained insignificant. Significant time effects 
in IFNγ expression were observed in the PPID Control to PPID Treatment (P=.0036), Non-
PPID to PPID (P=.0014), and all groups combined (P=.0004) comparisons. Significant 
time effects in TLR2 expression were observed in only the Non-PPID to PPID (P=.0149), 
and all groups combined (P=.0204) comparisons. 
No significant group or group by time effects were seen in IL-8 between the PPID 
Control and PPID Treatment horses. After combining these groups for comparison to Non-
PPID horses, a significant group (P=.0102) effect was seen with PPID horses having 
greater IL-8 expression than Non-PPID horses (Figure 3.10). Due to starting differences 
between Non-PPID and PPID horses, the analysis was run again with starting values as a 
covariate in the model to determine if significant group by time changes were present. This 
subsequent analysis revealed no significant group by time effects; therefore, these groups 
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did not change in their IL-8 response over time. Significant time effects were observed in 
the PPID Control to PPID Treatment (P=.0002) and Non-PPID to PPID (P<.0001) 
comparisons. 
Summary of significant whole blood (Tempus™) cytokine and receptor expression results: 
Aside from time effects in many of the measured cytokines and receptors, the only 
significant group or group by time difference was in the comparison of Non-PPID to all 
PPID horses for IL-8 expression. In this analysis, PPID horses had greater IL-8 expression 
in whole blood compared to Non-PPID horses. Significant time effects for the Non-PPID 
to PPID comparisons are shown in Figures 3.11 and 3.12. 
 
PBMC (unstimulated/stimulated) cytokine and receptor gene expression 
PBMC stimulation- Media: 
No significant group, time, or group by time effects were seen in TLR4, TNFα, 
TGFβ, IL-6, IL-13, and IFNγ between any of the groups. Due to starting differences 
between the PPID Control and PPID Treatment groups in the TLR4 analysis, the analysis 
was performed again with starting values as a covariate in the model; the group, time, and 
group by time effects remained insignificant. 
No significant group or group by time effects were seen in IL-1β, IL-8, IL-10, IL-
12α, and IL-17α between any of the groups. Significant time effects were seen in IL-1β 
expression for the Non-PPID to PPID comparison (P=.03) and when all groups were 
combined (P=.033). Significant time effects were seen in IL-8 expression for the Non-
PPID to PPID comparison (P=.034) and when all groups were combined (P=.024). 
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Significant time effects were seen in IL-10 and IL-12α expression for all comparisons 
(P<.01). Significant time effects were observed in IL-17α expression in the Non-PPID to 
PPID comparison (P=.045), but not when all groups were combined. 
Summary of PBMC stimulation- Media: 
Aside from time effects, there were no differences between PPID Treatment and 
PPID Control horses and between PPID and Non-PPID horses in the unstimulated samples.  
 
PBMC stimulation- R. equi: 
No significant group, time, or group by time effects were seen in TGFβ, TNFα, IL-
12α, and IL-6 between any of the groups. 
No significant group or group by time effects were seen in TLR4 between any of 
the groups. Significant time effects in TLR4 were observed when PPID Control and PPID 
Treatment horses were compared (P=.021), but not in the Non-PPID to PPID comparison 
or when all groups were combined. 
No significant group, time, or group by time effects were seen in IL-1β between the 
PPID Control and PPID Treatment horses or in the PPID to Non-PPID comparison. Due to 
starting differences between the PPID and Non-PPID groups, this analysis was run again 
with starting values as a covariate in the model; the group, time, and group by time effects 
remained insignificant. No time effects were observed when all groups were combined. 
No significant group, time, or group by time effects were seen in IL-8 between the 
PPID Control and PPID Treatment horses. Significant time (P=.02) and group by time 
effects (P=.042) were seen in IL-8 expression between the Non-PPID and PPID groups of 
horses. Due to starting differences between the PPID and Non-PPID groups, this analysis 
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was run again with starting values as a covariate in the model; significant time (P=.018) 
and group by time effects (P=.044) remained. Non-PPID and PPID horses differed at only 
one timepoint, Early September 2017, which appeared to drive the significant group by 
time effect seen. This suggests that the result is likely not biologically relevant. 
No significant group, time, or group by time effects were seen in IL-13 between the 
PPID Control and PPID Treatment horses. Significant time (P=.018) and group by time 
(P<.01) effects were seen in IL-13 expression between the Non-PPID and PPID groups of 
horses. Due to starting differences between the PPID and Non-PPID groups, this analysis 
was run again with starting values as a covariate in the model; the significant time effect 
was no longer present, but the significant group by time effect remained (P=.047). Non-
PPID and PPID horses differed at only one timepoint, Early September 2017, which 
appeared to drive the significant group by time effect seen. This suggests that the result is 
likely not biologically relevant. 
No significant group, time, or group by time effects were seen in IFNγ between the 
PPID Control and PPID Treatment horses. Due to starting differences between these 
groups, this analysis was run again with starting values as a covariate in the model; the 
group, time, and group by time effects remained insignificant. After combining these 
groups for comparison to Non-PPID horses, a significant group effect (P<.01), but not a 
time or group by time effect, was seen with PPID horses having less IFNγ expression than 
Non-PPID horses in response to R. equi stimulation (Figure 3.13B). Due to significant 
starting differences between Non-PPID and PPID horses, the analysis was run again with 
starting values as a covariate in the model to determine if significant group by time changes 
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were present (Figure 3.13C). This subsequent analysis revealed no significant group by 
time effects; therefore, these groups did not change over time. 
A significant group by time effect (P<.01), but not a group or time effect, was seen 
in IL-17α expression between the PPID Control and PPID Treatment groups. Therefore, 
the groups were kept separate for comparison to Non-PPID horses. Initial analyses of Non-
PPID to PPID Control and PPID Treatment horses showed a significant group by time 
(P<.001) effect, but not a group or time effect (Figure 3.14B). The only point at which 
significant differences existed between the three groups was at the Early February 2018 
timepoint, where the PPID Treatment horses had significantly higher expression of IL-17α 
in response to R. equi stimulation than both PPID Control and Non-PPID horses. Given 
that this was the only significant difference present, it appears that the significant group by 
time effects are being driven by the differences at this timepoint only. Therefore, it is 
unlikely that this result is biologically significant. 
Significant group effects were seen in IL-10 expression between the PPID Control 
and PPID Treatment groups (P=.039). Due to starting differences between these groups, 
this analysis was run again with starting values as a covariate in the model; the group effect 
was no longer significant. Significant time effects were seen in the analysis with starting 
values as a covariate in the model. After combining the PPID Control and PPID Treatment 
groups for comparison to Non-PPID horses, no significant group or group by time effects 
were seen. Significant time effects in IL-10 expression in response to R. equi stimulation 
were observed when all PPID horses were compared to Non-PPID horses and when all 




Summary of PBMC stimulation- R. equi: 
PPID horses had decreased IFNγ expression compared to Non-PPID horses in 
response to stimulation with R. equi. Significant time effects were also seen in some of the 
responses to in vitro R. equi stimulation. 
 
PBMC stimulation- E. coli: 
No significant group, time, or group by time effects were seen in IL-12α, IL-6, and 
TNFα, between any of the groups. 
No significant group or group by time effects were seen in IL-13, IL-8, or TLR4 
between any of the groups. Significant time effects were seen in IL-13 expression for the 
Non-PPID to PPID comparison (P=.007) and when all groups were combined (P=.006). 
Significant time effects were seen in IL-8 expression for the PPID Control to PPID 
Treatment comparison (P=.011), Non-PPID to PPID comparison (P<.0001), and when all 
groups were combined (P<.0001). Significant time effects were seen in TLR4 expression 
for the PPID Control to PPID Treatment comparison (P=.03), Non-PPID to PPID 
comparison (P<.0001), and when all groups were combined (P<.0001). 
No significant group or group by time effects were seen in IL-1β between any of 
the groups. Due to starting differences between Non-PPID and PPID horses, the analysis 
was run again with starting values as a covariate in the model to determine if significant 
group by time changes were present. This subsequent analysis revealed no significant 
group or group by time effects. Significant time effects were seen in IL-1β expression for 




No significant group or group by time effects were seen in IL-10 between any of 
the groups. Due to starting differences between the PPID Control and PPID Treatment 
groups, this analysis was run again with starting values as a covariate in the model; the 
group and group by time effects remained insignificant. Significant time effects in IL-10 
expression were observed in all comparisons (P<.0001). 
No significant group, time, or group by time effects were seen in IFNγ between the 
PPID Control and PPID Treatment horses. After combining these groups for comparison 
to Non-PPID horses, a significant group effect, but not a time or group by time effect, was 
seen with PPID horses having less IFNγ expression than Non-PPID horses in response to 
E. coli stimulation (P<.01) (Figure 3.15B). Due to starting differences between Non-PPID 
and PPID horses, the analysis was run again with starting values as a covariate in the model 
to determine if significant group by time changes were present (Figure 3.15C). This 
subsequent analysis revealed no significant group by time effects; therefore, the groups did 
not change in their IFNγ response over time as a result of their group status. 
A significant group by time (P=.0497) effect, but not a group effect, were seen in 
IL-17α expression between the PPID Control and PPID Treatment groups. Therefore, the 
groups were kept separate for comparison to Non-PPID horses. In the Non-PPID to PPID 
Control to PPID Treatment comparison, there were no significant group or group by time 
differences between any of the groups. There were no significant differences between the 
PPID Control and PPID Treatment horses in either comparison; the significant group by 
time effect in the PPID Control to PPID Treatment comparison appears to be driven by a 
single timepoint (Mid-October 2018), where the groups differed slightly, although were 
not statistically different (P=.075). Significant time effects were seen in PPID Control to 
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PPID Treatment (P=.04), Non-PPID to PPID Control to PPID Treatment (P=.013), and all 
groups combined (P=.008) comparisons. 
No significant group, time, or group by time effects were seen in TGFβ between 
the PPID Control and PPID Treatment horses. After combining these groups for 
comparison to Non-PPID horses, a significant group effect (P=.04) was seen with PPID 
horses having greater TGFβ expression than Non-PPID horses in response to E. coli 
stimulation (Figure 3.16B). No significant time or group by time effects were seen in the 
Non-PPID to PPID comparison. 
Summary of PBMC stimulation- E. coli:  
PPID horses had decreased IFNγ expression and increased TGFβ expression 
compared to Non-PPID horses in response to stimulation with E. coli. Time effects were 
often seen in responses to E. coli stimulation. 
 
PBMC stimulation- PMA/ionomycin: 
No significant group or group by time effects were seen in IFNγ, IL-6, IL-8, TNFα, 
TGFβ, or TLR4 between any of the groups. Significant time effects were seen in IFNγ 
expression for the PPID Control to PPID Treatment comparison (P=.04), Non-PPID to 
PPID comparison (P=.003), and when all groups were combined (P=.004). Significant time 
effects were seen in IL-6 expression for the PPID Control to PPID Treatment comparison 
(P=.0035), Non-PPID to PPID comparison (P<.0001), and when all groups were combined 
(P<.0001). Significant time effects were seen in IL-8 expression for the Non-PPID to PPID 
comparison (P=.0055) and when all groups were combined (P=.0083). Significant time 
effects were seen in TNFα expression for the PPID Control to PPID Treatment comparison 
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(P=.025), Non-PPID to PPID comparison (P=.029), and when all groups were combined 
(P=.024). Significant time effects were seen in TGFβ expression only for the Non-PPID to 
PPID comparison (P=.018). Significant time effects were seen in TLR4 expression for the 
Non-PPID to PPID comparison (P<.0001) and when all groups were combined (P=.0002). 
No significant group, time, or group by time effects were seen in IL-10 and IL-13 
between any of the groups. Due to significant starting differences between PPID Control 
and PPID Treatment horses, these analyses were run again with starting values as a 
covariate in the model; the results remained the same with no significant group, time, or 
group by time effects observed. 
No significant group, time, or group by time effects were seen in IL-17α between 
the PPID Control and PPID Treatment groups. Due to starting differences between the 
PPID Control and PPID Treatment groups, this analysis was run again with starting values 
as a covariate in the model; the group, time, and group by time effects remained 
insignificant. No significant group or group by time effects were seen in IL-17α for the 
Non-PPID to PPID comparison or when all groups were combined, but significant time 
effects in IL-17α expression were observed in the Non-PPID to PPID comparison (P=.027) 
and when all groups were combined (P=.032). 
No time or group by time effects were seen in IL-12α between the PPID Control 
and PPID Treatment horses, but significant group effects were seen (P=.032). Due to 
significant starting differences between PPID Control and PPID Treatment horses, the 
analysis was run again with starting values as a covariate in the model; this analysis 
revealed no significant group, time, or group by time effects. Since there were no 
significant group by time differences, these groups were combined for the comparison to 
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Non-PPID horses. No significant group, time, or group by time differences were seen in 
the Non-PPID to PPID comparison or when all groups were combined.  
Significant group (P=.034) and time effects (P=.015), but not group by time effects, 
were seen in IL-1β expression between the PPID Control and PPID Treatment horses. 
Since there were no significant group by time differences, these groups were combined for 
the comparison to Non-PPID horses. No significant group or group by time differences 
were seen in the Non-PPID to PPID comparison or when all groups were combined. 
Significant time effects in IL-1β expression were observed in the Non-PPID to PPID 
comparison (P=.005) and when all groups were combined (P=.0033). 
Summary of PBMC stimulation- PMA/ionomycin:  
Aside from some time effects, no differences were observed in PMA/ionomycin-
stimulated samples. 
 
Summary of overall PBMC stimulation results: 
PPID does not appear to affect the cytokine and receptor gene expression of 
unstimulated or PMA/ionomycin-stimulated PBMCs. However, PPID horses showed 
decreased in vitro expression of IFNγ in response to both R. equi and E. coli compared to 
Non-PPID horses. Additionally, PPID horses had greater in vitro TGFβ expression in 
response to E. coli than Non-PPID horses. Oral administration of PRASCEND does not 
appear to influence the in vitro immune responses of peripheral blood mononuclear cells. 
Significant time effects for the Non-PPID to PPID or PPID Control to PPID Treatment to 
Non-PPID comparisons are shown in Figures 3.17-3.21. 
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Stimulated whole blood cytokine and receptor gene expression 
Whole blood stimulation- unstimulated: 
No significant group, time, or group by time effects were seen in IL-1β and TLR2 
between any of the groups. 
No significant group or group by time effects were seen in IFNγ or TNFα between 
any of the groups. Significant time effects in IFNγ expression were observed in the PPID 
Control to PPID Treatment (P=.0086), Non-PPID to PPID (P<.0001), and all groups 
combined (P<.0001) comparisons. Significant time effects in TNFα expression were 
observed in the PPID Control to PPID Treatment (P=.0056), Non-PPID to PPID (P<.0001), 
and all groups combined (P<.0001) comparisons.  
No significant group or group by time effects were seen in IL-12α, IL-17α, IL-6, or 
IL-8 between any of the groups. Due to starting differences between the Non-PPID and 
PPID groups in the expression of these four cytokines, the analyses for these comparisons 
were run again with starting values as covariates in the model; the group and group by time 
effects remained insignificant. Significant time effects in IL-12α expression were observed 
in the PPID Control to PPID Treatment (P=.0263), Non-PPID to PPID (P<.0001), and all 
groups combined (P<.0001) comparisons. Significant time effects in IL-6 expression were 
observed in the PPID Control to PPID Treatment (P=.004), Non-PPID to PPID (P<.0001), 
and all groups combined (P<.0001) comparisons. Significant time effects in IL-8 
expression were observed in the PPID Control to PPID Treatment (P=.0018), Non-PPID 
to PPID (P=.0002), and all groups combined (P<.0001) comparisons. No time effects were 
seen for IL-17α in any of the comparisons. 
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No significant group or group by time effects were seen in TLR4 between the PPID 
Control and PPID Treatment groups, but a significant time effect was seen (P<.0001). After 
combining these groups for comparison to Non-PPID horses, significant group (P=.036), 
time (P<.0001), and group by time (P=.0319) effects were seen with PPID horses having 
greater TLR4 expression than Non-PPID horses (Figure 3.22A). Due to starting differences 
between Non-PPID and PPID horses, the analysis was run again with starting values as a 
covariate to determine if truly significant group by time changes were present (Figure 
3.22B). This subsequent analysis revealed no significant group by time effects; therefore, 
these groups did not actually change in their TLR4 expression over time based on their 
group status. The PPID horses differed from the Non-PPID horses at only one of the three 
timepoints (Early September 2017); it is likely that the significant group difference 
observed is driven by the large starting difference between the two groups, especially given 
that there are only three timepoints in this data set. 
No significant group or group by time effects were seen in TGFβ between the PPID 
Control and PPID Treatment horses. After combining these groups for comparison to Non-
PPID horses, a significant group effect (P=.031), but not a group by time effect, was seen 
with PPID horses having greater TGFβ expression than Non-PPID (Figure 3.23A). Due to 
starting differences between the Non-PPID and PPID groups, the analysis for this 
comparison was run again with starting values as a covariate; the group by time effects 
remained insignificant; therefore, these groups did not change in their TGFβ expression 
over time based on their group status (Figure 3.23B). Significant time effects were 




Significant time (P<.0001) and group by time (P=.0012) effects were observed in 
IL-13 expression between the PPID Control and PPID Treatment groups. Therefore, the 
groups were kept separate for comparison to Non-PPID horses. In the Non-PPID to PPID 
Control and PPID Treatment comparison, significant time (P<.0001) and group by time 
effects (P=.0035) were also seen (Figure 3.24A). Due to starting differences between the 
Non-PPID and PPID groups, the analysis for this comparison was run again with starting 
values as a covariate; the significant group by time effect remained (P=.0001) (Figure 
3.24B). However, the only point at which a significant difference existed between the three 
groups after including starting values as a covariate was between the PPID Control and 
PPID Treatment groups and between the Non-PPID and PPID Treatment horses at the Mid-
October timepoint only. At this timepoint, PPID Treatment horses had significantly lower 
expression of IL-13 than both PPID Control and Non-PPID horses. Given that this was the 
only significant difference present, it appears that the significant group by time effects are 
being driven by the differences at this timepoint only. These results are difficult to draw 
any conclusions from, because graphically, the groups appear quite similar. It is possible 
that this result is not biologically significant but is just statistically significant due to the 
few samples and timepoints for this data set. 
 
Summary of whole blood stimulation- unstimulated:  
PPID horses had significantly higher expression of TGFβ in whole blood than Non-
PPID horses. Aside from time effects, the other significant differences (TLR4 and IL-13) 
appeared to be driven by single timepoint differences within a group. 
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Whole blood stimulation- R. equi: 
No significant group or group by time effects were seen in IFNγ, IL-12α, IL-13, 
IL-17α, IL-1β, TLR2, TLR4, or TNFα between any of the groups. Significant time effects 
in IFNγ expression were observed in the PPID Control to PPID Treatment (P=.0004), Non-
PPID to PPID (P<.0001), and all groups combined (P<.0001) comparisons. Significant 
time effects in IL-12α expression were observed in the PPID Control to PPID Treatment 
(P<.0001), Non-PPID to PPID (P<.0001), and all groups combined (P<.0001) 
comparisons. Significant time effects in IL-13 expression were observed in the PPID 
Control to PPID Treatment (P=.0033), Non-PPID to PPID (P=.0001), and all groups 
combined (P=.0001) comparisons. Significant time effects in IL-17α expression were 
observed in the PPID Control to PPID Treatment (P<.0001), Non-PPID to PPID (P<.0001), 
and all groups combined (P<.0001) comparisons. Significant time effects in IL-1β 
expression were observed in the PPID Control to PPID Treatment (P<.0001), Non-PPID 
to PPID (P<.0001), and all groups combined (P<.0001) comparisons. Significant time 
effects in TLR2 expression were observed in the Non-PPID to PPID (P=.0026) and all 
groups combined (P=.0076) comparisons. Significant time effects in TLR4 expression 
were observed in the PPID Control to PPID Treatment (P=.0047), Non-PPID to PPID 
(P=.0013), and all groups combined (P=.0005) comparisons. Significant time effects in 
TNFα expression were observed in the PPID Control to PPID Treatment (P=.0083) and all 
groups combined (P=.0248) comparisons. 
Significant group, but not time or group by time, effects were seen in TGFβ 
expression between the PPID Control and PPID Treatment groups (P=.0396). Therefore, 
the groups were kept separate for comparison to Non-PPID horses. In the Non-PPID to 
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PPID Control to PPID Treatment comparison, there were no significant group, time, or 
group by time differences between any of the groups. Therefore, all of the groups were 
combined for analysis of time effects. No significant time effects were seen in any of the 
comparisons. The initial significant group effect seen between the PPID Control and PPID 
Treatment appears to have been driven by a significant difference between these two 
groups at only one timepoint, Mid-October 2017; given the small sample size and few 
timepoints in the data set, this likely led to the statistically significant difference, but not a 
biologically significant difference. 
No significant group or group by time effects were seen in IL-6 between the PPID 
Control and PPID Treatment horses. After combining these groups for comparison to Non-
PPID horses, a significant group effect (P=.0172), but not a group by time effect, was seen 
with PPID horses having less IL-6 expression than Non-PPID horses (Figure 3.25C). Due 
to starting differences between the Non-PPID and PPID groups, the analysis for this 
comparison was run again with starting values as a covariate; the group by time effects 
remained insignificant; therefore, these groups did not change in their IL-6 expression in 
response to R. equi over time based on their group status (Figure 3.25D). Significant time 
effects were observed in the PPID Control to PPID Treatment (P=.0001) and Non-PPID to 
PPID (P<.0001) comparisons. 
No significant group or group by time effects were seen in IL-8 between the PPID 
Control and PPID Treatment horses. After combining these groups for comparison to Non-
PPID horses, a significant group effect was seen with PPID horses having less IL-8 
expression than Non-PPID horses in response to R. equi (P=.034) (Figure 3.26C). 
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Significant time effects in IL-8 expression were also observed in the PPID Control to PPID 
Treatment (P<.0001) and Non-PPID to PPID (P<.0001) comparisons. 
Summary of whole blood stimulation- R. equi: 
PPID horses had less IL-6 and IL-8 expression than Non-PPID horses in response 
to in vitro R. equi stimulation of whole blood. Time effects were also observed in whole 
blood responses to R. equi stimulation. 
 
Whole blood stimulation- E. coli: 
No significant group, time, or group by time effects were seen in IFNγ, IL-12α, IL-
13, TGFβ, or TNFα between any of the groups. 
No significant group or group by time effects were seen in IL-17α, IL-1β, IL-8, 
TLR2 between any of the groups. Significant time effects in IL-17α expression were 
observed in the Non-PPID to PPID (P=.0038) comparison and the all groups combined 
(P=.0095) comparison. A significant time effect in IL-1β expression was observed in the 
all groups combined (P=.0317) comparison. Significant time effects in IL-8 expression 
were observed in the PPID Control to PPID Treatment (P=.0061), Non-PPID to PPID 
(P=.0005), and all groups combined (P=.0003) comparisons. Significant time effects in 
TLR2 expression were observed in the PPID Control to PPID Treatment (P=.0374), Non-
PPID to PPID (P=.0296), and all groups combined (P=.0266) comparisons. 
Significant group (P=.0327) and group by time (P=.0314) effects were seen in IL-
6 expression between the PPID Control and PPID Treatment groups. Due to initial starting 
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differences, the analysis was run again with starting values as a covariate in the model; the 
group by time effect remained significant (P=.045). Therefore, the groups were kept 
separate for comparison to Non-PPID horses. In the initial Non-PPID to PPID Control to 
PPID Treatment comparison, there were no significant group, time, or group by time 
differences between any of the groups. However, starting differences were present between 
the PPID Control and PPID Treatment horses, so the analysis was run again with starting 
values as a covariate in the model. The group, time, and group by time effects remained 
insignificant. Therefore, all of the groups were combined for analysis of time effects. No 
significant time effects were seen in any of the comparisons. 
No significant group, time, or group by time effects were seen in TLR4 between 
the PPID Control and PPID Treatment horses. After combining these groups for 
comparison to Non-PPID horses, a significant group effect (P=.0044), but not a time or 
group by time effect, was seen with PPID horses having greater TLR4 expression than 
Non-PPID horses in response to E. coli at both the Mid-October 2017 and Early November 
2017 timepoints (Figure 3.27C). 
Summary of whole blood stimulation- E. coli: 
PPID horses had greater TLR4 expression than Non-PPID horses in response to E. 
coli at both the Mid-October 2017 and Early November 2017 timepoints 
 
Whole blood stimulation- PMA/ionomycin: 
No significant group, time, or group by time effects were found in IL-12α and IL-
13 between any of the groups. 
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No significant group or group by time effects were seen in IFNγ, IL-1β, IL-6, 
TGFβ, or TNFα between any of the groups. Significant time effects in IFNγ expression 
were observed in the PPID Control to PPID Treatment (P=.0005), Non-PPID to PPID 
(P=.0023), and all groups combined (P=.0031) comparisons. Significant time effects in IL-
1β expression were observed in the Non-PPID to PPID (P=.0197) and all groups combined 
(P=.0194) comparisons. Significant time effects in IL-6 expression were observed in the 
PPID Control to PPID Treatment (P=.0275), Non-PPID to PPID (P=.0256), and all groups 
combined (P=.0276) comparisons. Significant time effects in TGFβ expression were 
observed in the PPID Control to PPID Treatment (P=.0162), Non-PPID to PPID (P=.0058), 
and all groups combined (P=.0064) comparisons. Significant time effects in TNFα 
expression were observed in the Non-PPID to PPID (P=.0177) and all groups combined 
(P=.0318) comparisons. 
A significant group by time effect (P=.0235) was seen in IL-17α expression 
between the PPID Control and PPID Treatment groups. Therefore, the groups were kept 
separate for comparison to Non-PPID horses. In the Non-PPID to PPID Control to PPID 
Treatment comparison, there were no significant group or group by time differences 
between any of the groups. Therefore, all of the groups were combined for analysis of time 
effects. Significant time effects in IL-17α expression were observed in the PPID Control 
to PPID Treatment (P=.0002), Non-PPID to PPID Control to PPID Treatment (P=.0046), 
and all groups combined (P=.0011) comparisons. 
No significant group or group by time effects were seen in TLR2 between PPID 
Control and PPID Treatment horses. Due to starting differences between these groups, this 
analysis was run again with starting values as a covariate in the model; the group, time, 
93 
 
and group by time effects remained insignificant. After combining the PPID Control and 
PPID Treatment groups for comparison to Non-PPID horses, no significant group or group 
by time effects were seen. Significant time effects in TLR2 expression were observed in 
the Non-PPID to PPID (P=.0179) and all groups combined (P=.0306) comparisons. 
A significant group effect (P=.036), but no group by time effect, was seen in TLR4 
expression between the PPID Control and PPID Treatment groups. Due to starting 
differences between these groups, this analysis was run again with starting values as a 
covariate in the model; the group effect was no longer significant and the group by time 
effect remained insignificant. After combining the PPID Control and PPID Treatment 
groups for comparison to Non-PPID horses, no significant group or group by time effects 
were seen. No significant time effects were observed between any of the groups. 
A significant group effect (P=.0401), but no group by time effect, was seen in IL-
8 expression between the PPID Control and PPID Treatment groups. Due to not having a 
significant group by time effect and having no starting differences, these groups were 
combined for comparison to the Non-PPID horses; no significant group or group by time 
differences were observed. Therefore, all of the groups were combined for analysis of time 
effects. No significant time effects were seen in any of the comparisons. 
Summary of whole blood stimulation- PMA/ionomycin: 





Summary of overall whole blood stimulation results: 
PPID horses had significantly higher expression of TGFβ in unstimulated whole 
blood than Non-PPID horses. PPID horses had less IL-6 and IL-8 expression than Non-
PPID horses in response to R. equi stimulation of whole blood. PPID horses had greater 
TLR4 expression than Non-PPID horses in response to E. coli stimulation at both the Mid-
October 2017 and Early November 2017 timepoints. Time effects were also often observed 
in the cytokine and receptor gene expression measured in unstimulated whole blood and in 
whole blood responses to in vitro R. equi, E. coli, and PMA/ionomycin stimulation. 
 
3.5 Discussion 
The goal of this study was to investigate systemic immune function in horses with 
PPID across seasons and to evaluate the extent to which PRASCEND treatment affects 
these measures. Immune function was measured using complete blood counts, plasma 
MPO concentrations, and gene expression of cytokines and receptors important for 
immune function in whole blood (Tempus™ Blood RNA tubes) and R. equi, E. coli, and 
PMA/ionomycin-stimulated whole blood and isolated PBMCs. Overall, the most striking 
and consistently significant results were related to the complete blood counts and PBMC 
stimulations.  
Decreased WBC and absolute lymphocyte counts were observed in the PPID horses 
compared to the Non-PPID horses and were not impacted by PRASCEND treatment; this 
is consistent with previously documented findings of decreased WBC counts in PPID 
horses 10,50. In theory, this alone is sufficient to place PPID horses at greater risk of 
infection. The inclusion of age-matched Non-PPID controls rules out the possibility that 
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these findings are related to normal decreases in the lymphocyte populations due to age-
related immunosenescence 105. This work also confirms that lymphocytes from PPID 
horses do not respond differently to in vitro PMA/ionomycin stimulation than those from 
age-matched Non-PPID horses; differences in lymphocyte responses to PMA/ionomycin 
in aged horses compared to younger, adult horses have been reported 101. However, for the 
bacterial stimulations, which can be considered more biologically relevant than 
PMA/ionomycin stimulations, significant differences in the PBMC responses were 
apparent between PPID and Non-PPID horses. 
For the PBMC stimulations with heat-inactivated R. equi and heat-inactivated E. 
coli, each horse’s PBMCs were counted and plated at 4 million cells per well. This allowed 
us to evaluate the activity of these cells without confounding due to the potential 
differences in a horse’s baseline WBC and absolute lymphocyte counts. Even after this 
normalization in the number of cells that were stimulated in vitro, PPID horses consistently 
demonstrated significantly decreased IFNγ production in response to in vitro R. equi and 
E. coli stimulation. PPID horses also displayed significantly increased TGFβ expression in 
response to in vitro E. coli stimulation compared to Non-PPID horses. PRASCEND 
treatment did not impact these responses. 
In foals with R. equi infection, it is widely accepted that a decreased ability to enact 
a Th1 response, combined with reduced IFNγ expression, allows R. equi to establish 
infection within the lung 66,82,106. It is not uncommon for foals to develop bacteremia in 
conjunction with R. equi pneumonia, and this has also been demonstrated in adult horses 
59,66,67. Decreased WBC counts have also been reported in foals that went on to later 
develop R. equi pneumonia 107. This supports the conclusion that insufficiencies in WBC 
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counts and decreased IFNγ expression may predispose adult horses with PPID to infection 
with R. equi and indicates that the response of PPID horses to R. equi bears resemblance 
to that of the foal.  
Of note, the bacteria used in this study were heat-inactivated; this method was 
selected to ensure that all samples could be processed in a short period of time, with 
minimal changes to the bacterial cultures. The ability to grow a single batch of bacteria 
(both R. equi and E. coli), obtain these bacteria during the logarithmic growth phase, and 
perform all stimulations at once was ideal for comparing the results with minimal 
confounding variables. Additionally, the added benefit of using dead bacteria was that the 
bacteria could not replicate during the incubation time (ensuring each well was exposed to 
the same dose for the entire incubation time) and could not infect the cells. The measured 
cytokine responses are truly the measurement of the initial immune responses to these 
stimuli, since these bacteria, particularly R. equi, were not permitted to establish infection.  
In the E. coli stimulation, PPID horses not only had decreased IFNγ expression 
compared to Non-PPID horses, but also had increased TGFβ expression. This decreased 
IFNγ expression is consistent with the PBMC responses to R. equi; however, the increased 
TGFβ difference was not observed in the R. equi stimulation. In the unstimulated whole 
blood samples, a significant increase in TGFβ expression was also seen in PPID horses 
compared to Non-PPID horses.  
In contrast to work by McFarlane and Holbrook, where lipopolysaccharide (LPS)-
stimulated PBMCs from PPID horses produced significantly greater TNFα than adult and 
age-matched Non-PPID horses, no differences in TNFα were observed in our analyses 50. 
This may be a consequence of the LPS model in general. In human work, the LPS model, 
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which is reflective of endotoxemia , does not achieve adequate similarities to actual sepsis 
cases 108,109. Nevertheless, LPS stimulations can prove valuable when it is desired to only 
view the pathways associated with LPS activation of PBMCs. The contrast in findings 
between the work of McFarlane and Holbrook and the current study may be due to the use 
of LPS versus intact, but inactivated, bacteria. However, these differences might also be 
due to the single timepoint of analysis in the McFarlane and Holbrook study, which may 
have been influenced by the significant temporal changes in the immune response as 
described in our findings from the present study; the timeframe in which samples were 
collected was not described in the study by McFarlane and Holbrook 50. Overall, the 
findings from the currently presented study suggest that PPID horses consistently are 
unable to mount a successful Th1 response to opportunistic bacteria, but also hint at 
differences within the Treg subpopulation of lymphocytes. 
In general, the immune response to gram-negative and gram-positive bacteria is 
initially characterized by IFNγ release, as well as IL-12 for gram-negative bacteria 110. This 
was observed in the R. equi and E. coli-stimulated samples of both the Non-PPID and PPID 
horses compared to their unstimulated samples, although with the PPID horses responding 
with significantly lower IFNγ release than Non-PPID horses in both stimulations. The most 
appropriate immune response to both the R. equi and E. coli stimulations for such a short 
incubation time (24 hours) would have been the activation of the Th1 response. An 
appropriate Th1 response is generally characterized by increased levels of IFNγ, produced 
by monocytes/macrophages depending on location, which then encourages Th1 
differentiation of CD4 T-cells 111. These differentiated Th1 CD4 T-cells also produce IFNγ, 
which further stimulates Th1 differentiation of CD4 T-cells 111. Additionally, this IFNγ 
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production can inhibit differentiation of CD4 T-cells into Th2 and Th17 subsets 111. The 
Th2 subset is most appropriate for extracellular infection, such as helminths, while the 
Th17 subset is important for neutrophil recruitment 111. The Treg subset of CD4 T-cells is 
stimulated to develop by TGFβ, and these cells continue to produce TGFβ to further 
promote the development of more Treg cells 111. This TGFβ production also shuts down 
differentiation of CD4 T-cells into the Th1 and Th2 lineage 111. Treg cells essentially serve 
as a check for the immune response, to ensure that an immune response is “turned off” 
when no longer required. 
Given the results of this study, it appears that PPID horses mount inadequate Th1 
responses to R. equi and E. coli stimulation. These findings also suggest that Treg cells may 
be shutting down the Th1 response with TGFβ expression in response to E. coli stimulation. 
While this study is one of the larger and more extensive studies on immune function in 
horses with PPID, the sample sizes are still small, so it is possible that a difference in TGFβ 
may have existed in response to R. equi stimulation between the Non-PPID and PPID 
horses, but there was not enough power to detect it. 
While the role of lymphocytes in the immune response is crucial, the innate immune 
response is also important to prevent infection. In foals with R. equi infection, inadequate 
neutrophil function also appears to play a role in the ability of R. equi to establish infection 
82,107. Neutrophil function in horses with PPID has been previously examined and reported; 
in one study, neutrophils of horses with PPID exhibited significantly lower oxidative burst, 
but no difference in phagocytosis, compared to Non-PPID horses 48. In a separate study, 
PPID horses and age-matched Non-PPID horses were found to have increased IL-8 
expression compared to Non-PPID adult horses 50. In the work currently presented, no 
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differences in IL-8 expression from unstimulated or stimulated PBMCs were observed. 
However, in the currently presented study, when whole blood was collected directly into 
Tempus™ Blood RNA tubes, which immediately stabilize any RNA, expression of IL-8 
was found to be increased in PPID horses compared to our age-matched Non-PPID horses. 
This suggests that PPID horses may have altered neutrophil activation and/or recruitment 
at a basal level. Due to the other published work that demonstrated decreased oxidative 
burst, plasma myeloperoxidase, a marker of neutrophil degranulation, was examined in this 
study 48. No differences were observed in plasma MPO in the present work, which 
contradicts the previous work that demonstrated differences in oxidative burst of 
neutrophils of PPID horses. 
In the remaining significant results, including body temperature, respiration, pulse, 
IL-17α  expression in the R. equi PBMC stimulation, as well as several of the unstimulated 
and stimulated whole blood samples, the significant differences appeared to be driven 
mainly by single timepoint differences, as well as differences in starting values. These 
differences were not consistent over time, unlike the results discussed at length above. In 
the whole blood unstimulated and stimulated samples, this was likely due to the decreased 
number of sampling timepoints, as these samples were only available for the first three 
timepoints of the study. The temperature differences, where PPID horses tended to have 
lower body temperature than Non-PPID horses, and the respiration differences, where 
PPID horses had higher respiration rates than Non-PPID horses, may also indicate an issue 
with temperature regulation in horses with PPID. Strong time effects were frequently seen 
in complete blood count results, plasma MPO results, and in both stimulated and 
unstimulated PBMC and whole blood cytokine and receptor expression, and in whole blood 
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(Tempus™ Blood RNA tubes) cytokine and receptor expression. With these significant 
time effects, having at least six timepoints of data appeared to minimize the effects of the 
wide variation in the immune response over time and provided more consistent, and likely 
more relevant, findings related to PPID status and PRASCEND treatment effects.  
Overall, the results from this study suggest that horses with PPID are likely at 
increased risk for opportunistic infection and may have a reduced ability to recover from 
bacteremia due to their decreased WBC counts, decreased expression of IFNγ to both R. 
equi and E. coli stimulations, increased expression of TGFβ in PBMC responses to E. coli, 
and increased IL-8 expression in whole blood (Tempus™ Blood RNA tubes). Indeed, these 
results suggest that PPID can cause inadequate immune responses to R. equi that are quite 
similar to those seen in foals under six months of age, which may offer an explanation as 
to why some adult horses appear susceptible to R. equi infection. The lack of difference in 
the PMA/ionomycin-stimulated samples demonstrates that in the presence of a strong 
stimuli, PPID horses do not respond differently than Non-PPID horses. This further 
supports the conclusion that PPID horses are likely at higher risk of opportunistic infection 
rather than infection from pathogens that also affect healthy hosts. In addition, the many 
significant time effects demonstrate that immune responses in horses, regardless of PPID 
status, are quite variable over time; this stresses the importance of careful study design and 
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 Table 3.1. Number of outliers removed from whole blood (Tempus™ Blood RNA 
tubes) cytokine and receptor gene expression sample analyses 

















Table 3.2. Number of outliers removed from peripheral blood mononuclear cell (PBMC) 
(unstimulated/stimulated) cytokine and receptor gene expression sample analyses 
Cytokine/Receptor # of media 
outliers 
removed 
# of R. equi 
outliers 
removed 
# of E. coli 
outliers 
removed 
# of PMA 
outliers 
removed 
IFNγ 4 1 2 0 
IL-10 2 2 2 0 
IL-17α 0 0 4 0 
IL-12α 0 0 0 0 
IL-13 2 0 0 0 
IL-6 0 4 4 3 
IL-8 1 2 3 0 
TLR4 2 1 4 2 
TGFβ 2 0 0 0 
TNFα 1 0 0 1 





Table 3.3. Number of outliers removed from whole blood (unstimulated/stimulated) 
cytokine and receptor gene expression sample analyses 




# of R. equi 
outliers 
removed 
# of E. coli 
outliers 
removed 
# of PMA 
outliers 
removed 
IFNγ 0 1 1 0 
IL-12α 0 1 2 0 
IL-13 0 0 0 0 
IL-17α 0 2 0 0 
IL-1β 1 0 2 0 
IL-6 0 0 0 0 
IL-8 0 0 3 1 
TGFβ 0 0 0 0 
TLR2 0 1 0 1 
TLR4 0 0 0 0 




















Figure 3.1. Body Temperature 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 
10 horses in the Non-PPID group and 18 horses in the PPID group. By the end of the study, 
there were 9 horses in the Non-PPID group and 13 horses in the PPID group. * denotes a 









































































Figure 3.2. (A) Pulse (B) Pulse (starting values as a covariate in the model) 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses are represented by lines with open 
squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 horses in the PPID group. By 
the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID group. * denotes a significant 








Figure 3.3. Respiration 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 
10 horses in the Non-PPID group and 18 horses in the PPID group. By the end of the study, 
there were 9 horses in the Non-PPID group and 13 horses in the PPID group. * denotes a 






































































































Figure 3.4. White Blood Cell count (x103/μl)  
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 
10 horses in the Non-PPID group and 18 horses in the PPID group. By the end of the study, 
there were 9 horses in the Non-PPID group and 13 horses in the PPID group. * denotes a 





























































































































Figure 3.5. (A) Absolute lymphocyte counts (B) Absolute lymphocyte counts (starting values as a covariate in the model) 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses are represented by lines with open 
squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 horses in the PPID group. By 
the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID group. * denotes a significant 



























































































































































































































Figure 3.6.  (A) Red blood cell counts (B) Red blood cell counts (starting values as covariate in the model) 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses are represented by lines with open 
squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 horses in the PPID group. By 
the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID group. * denotes a significant 




































































































































































































































































































































Figure 3.7. Significant time effects for (A) absolute banded neutrophils, (B) 
absolute monocytes, (C) absolute eosinophils, and (D) absolute basophils.  
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 
10 horses in the Non-PPID group and 18 horses in the PPID group. By the end of the study, 
there were 9 horses in the Non-PPID group and 13 horses in the PPID group. These graphs 





















































































































































































































































Figure 3.8. Significant time effects for (A) packed cell volume, (B) hemoglobin, and (C) total protein 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses are represented by lines with open 
squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 horses in the PPID group. By 
the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID group. These graphs show only the 















Figure 3.9. Plasma myeloperoxidase concentration 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses are represented by lines with open squares. 
At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 horses in the PPID group. By the end of the 









Figure 3.10. (A) Whole blood (Tempus™) IL-8 expression (B) Whole blood (Tempus™) IL-8 expression (starting values as 
covariate in the model) 
Mean +/- SEM. RQs are natural log-transformed (Ln). Non-PPID horses are represented by lines with closed circles. PPID 
horses are represented by lines with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID 
group and 18 horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in 
the PPID group. * denotes a significant difference (P<.05) between Non-PPID and PPID groups. PPID-pituitary pars 


























































































































































































































































































































































Figure 3.11. Significant time effects in whole blood (Tempus™) cytokine expression for (A) IFNγ, (B) IL-1β, (C) IL-6, (D) 
IL-12α, (E) IL-13, and (F) IL-17α 
Mean +/- SEM. (A-D, F) Non-PPID horses are represented by lines with closed circles. PPID horses are represented by lines with open 
squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 horses in the PPID group. By the end 
of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID group. (E) Non-PPID horses are represented by lines 
with closed circles. PPID Treatment horses are represented by lines with closed triangles. PPID Control horses are represented by lines 
with closed squares. At Day 0 (Early September 2017), there were 10, 9, and 9 horses in the Non-PPID, PPID Control, and PPID 





Treatment groups, respectively. These graphs show only the significant time effects (P<.05) for the respective analyses. PPID-pituitary 



































































































































































































































































Figure 3.12. Significant time effects in whole blood (Tempus™) cytokine and receptor expression for (A) TGFβ, (B) TLR2, 
(C) TLR4, (D) TNFα 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses are represented by lines with open squares. 
At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 horses in the PPID group. By the end of the 
study, there were 9 horses in the Non-PPID group and 13 horses in the PPID group. These graphs show only the significant time effects 
(P<.05) for the respective analyses. PPID-pituitary pars intermedia dysfunction.; TGFβ-transforming growth factor beta; TLR-toll-like 























































































































































































PBMC R. equi stimulation: IFNy





Figure 3.13. (A) Unstimulated peripheral blood mononuclear cell (PBMC) IFNγ expression (B) PBMC IFNγ expression after 
heat-inactivated R. equi-stimulation and with media as a covariate in the model. (C) PBMC IFNγ expression after heat-
inactivated R. equi-stimulation and with media and starting values as a covariate in the model 
Mean +/- SEM. RQs are natural log-transformed (Ln). Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 
18 horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID 
group. * denotes a significant difference (P<.05) between Non-PPID and PPID groups. PPID-pituitary pars intermedia 








Figure 3.14. (A) Unstimulated peripheral blood mononuclear cell (PBMC) IL-17α expression (B) PBMC IL-17α expression 
after heat-inactivated R. equi-stimulation and with media as a covariate in the model 
Mean +/- SEM. RQs are natural log-transformed (Ln). (A) Non-PPID horses are represented by lines with closed circles. PPID 
horses are represented by lines with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID 
group and 18 horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the 
PPID group. (B) Non-PPID horses are represented by lines with closed circles. PPID Treatment horses are represented by lines 
with closed triangles. PPID Control horses are represented by lines with closed squares. At Day 0 (Early September 2017), there 
were 10, 9, and 9 horses in the Non-PPID, PPID Control, and PPID Treatment groups, respectively. By the end of the study, 
there were 9, 7, and 6 horses in the Non-PPID, PPID Control, and PPID Treatment groups, respectively.  denotes a significant 
difference (P<.05) between Non-PPID and PPID Treatment. # denotes a significant difference (P<.05) between PPID Treatment 




























































































































































































Figure 3.15. (A) Unstimulated peripheral blood mononuclear cell (PBMC) IFNγ expression (B) PBMC IFNγ expression after 
heat-inactivated E. coli-stimulation and with media as a covariate in the model. (C) PBMC IFNγ expression after heat-
inactivated E. coli-stimulation and with media and starting values as a covariate in the model 
Mean +/- SEM. RQs are natural log-transformed (Ln). Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 
18 horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID 
group. * denotes a significant difference (P<.05) between Non-PPID and PPID groups. PPID-pituitary pars intermedia 
































































































































Figure 3.16. (A) Unstimulated peripheral blood mononuclear cell (PBMC) TGFβ expression (B) PBMC TGFβ expression after 
heat-inactivated E. coli-stimulation and with media as a covariate in the model 
Mean +/- SEM. RQs are natural log-transformed (Ln). Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 
18 horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID 
group. PPID-pituitary pars intermedia dysfunction; TGFβ-transforming growth factor beta; E. coli-Escherichia coli; RQ-relative 




























































































































































































































Figure 3.17. Significant time effects in unstimulated peripheral blood 
mononuclear cell (PBMC) cytokine expression for (A) IL-1β, (B) IL-8, (C) IL-10, 
(D) IL-12α 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 
10 horses in the Non-PPID group and 18 horses in the PPID group. By the end of the study, 
there were 9 horses in the Non-PPID group and 13 horses in the PPID group. These graphs 
show only the significant time effects (P<.05) for the respective analyses. PPID-pituitary 






Figure 3.18. Significant time effects in R. equi-stimulated peripheral blood mononuclear cell (PBMC) cytokine expression with 
media as a covariate in the model for (A) IL-8, (B) IL-10, (C) IL-13. 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses are represented by lines with open 
squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 horses in the PPID group. By 
the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID group. These graphs show only the 
significant time effects (P<.05) for the respective analyses. PPID-pituitary pars intermedia dysfunction; R. equi-Rhodococcus 



























































































































































































































































































































































































































Figure 3.19. Significant time effects in E. coli-stimulated peripheral blood mononuclear cell (PBMC) cytokine expression with 
media as a covariate in the model for (A) IL-1β, (B) IL-8, (C) IL-10, (D) IL-13, (E) IL-17α, and (F) TLR4. 
Mean +/- SEM. (A-D, F) Non-PPID horses are represented by lines with closed circles. PPID horses are represented by lines 
with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 horses in the PPID 
group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID group. (E) Non-PPID 
horses are represented by lines with closed circles. PPID Treatment horses are represented by lines with closed triangles. PPID 
Control horses are represented by lines with closed squares. At Day 0 (Early September 2017), there were 10, 9, and 9 horses in 
the Non-PPID, PPID Control, and PPID Treatment groups, respectively. By the end of the study, there were 9, 7, and 6 horses 
in the Non-PPID, PPID Control, and PPID Treatment groups, respectively. These graphs show only the significant time effects 
(P<.05) for the respective analyses. PPID-pituitary pars intermedia dysfunction; E. coli-Escherichia coli; IL-interleukin; TLR-






































































































































































































































































Figure 3.20. Significant time effects in PMA/ionomycin-stimulated peripheral 
blood mononuclear cell (PBMC) cytokine expression for (A) IFNγ, (B) IL-1β, (C) 
IL-6, and (D) IL-8 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 
10 horses in the Non-PPID group and 18 horses in the PPID group. By the end of the study, 
there were 9 horses in the Non-PPID group and 13 horses in the PPID group. These graphs 
show only the significant time effects (P<.05) for the respective analyses. PPID-pituitary 










































































































































































































































Figure 3.21. Significant time effects in PMA/ionomycin-stimulated peripheral 
blood mononuclear cell (PBMC) cytokine expression for (A) IL-17α, (B) TGFβ, 
(C) TLR4, and (D) TNFα 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 
10 horses in the Non-PPID group and 18 horses in the PPID group. By the end of the study, 
there were 9 horses in the Non-PPID group and 13 horses in the PPID group. These graphs 
show only the significant time effects (P<.05) for the respective analyses. PPID-pituitary 
pars intermedia dysfunction; IL-interleukin; TGFβ-transforming growth factor beta; TLR-








Figure 3.22. (A) Unstimulated whole blood TLR4 expression (B) Unstimulated whole blood TLR4 expression with starting 
values as a covariate in the model 
Mean +/- SEM. RQs are natural log-transformed (Ln). Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 
18 horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID 
group. * denotes a significant difference (P<.05) between Non-PPID and PPID groups. PPID-pituitary pars intermedia 







































Figure 3.23. (A) Unstimulated whole blood TGFβ expression (B) Unstimulated whole blood TGFβ expression with starting 
values as a covariate in the model 
Mean +/- SEM. RQs are natural log-transformed (Ln). Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 
18 horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID 
group. * denotes a significant difference (P<.05) between Non-PPID and PPID groups. PPID-pituitary pars intermedia 






Figure 3.24. (A) Unstimulated whole blood IL-13 expression (B) Unstimulated whole blood IL-13 expression with starting 
values as a covariate in the model 
Mean +/- SEM. RQs are natural log-transformed (Ln). Non-PPID horses are represented by lines with closed circles. PPID 
Treatment horses are represented by lines with closed triangles. PPID Control horses are represented by lines with closed squares. 
At Day 0 (Early September 2017), there were 10, 9, and 9 horses in the Non-PPID, PPID Control, and PPID Treatment groups, 
respectively. By the end of the study, there were 9, 7, and 6 horses in the Non-PPID, PPID Control, and PPID Treatment groups, 
respectively. ‡ denotes a significant difference (P<.05) between Non-PPID and PPID Treatment. # denotes a significant difference 


































































Figure 3.25. (A) Unstimulated whole blood IL-6 expression (B) Unstimulated whole 
blood IL-6 expression with starting values as a covariate in the model. (C) Heat-
inactivated R. equi-stimulated whole blood IL-6 expression (D) Heat-inactivated R. equi-
stimulated whole blood IL-6 expression with starting values as a covariate in the model 
Mean +/- SEM. RQs are natural log-transformed (Ln). Non-PPID horses are represented 
by lines with closed circles. PPID horses are represented by lines with open squares. At 
Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 horses 
in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 
13 horses in the PPID group. * denotes a significant difference (P<.05) between Non-PPID 
and PPID groups. PPID-pituitary pars intermedia dysfunction; IL-interleukin; R. equi-








Figure 3.26. (A) Unstimulated whole blood IL-8 expression (B) Unstimulated whole blood IL-8 expression with starting values 
as a covariate in the model. (C) Heat-inactivated R. equi-stimulated whole blood IL-8 expression 
Mean +/- SEM. RQs are natural log-transformed (Ln). Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 
18 horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID 
group. * denotes a significant difference (P<.05) between Non-PPID and PPID groups. PPID-pituitary pars intermedia 


















































































































Figure 3.27. (A) Unstimulated whole blood TLR4 expression (B) Unstimulated whole blood TLR4 expression with starting 
values as a covariate in the model. (C) Heat-inactivated E. coli-stimulated whole blood TLR4 expression 
Mean +/- SEM. RQs are natural log-transformed (Ln). Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 
18 horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID 
group. * denotes a significant difference (P<.05) between Non-PPID and PPID groups. PPID-pituitary pars intermedia 







































































































Figure 3.28. Significant time effects in unstimulated whole blood cytokine expression for (A) IFNγ, (B) IL-12α, and (C) TNFα 
Mean +/- SEM. RQs are natural log-transformed (Ln). Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 
18 horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID 
group. These graphs show only the significant time effects (P<.05) for the respective analyses. PPID-pituitary pars intermedia 






Figure 3.29. Significant time effects in R-equi-stimulated whole blood cytokine expression of (A) IFNγ, (B) IL-1β, and (C) IL-
12α 
Mean +/- SEM. RQs are natural log-transformed (Ln). Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 
18 horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID 
group. These graphs show only the significant time effects (P<.05) for the respective analyses. PPID-pituitary pars intermedia 


















































































































































































Figure 3.30. Significant time effects in R-equi-stimulated whole blood cytokine 
expression of (A) IL-13, (B) IL-17α, (C) TLR2, and (D) TLR4 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 
10 horses in the Non-PPID group and 18 horses in the PPID group. By the end of the study, 
there were 9 horses in the Non-PPID group and 13 horses in the PPID group. These graphs 
show only the significant time effects (P<.05) for the respective analyses. PPID-pituitary 



























































































































Figure 3.31. Significant time effects in E. coli-stimulated whole blood cytokine expression of (A) IL-8, (B) IL-17α, and (C) 
TLR2 
Mean +/- SEM. RQs are natural log-transformed (Ln). Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 
18 horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID 
group. These graphs show only the significant time effects (P<.05) for the respective analyses. PPID-pituitary pars intermedia 






Figure 3.32. Significant time effects in PMA/ionomycin-stimulated whole blood cytokine 
expression of (A) IFNγ, (B) IL-1β, (C) IL-6, and (D) IL-17α 
Mean +/- SEM. (A-C) Non-PPID horses are represented by lines with closed circles. PPID 
horses are represented by lines with open squares. At Day 0 (Early September 2017), there 
were 10 horses in the Non-PPID group and 18 horses in the PPID group. By the end of the 
study, there were 9 horses in the Non-PPID group and 13 horses in the PPID group. (D) 
Non-PPID horses are represented by lines with closed circles. PPID Treatment horses are 
represented by lines with closed triangles. PPID Control horses are represented by lines 
with closed squares. At Day 0 (Early September 2017), there were 10, 9, and 9 horses in 
the Non-PPID, PPID Control, and PPID Treatment groups, respectively. By the end of the 
study, there were 9, 7, and 6 horses in the Non-PPID, PPID Control, and PPID Treatment 
groups, respectively. These graphs show only the significant time effects (P<.05) for the 









Figure 3.33. Significant time effects in PMA/ionomycin-stimulated whole blood cytokine expression of (A) TGFβ, (B) TLR2, 
and (C) TNFα 
Mean +/- SEM. RQs are natural log-transformed (Ln). Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 
18 horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID 
group. These graphs show only the significant time effects (P<.05) for the respective analyses. PPID-pituitary pars intermedia 





CHAPTER 4. EFFECTS OF PITUITARY PARS INTERMEDIA DYSFUNCTION AND 
PRASCEND® TREATMENT ON LOCALIZED IMMUNE FUNCTION WITHIN 
THE LUNG OF HORSES 
4.1 Abstract 
Background: It remains unclear how Pituitary Pars Intermedia Dysfunction (PPID) and 
treatment with Prascend® (pergolide tablets) affect local immune function within the lung 
of horses. 
Hypotheses: Our hypotheses were that PPID horses would have altered immune function 
within the lung compared to Non-PPID horses, and that treatment with PRASCEND would 
normalize immune function in PPID Treatment horses to that of the Non-PPID horses. 
Animals: 28 horses from a research herd (10 Non-PPID, 9 untreated PPID (PPID Control), 
and 9 PRASCEND-treated PPID horses (PPID Treatment)) were used. 
Methods: Horses were sampled three times over approximately fifteen months for analysis 
of bronchoalveolar lavage fluid (BALF) cytology, BALF myeloperoxidase, and 
bronchoalveolar lavage (BAL) cell cytokine and receptor gene expression in response to 
stimuli. Bronchoalveolar lavages (BAL) were performed at Day 0, 8 weeks, and 1-year-
and-6-weeks to allow for evaluations of the short-term (8 weeks) and long-term (1-year-
and-6-weeks) effects of PRASCEND treatment. For the in vitro stimulations, heat-
inactivated R. equi, heat-inactivated E. coli, and phorbal 12-myristate 13-acetate 
(PMA)/ionomycin were used. PRASCEND treatment was initiated after Day 0 collections. 





Results: PPID horses had a lower percentage of eosinophils in BALF than Non-PPID 
horses at the Early September 2017 timepoint only. In unstimulated BAL samples, PPID 
horses had lower IL-13 expression than Non-PPID horses at the Mid-October 2018 
timepoint only. In R. equi-stimulated samples, PPID horses had lower IL-13 expression 
than Non-PPID horses at the Early November 2017 and Mid-October 2018 timepoints. The 
TGFβ analysis for R. equi-stimulated samples also showed significant group by time 
effects, but the Non-PPID and PPID horses were not different at any timepoint. For IL-12α 
and TLR2 expression in R. equi-stimulated samples, significant group by time effects were 
observed, but these appeared to be driven by starting differences. PPID horses had lower 
BALF myeloperoxidase concentrations than Non-PPID horses at the Mid-October 2018 
timepoint only. 
Conclusions: The identified significant effects may indicate altered Th2 responses within 
the lungs of PPID horses, but it is also possible that these results are not biologically 
significant or real differences as they were generally not temporally consistent. This was 
likely due to the small sample size and few timepoints. Often, significant results were only 
apparent at single timepoints and were likely heavily influenced by one or several values. 
Although it significantly reduced plasma ACTH concentrations, PRASCEND did not 
appear to affect immune function within the lung in this study. 
 
4.2 Introduction 
As a result of their increased plasma ACTH concentrations, horses with PPID are 
often thought to have reduced immune function compared to Non-PPID horses, which may 




the respiratory tract 7-9,48. Generally, this is thought to occur because of the normal 
hypothalamus-pituitary-adrenal axis response to increased ACTH, which is to increase 
cortisol concentrations, thereby impacting immune function 18,19. Unfortunately, the 
currently published literature on immune function in horses with PPID is rather sparse.  
Furthermore, to the author’s knowledge, there is currently no published research to 
investigate the immune function of the lung in horses with PPID. However, in individuals 
with compromised immune function, opportunistic infection is common within the 
respiratory tract due to its exposure to the external environment 58,59. It has been noted that 
horses with PPID frequently experience sinusitis, bronchopneumonia, and other infections 
7,47-49,58,59,112. When available, cultures often show infection with multiple bacterial and 
fungal species considered opportunistic 58,59,66,70. Additionally, one study that described 
pathological changes in PPID horses during post-mortem examinations showed increased 
findings of bronchiolitis and bronchointerstitial inflammation in PPID horses compared to 
both young and aged Non-PPID horses 56.  
Due to the anecdotal evidence for increased susceptibility to respiratory infections in 
horses with PPID, as well as the pathological findings reported in the lungs of PPID horses, 
it followed that analysis of the immune function within the lung of the PPID horse was 
needed to determine if altered local immune responses are responsible for the potential 
increased susceptibility to infection. In order to analyze this, bacteria considered 
opportunistic in adult horses were used for in vitro stimulation of cells obtained via 
bronchoalveolar lavage (BAL). In general, most pneumonia cases in horses are caused by 
bacteria or fungi that are considered opportunistic 58,59. Although frequently seen in foals 




and generally occurs when immune function is compromised 59,65-67,82. This can occur 
secondary to chronic diseases or viral infection, as well as after administration of 
immunosuppressive drugs, such as corticosteroids 58,59. Escherichia coli is commonly 
isolated from pneumonia cases in adult horses 58.  
R. equi and E. coli were selected for the in vitro stimulations of BAL cells in order 
to analyze the immune response to opportunistic bacteria for adult horses that were both 
gram-positive and gram-negative, respectively. The hypotheses for this work was that 
PPID horses would have altered localized immune responses basally and in response to 
stimuli within the lung when compared to Non-PPID horses; additionally, we anticipated 
that treatment with Prascend® (pergolide tablets) (Boehringer-Ingelheim Animal Health; 
Duluth, GA) would normalize the local immune responses within the lung to those of the 
age-matched Non-PPID horses. 
 
4.3 Materials and Methods 
 
4.3.1 Animal Selection and Study Design 
Horses were initially selected for potential inclusion in the study from a university-
owned research herd based on prior screenings and clinical history (absence or presence of 
hypertrichosis and/or absence or presence of history of hypertrichosis/difficulty shedding 
and/or results of multiple TRH stimulation tests). PPID status was confirmed using ACTH 
responses to TRH stimulation tests approximately two weeks prior to Day 0 of the study 
(Early September 2017) and basal ACTH values on Day 0. An oral sugar test (OST) was 




to assess hyperinsulinemia or insulin dysregulation status 87. Horses that did not screen as 
either Non-PPID or PPID for both the TRH stimulation test and basal ACTH screenings 
were excluded from the study.  As these initial screenings were obtained during the fall 
season in the USA (late August and early September), a basal ACTH value ≥100pg/mL 
and ACTH 10 minutes post-TRH injection (T10) value ≥400pg/mL were used for selection 
into the PPID group 8,9.  
Thirty-one horses were originally selected to proceed through the study. However, 
three horses assigned to the PRASCEND-treated group had ACTH values that failed to 
become controlled and remained uncontrolled throughout the study; these horses were 
excluded from all analyses and are not discussed further. Non-PPID horses (n=10) were all 
assigned to one group. An attempt was made to randomly assign the PPID horses into the 
untreated and treated groups, however, due to also attempting to block for insulin status, 
true randomization was not possible. PPID Control horses (n=9) remained untreated for 
the duration of the study, and PPID Treatment horses (n=9) began receiving PRASCEND 
within approximately 24 hours of their completion of all Day 0 sample collections. Horses 
were started at the lowest label dose (2 μg/kg) to the nearest half-tablet for their body 
weight, based on the manufacturer’s label recommendations. Basal ACTH was checked 
weekly for the first 4 weeks, and the dose was increased each week until basal ACTH levels 
were reduced to controlled (Non-PPID) values or until the maximum label dose (4 μg/kg) 
to the nearest half-tablet was reached.  
Throughout the approximately 15-month study, six horses were euthanized due to 
non-study related health issues. The study ended with 9, 7, and 6 horses in the Non-PPID, 




was no statistical difference in age between the groups (P=.1747) (Table 2.1). Age ranges 
were 20-29 years for Non-PPID horses, 21-31 years for PPID Control horses, and 19-29 
years for PPID Treatment horses. Only mares and geldings were included (Table 2.2). 
Breed representations, either confirmed or to the best of the researchers’ knowledge, 
included Thoroughbred (n=14), American Quarter Horse (n=4), Standardbred (n=1), 
Standardbred cross (n=1), Mustang (n=1), Paint (n=1), Arabian (n=1), Tennessee Walking 
Horse (n=1), Appaloosa (n=1), and unknown or mixed breed (n=3) horses (Table 2.2). 
Breakdowns of sex and breed by group are included in Table 2.2. All horses were cared for 
and sampled with approval of the University of Kentucky’s Institutional Animal Use and 
Care Committee (IACUC) (#2014-1225 and #2018-3004). 
4.3.2 Sampling 
On sampling days, horses were grain fasted (if part of their normal ration) until all 
collections were completed and had recovered from sedation. At three timepoints (Early 
September 2017, Early November 2017, and Mid-October 2018), bronchoalveolar lavages 
were performed within a four-hour window (approximately 10:00 to 14:00) of the blood 
collections for endocrine and systemic immune function analyses, as described in Chapters 
2 and 3. At each timepoint, all samples (not including the TRH stimulation tests or OSTs) 
were collected over a period of 1-4 days, but within the same time window above (10:00 
to 14:00); when multiple days were needed to complete all of the collections, a mixture of 
horses from the three groups were screened each day. Blood and BAL collections for each 
horse were performed on the same day. The local immune function measures investigated 
at the three time points included BALF cytology, BALF myeloperoxidase (MPO) analysis, 




bronchoalveolar lavage cells. Rectal temperature, pulse, and respiration were also recorded 
at these three timepoints. Appendix 2 contains a sample timeline. 
BALF cytology and BAL sample collections 
Horses were sedated intravenously (dormosedan and torbugesic) prior to the start 
of the procedure. A sterile bronchoalveolar lavage tube was lubricated with sterile lube, 
inserted into the nasal passage, and guided until seated in a bronchiole. Approximately 
60mL of sterile saline (0.9% NaCl) was infused into the lung and immediately removed. 
This was repeated five times for a total saline infusion of approximately 300mL, with total 
recovery of approximately 200mL of BALF, which was then kept on ice. Approximately 
6mL of the recovered sample was placed into a blood tube with EDTA for cytological 
analysis. A sterile swab was used to make slides for each sample. BALF differential counts 
were performed by a board-certified pathologist at the University of Kentucky’s Veterinary 
Diagnostic Laboratory (Lexington, KY). 
BAL cell (unstimulated and stimulated) cytokine and receptor gene expression 
The recovered BAL specimens were centrifuged at 400g for ten minutes to allow 
for isolation of the BAL cells. The supernatant was then collected and filtered through a 2-
micron filter and frozen at -20°C. The remaining cells were washed twice with cold 
phosphate-buffered saline (PBS) and filtered through a sterile gauze square to remove any 
mucous 113. The cells were then frozen in freeze media (50% HyClone™ RPMI 1640 media 
(GE Healthcare), 40% fetal bovine serum (Sigma Aldrich; St. Louis, MO), and 10% 
dimethyl sulfoxide (DMSO) (Sigma Aldrich)) at -80°C, and transferred to liquid nitrogen 




After thawing the BAL cells and resuspending in complete RPMI ( 96.4% 
HyClone™ RPMI 1640 media (GE Healthcare), 2.5% fetal equine serum, 1% penicillin, 
streptomycin, L-Glutamine solution (Sigma Aldrich), and 0.1% 2-mercaptoethanol 
(Gibco™)), the cells were counted using a Vi-CELL counter (Beckman Coulter; 
Indianapolis, Indiana), and plated at 4x106 cells per well into a total of four wells of a cell 
culture plate. Due to the lower cell counts associated with BAL collections, not all horses 
had enough cells for all stimulations, therefore, the number of samples available for each 
stimulation and timepoint varied. If cell counts permitted, each horse had a total of four 
cell stimulations. One well remained unstimulated, one well was stimulated with heat-
inactivated Rhodococcus equi 103+ (107 CFU in 10 μL of complete RPMI) for 24 hours, 
one well was stimulated with heat-inactivated Escherichia coli (ATCC #35218) (107 CFU 
in 10 μL of complete RPMI) for 24 hours, and one well was stimulated with 10 μL phorbal 
12-myristate 13-acetate (PMA)/ionomycin for the last four hours of incubation. A dose 
response pilot study was conducted in advance to determine the best dose for each of the 
bacteria used in the stimulations that would elicit a sub-maximal response. The cells were 
incubated at 37°C with 5% CO2 after plating and bacterial stimulations. Brefeldin A was 
added to all wells after 20 hours of incubation. After 24 hours, approximately half of the 
cells were removed, and TRIzol™ (Invitrogen™) was added. These samples were stored at 
-80°C until RNA was isolated via phenol-chloroform extraction. After RNA isolation, the 
samples were placed back in the -80°C freezer until reverse transcribed (described below). 
Gene expression of IFNγ, IL-12α, IL-13, IL-17α, IL-1β, IL-6, IL-8, TGFβ, TNFα, TLR2, 






Prior to reverse transcription, RNA was quantified via Epoch microplate 
spectrophotometer (Biotek; Winooski, Vermont). Master mix reagents (Promega; 
Madison, Wisconsin) were used to transcribe the RNA; after addition of the reagents, 
samples were placed into a thermocycler (Applied Biosystems; Foster City, California) for 
a cycle of 15 minutes at 42oC, followed by a cycle of 5 minutes at 95oC 98-102. After 
completion of RNA reverse transcription to cDNA, the samples were stored -80oC until 
used for RT-PCR (described below).  
RT-PCR 
For the desired cytokine analyses and the endogenous control gene, β-gus, equine-
specific intron spanning primers and probes (Applied Biosystems), nuclease-free water 
(Qiagen), TaqMan™ (Applied Biosystems), and the desired cDNA samples were loaded 
onto plates in duplicate via a robotic pipetting machine (Eppendorf) 98-102. RT-PCR was 
then performed using the 7900HT Fast RT-PCR System (Applied Biosystems) with the 
first cycle of 10 minutes at 95oC, and an additional 40 cycles of 15 seconds at 95oC and 60 
seconds at 60oC 98-102. After determination of cycle threshold values using linear regression 
analysis (LinRegPCR version 2018; Heart Failure Research Center, Amsterdam University 
Medical Centers), relative quantity (RQ) values were calculated using the 2-ΔΔCt method 98-
103. The calibrator for the BAL stimulations was the average ΔCT of the Day 0 (Early 
September 2017) media values for all of the Non-PPID horses. All RQs were natural log 





Rhodococcus equi culture and heat-inactivation 
A Rhodococcus equi 103+ culture was kindly supplied by the lab of Dr. David 
Horohov. The stock solution was streaked onto plates containing tryptic soy agar (VWR®) 
using a sterile inoculating loop (VWR® International). After approximately 48 hours of 
growth at 37°C, one colony was selected and used to inoculate a tube of tryptic soy broth 
(Corning®). After sealing the tube and briefly vortexing, a sterile inoculating loop was used 
to inoculate additional broth tubes. These broth tubes were then incubated at 37°C for 
approximately 48 hours with caps in aerobic growth positioning. The main broth tube was 
then aliquoted and frozen for future use. The additional broth tubes were used to establish 
a growth curve and to determine the ideal time to heat-inactivate the bacteria. Based on the 
growth curve results, the bacteria were then pulled in the exponential growth period (after 
approximately 40 hours of growth) for all further work. Heat inactivation time was selected 
so that the minimum heat and time necessary for inactivation was achieved, in order to 
minimize any changes to the bacteria. After approximately 40 hours of growth, the 
inoculated broth tubes were placed into a water bath at 60°C for various times and then 
streaked onto tryptic soy agar plates to confirm inactivation. The plates were checked at 48 
hours after plating to determine if growth was present. The minimum time needed for heat-
inactivation of R. equi was 50 minutes at 60°C.  
Once the growth curve and heat inactivation time were determined, the final batches 
were prepared in similar fashion to the above descriptions. The stock solution was streaked 
onto tryptic soy agar plates and after approximately 48 hours of growth, a colony was 
selected to inoculate a broth tube. After sealing the tube and briefly vortexing it, a sterile 




37°C. After approximately 40 hours, the broth tubes were removed from the incubator, and 
the volume of broth was measured as the tubes were combined into a sterile glass bottle. 
After a brief vortex, 100μL of broth was removed and serially diluted five times before 
plating 25μL in duplicate. The number of colonies was then counted on these two plates at 
approximately 48 hours of growth and averaged; this count was used to determine the 
colony-forming units (CFU) per milliliter.  Then, the broth was aliquoted into new sterile 
tubes, and heat-inactivated for 50 minutes at 60°C. After heat inactivation, the broth was 
combined again into a sterile glass bottle, 25μL was plated in duplicate to confirm 
inactivation, and the final volume of broth was measured, so that accurate counts could be 
obtained. The final heat-inactivated broth was then frozen at -20°C. When needed for 
stimulations, the broth was thawed, centrifuged at 3,400g for ten minutes, and the pellet 
resuspended in complete RPMI. The final broth was positive for R. equi and VapA 
expression on Real Time PCR, performed by the University of Kentucky Veterinary 
Diagnostic Lab (Lexington, Kentucky). 
Escherichia coli culture and heat-inactivation 
Escherichia coli (ATCC #35218) was obtained from VWR (Microbiologics, Inc.; 
St. Cloud, Minnesota) in KWIK-STIK™ vials. The KWIK-STIK™ vial was crushed, and 
the sterile swab was streaked onto plates containing Difco™ nutrient agar (VWR®; BD 
Biosciences). After approximately 24 hours of growth at 37°C, one colony was selected 
and used to inoculate a tube of Difco™ nutrient broth (VWR®, BD Biosciences). After 
sealing the tube and briefly vortexing, a sterile inoculating loop was used to inoculate 
additional broth tubes. These broth tubes were then incubated at 37°C for approximately 




and frozen for future use. The additional broth tubes were used to establish a growth curve 
and to determine the ideal time to heat-inactivate the bacteria. Based on the growth curve 
results, the bacteria were then pulled in the exponential growth period (after approximately 
24 hours of growth) for all further work. Heat inactivation time was selected so that the 
minimum heat and time necessary for inactivation was achieved, in order to minimize any 
changes to the bacteria. Bacteria were placed into a water bath at 60°C for various times 
and then streaked onto tryptic soy agar plates to confirm inactivation. The plates were 
checked at 24 hours after plating to determine if growth was present. The minimum time 
needed for heat-inactivation of E. coli was 7.5 minutes at 60°C.  
Once the growth curve and heat inactivation time were determined, the final batches 
were prepared in similar fashion to the above descriptions. The stock solution was streaked 
onto Difco™ nutrient agar plates and after approximately 24 hours of growth, a colony was 
selected to inoculate a broth tube. After sealing the tube and briefly vortexing it, a sterile 
inoculating loop was used to inoculate multiple broth tubes, which were then incubated at 
37°C. After approximately 24 hours, the broth tubes were removed from the incubator, and 
the volume of broth was measured as the tubes were combined into a sterile glass bottle. 
After a brief vortex, 100μL of broth was removed and serially diluted six times before 
plating 25μL in duplicate. The number of colonies was then counted on these two plates at 
approximately 24 hours of growth and averaged; this count was used to determine the 
CFU/mL. Then, the broth was aliquoted into new sterile tubes, and heat-inactivated for 7.5 
minutes at 60°C. After heat inactivation, the broth was combined again into a sterile glass 
bottle, 25μL was plated in duplicate, and the final volume of broth was measured, so that 




20°C. When needed for stimulations, the broth was thawed, centrifuged at 3,400g for ten 
minutes, and the pellet resuspended in complete RPMI.  
 
BALF myeloperoxidase: 
For BALF MPO analysis, the filtered BALF obtained during the BAL cell isolation 
process was used for a previously-validated equine MPO ELISA 97. Filtered BALF was 
diluted 1:50 in phosphate-buffered saline (PBS) (Gibco™; Life Technologies) for the assay 
and absorbance was read at 450nm, as recommended by the manufacturer 97,114. 
 
4.3.3 Statistical Methods 
Distributional assumptions were evaluated using graphical and numerical 
summaries for the presence of gross normality violations. The primary analyses were the 
longitudinal analysis of all measures over time; linear mixed models included main effects 
for group and time. The primary comparisons were the PPID Treatment to PPID Control 
groups and the PPID to Non-PPID groups, when the PPID groups were combined. To 
determine if groups changed differently over time, an F-test for the interaction of group 
and time was used. Graphical summaries and model fit were used to determine the 
specifications of the linear mixed model (PROC MIXED, SAS v9.4). To account for 
repeated measures, an UN, ARMA(1,1), AR(1), TOEP, or TOEPH variance-covariance 
structure was used for each measure, depending on the best model fit based on information 




and a two-sided significance level of .05 was used for all statistical tests. Graphs were 
created using GraphPad Prism v.8.0.2 (San Diego, California). 
Results for PPID Control and PPID Treatment horses were analyzed first. If 
significant group by time differences were observed, these groups remained separate for 
comparison to Non-PPID horses. If no significant group by time differences were observed, 
the PPID Control and PPID Treatment groups were combined before comparison to Non-
PPID horses. If no significant group or group by time differences were observed between 
the combined PPID group and Non-PPID group, all groups were combined for analysis of 
time effects only. 
If starting differences (P<.1) were observed between PPID Control and PPID 
Treatment horses in the initial analyses, starting values were included as a covariate within 
the model. If starting differences (P<.1) were observed between PPID and Non-PPID 
horses, analyses were performed without starting values as a covariate within the model, 
in order to analyze group effects, and then with starting values as a covariate, in order to 
analyze group by time effects; results for each of the methods are presented if applicable. 
For the BAL stimulations, the media (unstimulated) values for each 
cytokine/receptor were included within the model as a covariate to account for changes 
based on where the individual animals started. Additionally, for the RT-PCR and BALF 
MPO results, outliers were removed prior to statistical analyses if they were determined to 
be more than five times lower or higher than the median absolute deviation (MAD) from 







Percent mast cells in BALF: 
No significant group, time, or group by time effects were seen in percent mast cells 
in BALF between any of the groups. 
Percent macrophages, percent lymphocytes, and percent neutrophils in BALF: 
No significant group or group by time effects were seen in percent macrophages, 
percent lymphocytes, or percent neutrophils in BALF between any of the groups. 
Significant time effects in percent macrophages in BALF were observed in the PPID 
Control to PPID Treatment (P<.0001), Non-PPID to PPID (P<.0001), and all groups 
combined (P<.0001) comparisons. Significant time effects in percent lymphocytes in 
BALF were observed in the PPID Control to PPID Treatment (P<.0001), Non-PPID to 
PPID (P<.0001), and all groups combined (P<.0001) comparisons. Significant time effects 
in percent neutrophils in BALF were observed in the Non-PPID to PPID (P=.0082), and 
all groups combined (P=.0195) comparisons. 
Percent eosinophils in BALF: 
No significant group, time, or group by time effects were seen in percent 
eosinophils in BALF between the PPID Control and PPID Treatment horses. After 
combining the PPID Control and PPID Treatment groups for comparison to Non-PPID 
horses, significant time (P=.0311) and group by time (P=.0311) effects, but not a group 
effect alone, were found (Figure 4.1A). In this analysis, the PPID horses had lower 




compared to Non-PPID horses. Due to starting differences between the Non-PPID and 
PPID horses, the analysis was run again with starting values as a covariate to determine if 
the significant group by time changes remained (Figure 4.1B). This subsequent analysis 
still revealed significant group by time effects; therefore, these groups did change over time 
as a result of their group status. 
Summary of significant BALF cytology results: 
Aside from time effects, the only significant difference observed was in the 
percentage of eosinophils in BALF, with PPID horses having a lower percentage of 
eosinophils in BALF than Non-PPID horses at the Early September 2017 timepoint only. 
It is likely that this effect was driven by the significant starting differences, which 
combined with the small sample sizes, may have led to this significant result, and may not 
be biologically relevant. Significant time effects for the Non-PPID to PPID comparisons 
are shown in Figure 4.2. 
 
BAL (unstimulated/stimulated) cytokine and receptor gene expression 
BAL stimulation- Media: 
No significant group, time, or group by time effects were seen in IL-12α, IL-6, IL-
8, or TLR2 between any of the groups. 
No significant group or group by time effects were seen in TGFβ or TLR4 between 
any of the groups. Significant time effects in TGFβ expression were observed in the PPID 




combined (P=.0004) comparisons. Significant time effects in TLR4 expression were 
observed in the PPID Control to PPID Treatment (P=.0087), Non-PPID to PPID (P=.002), 
and all groups combined (P=.0007) comparisons. 
No significant group or group by time effects were seen in IFNγ, TNFα, or IL-1β 
between any of the groups. Due to starting differences between the PPID Control and PPID 
Treatment groups, these analyses were run again with starting values as a covariate in the 
model; the group and group by time effects remained insignificant. No significant time 
effects in IFNγ and IL-1β expression were observed in any of the comparisons. Significant 
time effects in TNFα expression were observed in the PPID Control to PPID Treatment 
(P=.0483) and all groups combined (P=.0385) comparisons. 
A significant group effect (P=.0193), but not a group by time effect, was seen in 
IL-17α expression between the PPID Control and PPID Treatment groups. Due to starting 
differences between these groups, this analysis was run again with starting values as a 
covariate in the model; the group effect was no longer significant and the group by time 
effect remained insignificant. After combining the PPID Control and PPID Treatment 
groups for comparison to Non-PPID horses, no significant group or group by time effects 
were seen. No significant time effects were observed between any of the groups. 
Results for IL-13 are reported very cautiously as there was very late and/or no 
amplification of IL-13 in many of the samples. Therefore, the number of samples available 
for interpretation is very small. In the PPID Control to PPID Treatment comparison, 19 of 
the 45 samples were missing. In the Non-PPID to PPID comparison, 33 of the 75 samples 
were missing. No significant group or group by time effects were seen in IL-13 between 




(P=.021). A significant group by time effect, but not a group or time effect alone, was seen 
in the Non-PPID to PPID comparison (P=.0002) (Figure 4.3). This appears to be driven by 
a significant difference between the groups at the Mid-October 2018 timepoint only; 
however, this must be interpreted cautiously as only 3 Non-PPID and 4 PPID samples were 
available for this timepoint. 
Summary of BAL stimulation- Media:  
There was a possible IL-13 difference with PPID horses having lower IL-13 
expression than Non-PPID horses at the Mid-October 2018 timepoint only, but this is likely 
driven by a few timepoints and the small number of samples, given how many samples had 
no amplification for this analysis. Significant time effects were observed. 
 
BAL stimulation- R. equi: 
No significant group, time, or group by time effects were seen in IL-1β, TLR4, or 
TNFα between any of the groups. 
A significant group effect (P=.0142), but not a group by time effect, was seen in 
IFNγ expression between the PPID Control and PPID Treatment groups. Due to starting 
differences between these groups, this analysis was run again with starting values as a 
covariate; the group effect remained significant and the group by time effect remained 
insignificant. After combining the PPID Control and PPID Treatment groups for 
comparison to Non-PPID horses, no significant group or group by time effects were seen. 




A significant group effect (P=.0013), but no group by time effect, was seen in IL-
6 expression between the PPID Control and PPID Treatment groups. Due to starting 
differences between these groups, this analysis was run again with starting values as a 
covariate; the group effect remained significant and the group by time effect remained 
insignificant. After combining the PPID Control and PPID Treatment groups for 
comparison to Non-PPID horses, no significant group or group by time effects were seen. 
No significant time effects were observed between any of the groups. 
No significant group or group by time effects were seen in IL-8 expression between 
the PPID Control and PPID Treatment groups. Due to starting differences between these 
groups, this analysis was run again with starting values as a covariate; the group effect was 
then significant (P=.0193), but the group by time effect remained insignificant. After 
combining the PPID Control and PPID Treatment groups for comparison to Non-PPID 
horses, no significant group or group by time effects were seen. Significant time effects 
were observed in the all horses combined comparison only (P=.0488). 
A significant group effect (P=.0331), but not a group by time effect, was seen in 
IL-17α expression between the PPID Control and PPID Treatment groups. After combining 
the PPID Control and PPID Treatment groups for comparison to Non-PPID horses, no 
significant group or group by time effects were seen. No significant time effects were 
observed between any of the groups. 
No significant group, time, or group by time effects were seen in TGFβ between 
the PPID Control and PPID Treatment groups. After combining these groups for 
comparison to Non-PPID horses, a significant group by time effect (P=.048) was observed; 




the small sample size as the Non-PPID and PPID groups were not statistically different at 
any timepoint, therefore, this result may have been heavily influenced by one or a few 
individual values. 
A significant group effect (P=.0383), but no group by time effect, was seen in TLR2 
expression between the PPID Control and PPID Treatment groups. Due to starting 
differences between these groups, this analysis was run again with starting values as a 
covariate; the group effect was no longer significant, but the group by time effect was then 
significant (P=.0146) (Figure 4.5C). Due to the significant group by time effects, the PPID 
Control and PPID Treatment groups remained separate for comparison to the Non-PPID 
group. In the PPID Control to PPID Treatment to Non-PPID comparison, no significant 
group or group by time effects were observed (Figure 4.5B). Due to starting differences 
between the PPID Treatment and PPID Control groups only, this analysis was run again 
with starting values as a covariate; the group effect remained not significant, but the group 
by time effect (P=.0196) was then significant (Figure 4.5C). No significant time effects 
were observed in any of the comparisons. The statistically significant results reported here 
appear to be a consequence of the small sample size, which allowed one or a few values to 
influence the results. 
Significant group (P<.0001) and group by time (P=.0178) effects were seen in IL-
12α expression between the PPID Control and PPID Treatment groups. Due to starting 
differences between these groups, this analysis was run again with starting values as a 
covariate; the group effect (P=.0002) and group by time effect (P=.0144) remained 
significant; however, the starting differences were not able to be corrected by including 




PPID Treatment groups remained separate for comparison to the Non-PPID group. In the 
PPID Control to PPID Treatment to Non-PPID comparison, significant group (P=.0047) 
and group by time (P=.0402) effects were observed (Figure 4.6B). Due to starting 
differences between the PPID Treatment and PPID Control groups in this comparison, the 
analysis was run again with starting values as a covariate in the model (Figure 4.6C). The 
group effect (P=.0013) and group by time effect (P=.0284) remained significant; however, 
the starting differences were not able to be corrected by including them as a covariate 
(Figure 4.6C). PPID Treatment horses did not differ from Non-PPID horses at any 
timepoint, and PPID Control horses differed from Non-PPID horses at only the Early 
November 2017 timepoint (Figure 4.6B). PPID Control and PPID Treatment horses 
differed at the Early September 2017 and Early November 2017 timepoint, but not at the 
Mid-October 2018 timepoint (Figure 4.6B). No significant time effects were observed in 
any of the comparisons. Graphically, the significant group by time effect appears to be 
driven by a single value at the Early November 2017 timepoint in the PPID Control group, 
which heavily influenced the analysis. Removal of this value in the PPID Control to PPID 
Treatment to Non-PPID analysis eliminated the significant group by time effect, but not 
the significant group effect. The group effect appears to be driven by significant starting 
differences that were not able to be corrected by including them in the model as a covariate. 
Results for IL-13 are reported very cautiously as there was very late and/or no 
amplification of IL-13 in many of the samples. Therefore, the number of samples available 
for interpretation is very small. In the PPID Control to PPID Treatment comparison, 22 of 
the 41 samples were missing. In the Non-PPID to PPID comparison, 38 of the 67 samples 




between the PPID Control and PPID Treatment groups. Significant group (P=.01) and 
group by time effects (P=.0051), but not time effects, were seen in the Non-PPID to PPID 
comparison (Figure 4.7B). However, these results must be interpreted cautiously as few 
samples were available and results may be heavily influenced by only one or a few values. 
Summary of BAL stimulation- R. equi:  
There was a possible IL-13 difference with PPID horses having lower IL-13 
expression than Non-PPID horses at the Early November 2017 and Mid-October 2018 
timepoints, but this was likely driven by a few timepoints and the small number of samples, 
given how many samples had no amplification for this analysis. For TGFβ responses to in 
vitro R. equi stimulation, the significant group by time result appears to be a consequence 
of the small sample size as the Non-PPID and PPID groups were not statistically different 
at any timepoint, therefore, this result may have been heavily influenced by one or a few 
values. For IL-12α and TLR2 expression, significant effects were observed, but these 
appear driven by starting differences and were likely impacted by the small sample sizes 
and single timepoint differences. 
 
BAL stimulation- E. coli: 
No significant group, time, or group by time effects were seen in IL-17α, IL-1β, IL-
6, IL-8, TGFβ, TLR4, or TNFα between any of the groups. 
No significant group or group by time effects were seen in IL-13 expression 
between the PPID Control and PPID Treatment groups. After combining the PPID Control 




group by time effects were seen. Significant time effects were observed in the Non-PPID 
to PPID comparison (P=.0022) and the all horses combined comparison only (P=.0003). 
No significant group or group by time effects were seen in TLR2 expression 
between the PPID Control and PPID Treatment groups. Due to starting differences between 
these groups, this analysis was run again with starting values as a covariate in the model; 
the group and group by time effects remained insignificant. After combining the PPID 
Control and PPID Treatment groups for comparison to Non-PPID horses, no significant 
group or group by time effects were seen. Significant time effects were observed in the 
PPID Control and PPID Treatment (P=.0488), Non-PPID to PPID (P=.004), and all horses 
combined comparisons (P=.0028). 
Significant group by time (P=.005) effects were seen in IL-12α expression between 
the PPID Control and PPID Treatment groups; no significant group or time effects were 
seen in this comparison. Due to starting differences between these groups, this analysis was 
run again, with starting values as a covariate in the model; the results remained the same. 
Due to the significant group by time effects, the PPID Control and PPID Treatment groups 
remained separate for comparison to the Non-PPID group. In the PPID Control to PPID 
Treatment to Non-PPID comparison, no significant group, time, or group by time effects 
were observed. Starting differences between the groups were again present, so the analysis 
was run again with starting values as a covariate in the model; the results remained the 
same. Therefore, all horses were combined for analysis of time effects; no significant time 
effects were observed. 
Significant group by time (P=.011) effects were seen in IFNγ expression between 




seen in this comparison. Due to the significant group by time effects, the PPID Control and 
PPID Treatment groups remained separate for comparison to the Non-PPID group. In the 
PPID Control to PPID Treatment to Non-PPID comparison, no significant group, time, or 
group by time effects were observed. Therefore, all horses were combined for analysis of 
time effects; no significant time effects were observed. 
Summary of BAL stimulation- E. coli:  
Aside from significant time effects, there were no significant findings. 
 
BAL stimulation- PMA/ionomycin: 
No significant group, time, or group by time effects were seen in IL-13, TGFβ, 
TLR4, or TNFα between any of the groups. 
No significant group or group by time effects were seen in TLR2 between any of 
the groups. Significant time effects in TLR2 expression were observed in the Non-PPID to 
PPID (P=.0245) and all horses combined comparisons (P=.0195). 
No significant group or group by time effects were seen in IL-1β expression 
between the PPID Control and PPID Treatment groups. After combining the PPID Control 
and PPID Treatment groups for comparison to Non-PPID horses, no significant group or 
group by time effects were seen. Significant time effects were observed only in the PPID 
Control and PPID Treatment (P=.033) comparison. 
Significant group by time (P=.016) effects were seen in IL-17α expression between 




seen in this comparison. Due to starting differences between these groups, this analysis was 
run again with starting values as a covariate in the model; the results remained the same, 
except that the group by time effect was no longer significant. This indicates that the initial 
significant group by time effect was caused by the starting differences between the two 
groups and was not a truly significant effect. After combining the PPID Control and PPID 
Treatment groups for comparison to Non-PPID horses, no significant group, time, or group 
by time effects were seen. No significant time effects were observed in the all groups 
combined comparison. 
Significant group by time (P=.0329) effects were seen in IL-8 expression between 
the PPID Control and PPID Treatment groups; no significant group or time effects were 
seen in this comparison. Due to starting differences between these groups, this analysis was 
run again with starting values as a covariate in the model; the results remained the same, 
except that the group by time effect was no longer significant. This indicates that the initial 
significant group by time effect was caused by the starting differences between the two 
groups and was not a truly significant effect. After combining the PPID Control and PPID 
Treatment groups for comparison to Non-PPID horses, no significant group, time, or group 
by time effects were seen. No significant time effects were observed in the all groups 
combined comparison. 
Significant time (P=.0442) and group by time (P=.0003) effects were seen in IFNγ 
expression between the PPID Control and PPID Treatment groups; no significant group 
effects were seen in this comparison. Due to starting differences between these groups, this 
analysis was run again with starting values as a covariate in the model; the results remained 




Treatment groups remained separate for comparison to the Non-PPID group. In the PPID 
Control to PPID Treatment to Non-PPID comparison, no significant group, time, or group 
by time effects were observed. Due to starting differences between these groups, this 
analysis was run again with starting values as a covariate in the model; the group and group 
by time effects remained insignificant, but a significant time effect was observed 
(P=.0257). Therefore, all horses were combined for analysis of time effects; no significant 
time effects were observed in this comparison. 
Significant group by time (P=.0485) effects were seen in IL-6 expression between 
the PPID Control and PPID Treatment groups; no significant group or time effects were 
seen in this comparison. Due to the significant group by time effects, the PPID Control and 
PPID Treatment groups remained separate for comparison to the Non-PPID group. In the 
PPID Control to PPID Treatment to Non-PPID comparison, significant group by time 
effects, but not group or time effects alone, were observed. Due to starting differences 
between these groups, this analysis was run again with starting values as a covariate in the 
model; the group by time effects were no longer significant, indicating that these groups 
did not change over time based on their group status. Since no significant group or group 
by time effects were observed in this comparison, all horses were combined for analysis of 
time effects; no significant time effects were observed. 
Significant group (P=.0205) and group by time (P=.0012) effects were seen in IL-
12α expression between the PPID Control and PPID Treatment groups; no significant time 
effects were seen in this comparison. Due to starting differences between these groups, this 
analysis was run again with starting values as a covariate in the model; the group by time 




by time effects, the PPID Control and PPID Treatment groups remained separate for 
comparison to the Non-PPID group. In the PPID Control to PPID Treatment to Non-PPID 
comparison, no significant group, time, or group by time effects were observed. Due to 
starting differences between these groups, this analysis was run again with starting values 
as a covariate in the model; the results remained the same. Since no significant group or 
group by time effects were observed in this comparison, all horses were combined for 
analysis of time effects; no significant time effects were observed. 
Summary of BAL stimulation- PMA/ionomycin:  
Aside from significant time effects, there were no significant findings. 
 
Summary of overall BAL stimulation results: 
Some significant group and group by time effects were observed in the R. equi-
stimulated samples; however, most of these effects appeared to have been influenced by 
the small sample sizes and were difficult to draw any conclusions from. Significant IL-13 
effects were noted in the media and R. equi-stimulated samples, but there were many 
samples with late or no amplification during the RT-PCR for IL-13, so only about half of 
the samples were able to be used in the analysis. No significant findings were observed in 
the E. coli and PMA/ionomycin stimulations aside from time effects. Significant time 
effects were often observed; for the Non-PPID to PPID comparisons, the significant time 







No significant group or group by time effects were found in BALF 
myeloperoxidase concentrations between the PPID Control and PPID Treatment horses; a 
significant time effect (P=.0133) was observed in this comparison. After combining the 
PPID horses for comparison to the Non-PPID horses, significant group (P=.0322) and 
group by time (P=.0322) effects were observed with PPID horses having lower BALF 
myeloperoxidase concentrations than Non-PPID horses at the Mid-October 2018 timepoint 
only (Figure 4.9). A significant time effect was not observed in the PPID to Non-PPID 
comparison. It is possible that these significant effects are not biologically significant as 
they were only apparent at one timepoint (Mid-October 2018), and the data set for the BAL 
samples was small. 
 
4.5 Discussion 
The goal of this study was to examine localized immune function in horses with 
PPID and to evaluate the extent to which short-term (8 weeks) and long-term (1-year-and-
6-weeks) PRASCEND treatment affects these measures. Localized immune function was 
measured using BALF cytology, BALF myeloperoxidase concentrations, and gene 
expression of cytokines and receptors important for immune function in heat-inactivated 
R. equi, heat-inactivated E. coli, and PMA/ionomycin stimulations of BAL cells. Overall, 
the findings suggested that alterations may exist in the Th2 response within the lung of 
PPID horses when compared to Non-PPID horses but are opposite to what would be 
expected in asthmatic lungs. However, it was difficult to draw conclusions as the sample 




Low cell counts in the recovered BAL fluid limited the number of stimulations that 
could be done. In these cases, the unstimulated and R. equi and E. coli stimulations were 
prioritized over the PMA/ionomycin stimulation. Additionally, unlike in the peripheral 
blood mononuclear cell stimulations, which had six timepoints over the study, the BAL 
cells were only collected at three main timepoints (Early September 2017, Early November 
2017, and Mid-October 2018). Due to frequently observed significant time effects 
associated with the local immune response of the lung, the fewer timepoints and fewer 
samples due to low cell counts made it more difficult to analyze any effects of PPID status 
or PRASCEND treatment that were temporally consistent as well as significant. 
Several of the significant results that may warrant further investigation included the 
differences in the percentage of eosinophils in BALF with PPID horses having lower 
counts at the initial starting timepoint (Early September 2017), as well as the decreased IL-
13 in the unstimulated BAL cells and BALF MPO at the Mid-October 2018 timepoint, and 
the decreased IL-13 in the R. equi-stimulated BAL cells at the Early November 2017 and 
Mid-October 2018 timepoints when comparing PPID horses to Non-PPID horses. 
Unfortunately, many of the IL-13 samples had no or late amplification on the RT-PCR 
results, which combined with the already small sample sizes, left the IL-13 analyses 
vulnerable to the influence of one or a few sample values. If indeed the cytology results for 
the percentage of eosinophils in BALF are real, this points towards an decrease in the Th2 
immune response of the lung in PPID horses compared to Non-PPID horses, which also 
may have coincided with the decrease in neutrophil degranulation, based on the BALF 
MPO results. In the general, a Th1 immune response would have been most appropriate in 




replicate within macrophages 82,106,111. Overzealous eosinophil and Th2 responses in the 
lung are associated with asthma and are responsible for the aberrant allergic and asthmatic 
responses of the lung in both humans and horses, but these were not seen in the available 
results from this study 115-118.  
Overall, it is difficult to draw conclusions regarding the immune response within 
the lung of PPID horses based on the results obtained in this study. However, the slight 
differences that were found may point towards an altered immune response in the lung of 
PPID horses that is worth further exploring, albeit with either a larger sample size or more 
frequent sampling. An altered Th2 response in the lung would be consistent with the higher 
rates of bronchiolitis and bronchointerstitial inflammation observed in the post-mortem 
evaluations of Glover et al. in PPID horses and the anecdotal evidence suggesting that 
PPID horses have higher risk of respiratory infections 56. Despite significantly reducing 
plasma ACTH concentrations, PRASCEND treatment did not appear to affect immune 
function within the lungs of PPID horses as measured in this study. Additionally, the 
significant time effects seen in the BALF cytology results (percentages of neutrophils, 
lymphocytes, macrophages, and eosinophils) and in some of the BAL immune responses 
emphasize the importance of having appropriate control groups when investigating the 













Table 4.1. Number of outliers removed from bronchoalveolar lavage cell (BAL) 
(unstimulated/stimulated) cytokine and receptor gene expression sample analyses 
Cytokine/Receptor # of media 
outliers 
removed 
# of R. equi 
outliers 
removed 
# of E. coli 
outliers 
removed 
# of PMA 
outliers 
removed 
IFNγ 0 0 0 1 
IL-12α 0 0 0 0 
IL-13 0 0 1 0 
IL-17α 1 0 1 0 
IL-1β 0 1 0 0 
IL-6 0 0 3 0 
IL-8 0 0 0 0 
TGFβ 0 0 0 0 
TLR2 1 1 0 1 
TLR4 1 1 1 1 



















































































Figure 4.1. (A) Percent eosinophils in bronchoalveolar lavage fluid (BALF) cytology (B) Percent eosinophils in 
bronchoalveolar lavage fluid (BALF) cytology (starting values as a covariate in the model) 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses are represented by lines with open 
squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 horses in the PPID group. By 
the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID group. * denotes a significant 









Figure 4.2. Significant time effects in bronchoalveolar lavage fluid (BALF) cytology for (A) percent neutrophils (B) percent 
lymphocytes, (C) percent macrophages 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses are represented by lines with open 
squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 horses in the PPID group. By 
the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID group. These graphs show only the 


















Figure 4.3. Unstimulated bronchoalveolar lavage (BAL) cell IL-13 expression 
Mean +/- SEM. RQs are natural log-transformed (Ln). Non-PPID horses are represented 
by lines with closed circles. PPID horses are represented by lines with open squares. At 
Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 18 horses 
in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 
13 horses in the PPID group. * denotes a significant difference (P<.05) between Non-PPID 
















Figure 4.4. (A) Unstimulated bronchoalveolar lavage (BAL) cell TGFβ expression (B) Heat-inactivated R. equi-stimulated 
BAL cell TGFβ expression with media values as a covariate in the model 
Mean +/- SEM. RQs are natural log-transformed (Ln). Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 
18 horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID 









Figure 4.5. (A) Unstimulated bronchoalveolar lavage (BAL) cell TLR2 expression (B) Heat-inactivated R. equi-stimulated 
BAL cell TLR2 expression with media values as a covariate in the model. (C) Heat-inactivated R. equi-stimulated BAL cell 
TLR2 expression with media and starting values as covariates in the model 
Mean +/- SEM. RQs are natural log-transformed (Ln). (A) Non-PPID horses are represented by lines with closed circles. PPID 
horses are represented by lines with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID 
group and 18 horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the 
PPID group. (B, C) Non-PPID horses are represented by lines with closed circles. PPID Treatment horses are represented by 
lines with closed triangles. PPID Control horses are represented by lines with closed squares. At Day 0 (Early September 2017), 
there were 10, 9, and 9 horses in the Non-PPID, PPID Control, and PPID Treatment groups, respectively. By the end of the 
study, there were 9, 7, and 6 horses in the Non-PPID, PPID Control, and PPID Treatment groups, respectively. * denotes a 
significant difference (P<.05) between Non-PPID and PPID Control. # denotes a significant difference (P<.05) between PPID 
Treatment and PPID Control groups. PPID-pituitary pars intermedia dysfunction; TLR2-toll-like receptor 2; R. equi-
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Figure 4.6. (A) Unstimulated bronchoalveolar lavage (BAL) cell IL-12α expression (B) Heat-inactivated R. equi-stimulated 
BAL cell IL-12α expression with media values as a covariate in the model. (C) Heat-inactivated R. equi-stimulated BAL cell 
IL-12α expression with media and starting values as covariates in the model 
Mean +/- SEM. RQs are natural log-transformed (Ln). (A) Non-PPID horses are represented by lines with closed circles. PPID 
horses are represented by lines with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID 
group and 18 horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the 
PPID group. (B, C) Non-PPID horses are represented by lines with closed circles. PPID Treatment horses are represented by 
lines with closed triangles. PPID Control horses are represented by lines with closed squares. At Day 0 (Early September 2017), 
there were 10, 9, and 9 horses in the Non-PPID, PPID Control, and PPID Treatment groups, respectively. By the end of the 
study, there were 9, 7, and 6 horses in the Non-PPID, PPID Control, and PPID Treatment groups, respectively. * denotes a 
significant difference (P<.05) between Non-PPID and PPID Control. # denotes a significant difference (P<.05) between PPID 











Figure 4.7. (A) Unstimulated bronchoalveolar lavage (BAL) cell IL-13 expression (B) Heat-inactivated R. equi-stimulated 
BAL cell IL-13 expression with media values as a covariate in the model 
Mean +/- SEM. RQs are natural log-transformed (Ln). Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 10 horses in the Non-PPID group and 
18 horses in the PPID group. By the end of the study, there were 9 horses in the Non-PPID group and 13 horses in the PPID 
group. * denotes a significant difference (P<.05) between Non-PPID and PPID groups. PPID-pituitary pars intermedia 








































































































































Figure 4.8. Significant time effects for bronchoalveolar lavage (BAL) cell cytokine 
expression for (A) TLR4 in unstimulated samples, (B) IL-13 in E. coli-stimulated 
samples, (C) TLR2 in E. coli-stimulated samples, and (D) TLR2 in PMA/ionomycin-
stimulated samples 
Mean +/- SEM. (A-C) Non-PPID horses are represented by lines with closed circles. PPID 
horses are represented by lines with open squares. At Day 0 (Early September 2017), there 
were 10 horses in the Non-PPID group and 18 horses in the PPID group. By the end of the 
study, there were 9 horses in the Non-PPID group and 13 horses in the PPID group. These 
graphs show only the significant time effects (P<.05) for the respective analyses. PPID-
pituitary pars intermedia dysfunction; TLR-toll-like receptor; E. coli-Escherichia coli; IL-










Figure 4.9. Myeloperoxidase concentrations in bronchoalveolar lavage fluid (BALF). 
Mean +/- SEM. Non-PPID horses are represented by lines with closed circles. PPID horses 
are represented by lines with open squares. At Day 0 (Early September 2017), there were 
10 horses in the Non-PPID group and 18 horses in the PPID group. By the end of the study, 
there were 9 horses in the Non-PPID group and 13 horses in the PPID group. * denotes a 





CHAPTER 5. FINAL CONCLUSIONS AND FUTURE RESEARCH 
In this study, PPID horses did not differ from age-matched Non-PPID horses in their 
serum insulin, total cortisol, or free cortisol concentrations. PPID horses had significantly 
higher resting plasma ACTH concentrations than Non-PPID horses at the beginning of the 
study. In the PPID Treatment horses, PRASCEND treatment successfully reduced ACTH 
to the level of a Non-PPID horses within only a few weeks of treatment, despite being in 
the midst of the seasonal fall rise in ACTH. However, PRASCEND treatment only 
appeared to influence the ACTH response to TRH stimulation tests at non-fall timepoints. 
Therefore, the authors conclude that current recommendations for veterinarians to assess 
resting ACTH concentrations for the purpose of monitoring responses to PRASCEND 
treatment to be appropriate, even if the original method to diagnose PPID was the TRH 
stimulation test. Other than significantly reducing ACTH in PPID horses, PRASCEND 
treatment did not appear to influence other endocrine measures in this study. 
While laminitis and associated hyperinsulinemia are often thought to be more common 
in PPID horses, no differences were seen in basal insulin or in the insulin response to an 
oral sugar test between PPID and Non-PPID horses in this study. This supports the 
conclusion that hyperinsulinemia/insulin dysregulation and PPID are distinct endocrine 
conditions rather than related to one another, although they can both occur simultaneously 
in the same horse. 
In contrast to what is expected in a normal hypothalamus-pituitary-adrenal axis 
response to increased ACTH concentrations, no differences were seen in total or free 
cortisol between PPID and Non-PPID horses. Therefore, it is reasonable to conclude that 




pars intermedia of horses is not capable of stimulating a downstream cortisol response and 
may not be bioavailable. 
The results from this study indicate that PPID horses are likely at risk of 
opportunistic infection but do not appear to respond differently to strong stimuli, such as 
PMA/ionomycin. This conclusion is also consistent with work published by McFarlane et 
al. regarding neutrophils in horses with PPID; they found that neutrophils from horses with 
PPID responded similarly to Non-PPID horses in response to PMA, but differently when 
exposed to weaker stimuli 48. In our work, PPID horses had decreased WBC and absolute 
lymphocyte counts compared to the Non-PPID horses. Further, PPID horses consistently 
demonstrated significantly decreased IFNγ production from PBMCs in response to in vitro 
stimulations with R. equi and E. coli. PPID horses also had consistent and significant 
increases in TGFβ expression from E. coli-stimulated PBMCs and in unstimulated whole 
blood samples compared to Non-PPID horses. Additionally, in whole blood (Tempus™ 
Blood RNA tubes) analyses, PPID horses had increased IL-8 expression compared to age-
matched Non-PPID horses. In this study, PRASCEND treatment did not appear to affect 
these immune responses. 
It was difficult to draw conclusions from the analyses of localized immune function 
within the lung due to small sample sizes combined with low BAL cell counts and poor or 
no amplification of IL-13 for RT-PCR results. Nevertheless, some of the significant results 
included a lower percentage of eosinophils in BALF in PPID horses compared to Non-
PPID horses at the initial starting timepoint (Early September 2017), decreased IL-13 in 




PPID horses, as well as decreased IL-13 in the R. equi-stimulated BAL cells of PPID horses 
at the Early November 2017 and Mid-October 2018 timepoints.  
Overall, the systemic immune function results are suggestive of a reduced ability 
of PPID horses to generate a Th1 response in vitro to heat-inactivated R. equi and E. coli, 
but not to stronger stimuli, such as PMA/ionomycin. Additionally, the TGFβ results 
indicate that the Treg subpopulation of lymphocytes may be contributing to this inability to 
evoke a Th1 response. Altogether, this would be consistent with a higher risk of 
opportunistic infection in PPID horses. 
If indeed the differences in the percentage of eosinophils in BALF and MPO in 
BALF noted in the localized immune function analyses are real, the results point to possible 
alterations in the Th2 immune response within the lung of PPID horses. This would also 
be consistent with a higher risk of opportunistic infection in PPID horses, as an altered Th2 
response in the lung may predispose a horse to infection, while a Th1 response would be 
more protective. However, due to the statistical difficulties in interpreting the BAL 
analyses, this conclusion is mostly speculative at this time. 
Given that clear differences in the immune responses of PPID horses were found in 
this work despite finding no difference in free or total cortisol concentrations compared to 
Non-PPID horses, the question of what is causing the differences in immune function 
arises. In other species, ACTH has been shown to have immune-modulating capabilities 
119-122. Therefore, it is certainly possible that despite the ACTH from the pars intermedia 
appearing to be incapable of eliciting a normal downstream cortisol response, it may still 
be capable of exerting its immunomodulatory effects. Additionally, it is possible that the 




α-MSH and CLIP, may be contributing to these immunological changes. Treatment with 
PRASCEND did not appear to influence the measured immune responses though, which 
would have been expected; this could be an indication that the statistical power was 
insufficient to detect these changes or that an entirely different mechanism is responsible 
for altering immune function in PPID horses. 
Additional research is needed to elucidate the causes of immune dysfunction in 
horses with PPID. Ideally, work would continue to analyze individual factors of immune 
function in PPID horses to determine exactly where the breakdowns in function occur. 
Furthermore, determining what changes within the endocrine system are responsible for 






















APPENDIX 1. LIST OF ABBREVIATIONS 
ACTH: adrenocorticotropic hormone 
α-MSH: alpha-melanocyte-stimulating hormone 
BAL: bronchoalveolar lavage 
BALF: bronchoalveolar lavage fluid 
BCS: body condition score 
β-Gus: beta-glucuronidase 
CBC: complete blood count 
CBG: cortisol-binding globulin 
CD: cluster of differentiation 
CLIP: corticotropin-like intermediate peptide 
CFU: colony-forming units 
CNS: cresty neck score 
CRH: corticotropin-releasing hormone 
DST: dexamethasone suppression test 
DMSO: dimethyl sulfoxide 




EDTA: ethylenediaminetetraacetic acid 
ELISA: enzyme-linked immunosorbent assay 
HPA: hypothalamus-pituitary-adrenal 









OST: oral sugar test 
PBMC: peripheral blood mononuclear cell 
PBS: phosphate-buffered saline 
PC-I: prohormone convertase I 
PC-II: prohormone convertase II 





PPID: Pituitary Pars Intermedia Dysfunction 
RBC: red blood cell 
R. equi: Rhodococcus equi 
RNA: ribonucleic acid 
RQ- relative quantity 
RT-PCR: reverse-transcription polymerase chain reaction 
TGFβ- transforming growth factor-beta 
Th1: CD4 T-cell subset 1 
Th2: CD4 T-cell subset 2 
Th17: CD4 T-cell subset 17 
TLR2: Toll-like receptor 2 
TLR4: Toll-like receptor 4 
TNFα- tumor necrosis factor alpha 
Treg: Regulatory T-cell 
TRH: thyrotropin-releasing hormone 
VapA: virulence-associated protein A 
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